0001193125-12-437971.txt : 20121029 0001193125-12-437971.hdr.sgml : 20121029 20121026175801 ACCESSION NUMBER: 0001193125-12-437971 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20120930 FILED AS OF DATE: 20121029 DATE AS OF CHANGE: 20121026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUIDEL CORP /DE/ CENTRAL INDEX KEY: 0000353569 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 942573850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-10961 FILM NUMBER: 121165347 BUSINESS ADDRESS: STREET 1: 10165 MCKELLAR CT CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8585521100 FORMER COMPANY: FORMER CONFORMED NAME: MONOCLONAL ANTIBODIES INC /DE/ DATE OF NAME CHANGE: 19910210 10-Q 1 d398839d10q.htm FORM 10-Q Form 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

 

(Mark One)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012

or

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to            

Commission File Number: 0-10961

 

 

QUIDEL CORPORATION

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   94-2573850

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

10165 McKellar Court, San Diego, California 92121

(Address of principal executive offices, including zip code)

(858) 552-1100

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

 

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   ¨    Accelerated filer    x
Non-accelerated filer   ¨  (Do not check if a smaller reporting company)    Smaller reporting company    ¨

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of October 24, 2012, 33,350,305 shares of common stock were outstanding.

 

 

 


Table of Contents

INDEX

 

PART I—FINANCIAL INFORMATION

     3   
ITEM 1. Financial Statements (unaudited)      3   

Consolidated Balance Sheets as of September 30, 2012 and December 31, 2011

     3   

Consolidated Statements of Operations for the three and nine months ended September 30, 2012 and 2011

     4   

Consolidated Statements of Cash Flows for the nine months ended September 30, 2012 and 2011

     5   

Notes to Consolidated Financial Statements

     6   
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations      14   
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk      21   
ITEM 4. Controls and Procedures      21   
PART II—OTHER INFORMATION      22   
ITEM 1. Legal Proceedings      22   
ITEM 1A. Risk Factors      22   
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds      22   
ITEM 3. Defaults Upon Senior Securities      22   
ITEM 4. Mine Safety Disclosures      22   
ITEM 5. Other Information      22   
ITEM 6. Exhibits      23   
Signatures      24   

 

2


Table of Contents

PART I FINANCIAL INFORMATION

 

ITEM 1. Financial Statements

QUIDEL CORPORATION

CONSOLIDATED BALANCE SHEETS

(in thousands, except par value; unaudited)

 

     September 30,
2012
     December 31,
2011
 

ASSETS

     

Current assets:

     

Cash and cash equivalents

   $ 17,842       $ 61,332   

Accounts receivable, net

     17,132         14,646   

Inventories

     16,909         14,654   

Deferred tax asset—current

     10,681         10,681   

Income tax receivable

     136         167   

Prepaid expenses and other current assets

     6,380         3,246   
  

 

 

    

 

 

 

Total current assets

     69,080         104,726   

Property and equipment, net

     30,535         28,086   

Goodwill

     71,013         71,013   

Intangible assets, net

     64,179         73,830   

Other non-current assets

     1,970         1,239   
  

 

 

    

 

 

 

Total assets

   $ 236,777       $ 278,894   
  

 

 

    

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

     

Current liabilities:

     

Accounts payable

   $ 4,679       $ 5,001   

Accrued payroll and related expenses

     5,394         5,377   

Accrued royalties

     229         15,093   

Current portion of lease obligation

     367         329   

Other current liabilities

     4,760         7,126   
  

 

 

    

 

 

 

Total current liabilities

     15,429         32,926   

Long term debt

     19,000         42,000   

Lease obligation, net of current portion

     5,667         5,947   

Deferred tax liability—non-current

     4,648         7,040   

Income taxes payable

     4,413         4,667   

Other non-current liabilities

     952         928   

Commitments and contingencies

     

Stockholders’ equity:

     

Preferred stock, $.001 par value per share; 5,000 shares authorized; none issued or outstanding at September 30, 2012 and December 31, 2011

     —           —     

Common stock, $.001 par value per share; 50,000 shares authorized; 33,297 and 33,276 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively

     33         33   

Additional paid-in capital

     180,059         175,030   

Retained earnings

     6,576         10,323   
  

 

 

    

 

 

 

Total stockholders’ equity

     186,668         185,386   
  

 

 

    

 

 

 

Total liabilities and stockholders’ equity

   $ 236,777       $ 278,894   
  

 

 

    

 

 

 

 

See accompanying notes.

 

3


Table of Contents

QUIDEL CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data; unaudited)

 

     Three months ended
September 30,
    Nine months ended
September 30,
 
     2012     2011     2012     2011  

Total revenues

   $ 32,998      $ 33,108      $ 101,816      $ 120,212   

Costs and expenses

        

Cost of sales (excludes amortization of intangible assets of $1,438, $1,670, $4,315 and $5,009, respectively)

     14,872        14,996        43,688        47,579   

Research and development

     5,085        5,884        20,433        19,559   

Sales and marketing

     7,776        6,487        21,989        18,996   

General and administrative

     4,759        5,194        15,812        17,135   

Amortization of intangible assets from acquired businesses and technology

     1,728        1,791        5,165        5,342   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total costs and expenses

     34,220        34,352        107,087        108,611   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating (loss) income

     (1,222     (1,244     (5,271     11,601   

Other (expense) income

        

Interest income

     8        42        35        151   

Interest expense

     (286     (485     (985     (1,639

Other expense

     (27     —          (27     —     
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other expense

     (305     (443     (977     (1,488
  

 

 

   

 

 

   

 

 

   

 

 

 

(Loss) income before taxes

     (1,527     (1,687     (6,248     10,113   

(Benefit) provision for income taxes

     (851     (574     (2,501     3,438   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net (loss) income

   $ (676   $ (1,113   $ (3,747   $ 6,675   
  

 

 

   

 

 

   

 

 

   

 

 

 

Basic and diluted (loss) earnings per share

   $ (0.02   $ (0.03   $ (0.11   $ 0.20   

Shares used in basic per share calculation

     33,004        33,019        33,036        32,833   

Shares used in diluted per share calculation

     33,004        33,019        33,036        33,189   

See accompanying notes.

 

4


Table of Contents

QUIDEL CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands; unaudited)

 

     Nine months ended
September 30,
 
     2012     2011  

OPERATING ACTIVITIES:

    

Net (loss) income

   $ (3,747   $ 6,675   

Adjustments to reconcile net (loss) income to net cash provided by operating activities:

    

Depreciation, amortization and other

     16,485        12,063   

Loss on disposal of assets

     27        —     

Stock-based compensation expense

     5,001        5,798   

Change in deferred tax assets and liabilities

     (2,392     2,527   

Changes in assets and liabilities:

    

Accounts receivable

     (2,486     (3,828

Inventories

     (2,140     2,856   

Income tax receivable

     31        8,267   

Prepaid expenses and other current assets

     (2,611     (594

Accounts payable

     (877     (289

Accrued payroll and related expenses

     (160     2,155   

Accrued royalties

     (148     (1,858

Accrued income taxes payable

     (254     —     

Other current and non-current liabilities

     (844     521   
  

 

 

   

 

 

 

Net cash provided by operating activities

     5,885        34,293   
  

 

 

   

 

 

 

INVESTING ACTIVITIES:

    

Acquisitions of property and equipment

     (6,903     (3,254

Acquisitions of intangibles

     (15,359     (14,264

Purchase of business

     (1,000     —     

Proceeds from sale of fixed assets

     115        —     
  

 

 

   

 

 

 

Net cash used for investing activities

     (23,147     (17,518
  

 

 

   

 

 

 

FINANCING ACTIVITIES:

    

Payments on lease obligation

     (242     (207

Purchases of common stock

     (3,407     (625

Payments on line of credit

     (23,000     (30,000

Payments on note payable to state agency

     (1,498     —     

Issuance of common stock, net of cancellations

     2,960        59,221   

Other

     (1,041     (907
  

 

 

   

 

 

 

Net cash (used for) provided by financing activities

     (26,228     27,482   
  

 

 

   

 

 

 

Net (decrease) increase in cash and cash equivalents

     (43,490     44,257   

Cash and cash equivalents, beginning of period

     61,332        6,788   
  

 

 

   

 

 

 

Cash and cash equivalents, end of period

   $ 17,842      $ 51,045   
  

 

 

   

 

 

 

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

    

Cash paid during the period for interest

   $ 985      $ 1,639   
  

 

 

   

 

 

 

Cash paid during the period for income taxes

   $ —        $ 200   
  

 

 

   

 

 

 

NON-CASH INVESTING ACTIVITIES:

    

Purchase of capital equipment by incurring current liabilities

   $ 555      $ 157   
  

 

 

   

 

 

 

Purchase of licensed technology by incurring current liabilities

   $ —        $ 16,563   
  

 

 

   

 

 

 

NON-CASH FINANCING ACTIVITIES:

    

Reduction of other non-current assets upon issuance of common stock

   $ —        $ 478   
  

 

 

   

 

 

 

Increase of other non-current assets upon issuance of common stock

   $ 652      $ —     
  

 

 

   

 

 

 

 

5


Table of Contents

Quidel Corporation

Notes to Consolidated Financial Statements

(Unaudited)

Note 1. Basis of Presentation

The accompanying unaudited consolidated financial statements of Quidel Corporation and its subsidiaries (the “Company”) have been prepared in accordance with generally accepted accounting principles in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements.

Certain reclassifications have been made to prior year amounts to conform to the current year presentation. The Company reclassified patent and trademark expenses of $0.3 million and $0.8 million from research and development expense to general and administrative expense on the Consolidated Statements of Operations for the three and nine months ended September 30, 2011, respectively. The Company reclassified stock-based compensation expense of $0.6 million from accrued payroll and related expenses to stock-based compensation expense on the Consolidated Statements of Cash Flows for the nine months ended September 30, 2011. For the nine months ended September 30, 2011, the Company reclassified a reduction of other non-current assets of $0.5 million from cash provided by financing activities and from cash provided by operating activities to non-cash financing activities on the Consolidated Statements of Cash flows.

The information at September 30, 2012, and for the three and nine months ended September 30, 2012 and 2011, is unaudited. Operating results for the three and nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012. For further information, refer to the Company’s consolidated financial statements and footnotes thereto for the year ended December 31, 2011 included in the Company’s 2011 Annual Report on Form 10-K. Subsequent events have been evaluated up to and including the date these financial statements were issued. In the opinion of management, all adjustments considered necessary for a fair presentation (consisting of normal recurring accruals) have been included. Operating results for any quarter are historically seasonal in nature and are not necessarily indicative of the results expected for the full year.

For 2012 and 2011, the Company’s fiscal year will or has ended on December 30, 2012 and January 1, 2012, respectively. For 2012 and 2011, the Company’s third quarter ended on September 30, 2012 and October 2, 2011, respectively. For ease of reference, the calendar quarter end dates are used herein. The three and nine month periods ended September 30, 2012 and 2011 both included 13 and 39 weeks, respectively.

Note 2. Comprehensive (loss) income

Net (loss) income is equal to comprehensive (loss) income for the three and nine months ended September 30, 2012 and 2011. During the first quarter ended March 31, 2012, the Company adopted Accounting Standards Update No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income.

Note 3. Computation of Earnings Per Share

Diluted net income per share is reported based on the more dilutive of the treasury stock or the two-class method. Under the two-class method, net income is allocated to common stock and participating securities. The Company’s unvested restricted stock awards and certain unvested restricted stock units meet the definition of participating securities. Basic net income per share under the two-class method is computed by dividing net income adjusted for earnings allocated to unvested stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share under the two-class method is computed by dividing net income adjusted for earnings allocated to unvested stockholders for the period by the weighted average number of common and common equivalent shares outstanding during the period. The Company excludes stock options from the calculation of diluted net income per share when the combined exercise price, unrecognized stock-based compensation and assumed tax benefits upon exercise are greater than the average market price for the Company’s common stock because their effect is anti-dilutive. For the nine months ended September 30, 2011, 1.9 million shares were excluded from the calculation of diluted earnings per share (“EPS”) as their effect was anti-dilutive.

 

6


Table of Contents

Quidel Corporation

Notes to Consolidated Financial Statements

(Unaudited)

Note 3. Computation of Earnings Per Share (Continued)

 

For the three and nine months ended September 30, 2012 and the three months ended September 30, 2011 there were no differences between the number of common shares used for the basic and diluted EPS computations as they were periods in which the Company incurred a net loss. Due to the fact that the holders of participating securities are not contractually required to share in the Company’s losses, in applying the two-class method to compute basic net loss per common share, no allocation to participating securities was made for periods in which the Company incurred a net loss.

The following table sets forth the computation of basic and diluted EPS for the nine months ended September 30, 2011 (in thousands, except per share amounts):

 

     2011  

Basic net income per share:

  

Net income

   $ 6,675   

Less: income allocated to participating securities

     (61
  

 

 

 

Net income allocated to common stockholders

   $ 6,614   
  

 

 

 

Weighted average common shares outstanding — basic

     32,833   
  

 

 

 

Net income per share — basic

   $ 0.20   
  

 

 

 

Diluted net income per share:

  

Net income

   $ 6,675   

Less: income allocated to participating securities

     (60
  

 

 

 

Net income allocated to common stockholders

   $ 6,615   
  

 

 

 

Weighted average common shares outstanding — basic

     32,833   

Dilutive securities

     356   
  

 

 

 

Weighted average common shares outstanding — diluted

     33,189   
  

 

 

 

Net income per share — diluted

   $ 0.20   
  

 

 

 

Note 4. Inventories

Inventories are recorded at the lower of cost (first-in, first-out) or market and consist of the following (in thousands):

 

     September 30,
2012
     December 31,
2011
 

Raw materials

   $ 5,554       $ 5,239   

Work-in-process (materials, labor and overhead)

     4,708         3,632   

Finished goods (materials, labor and overhead)

     6,647         5,783   
  

 

 

    

 

 

 
   $ 16,909       $ 14,654   
  

 

 

    

 

 

 

 

7


Table of Contents

Quidel Corporation

Notes to Consolidated Financial Statements

(Unaudited)

 

Note 5. Other Current Liabilities

Other current liabilities consist of the following (in thousands):

 

     September 30,
2012
     December 31,
2011
 

Accrued liability for technology licenses

   $ 530       $ 863   

Customer incentives

     1,400         2,352   

Accrued interest – income taxes

     607         491   

Customer prepayments

     48         202   

Current portion of note payable to state agency

     —           1,498   

Unearned research and development collaboration funds received

     1,222         —     

Other

     953         1,720   
  

 

 

    

 

 

 
   $ 4,760       $ 7,126   
  

 

 

    

 

 

 

Note 6. Income Taxes

The Company’s effective tax rate for the nine months ended September 30, 2012 and 2011 was 40.0% and 34.0%, respectively. The Company recognized an income tax benefit of $2.5 million and an income tax expense of $3.4 million for the nine months ended September 30, 2012 and 2011, respectively. The primary difference between the September 30, 2012 and September 30, 2011 effective tax rate is due to the exclusion of the federal research and development tax credit due to the expiration of the statute. In addition, the Company reduced the reserve for uncertain tax positions resulting from a federal statutory audit. During the quarter ended September 30, 2012, the Company was notified by the Internal Revenue Service that it is examining the Company’s federal tax returns for the years ended 2007 through 2010.

The Company is subject to periodic audits by domestic and foreign tax authorities. The Company’s federal tax years for 1995 and forward are subject to examination by the U.S. authorities due to the carry forward of unutilized net operating losses and research and development credits. With few exceptions, the Company’s tax years for 1999 and forward are subject to examination by state and foreign tax authorities. The Company believes that it has appropriate support for the income tax positions taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors, including past experience and interpretations of tax law applied to the facts of each matter.

Note 7. Line of Credit

On August 10, 2012, the Company entered into an amended and restated $140.0 million senior secured syndicated credit facility (the “Senior Credit Facility”), which matures on August 10, 2017. The Senior Credit Facility amends and restates the Company’s $120.0 million senior secured credit facility dated October 8, 2008. As part of this amendment, the Company incurred $1.0 million in deferred financing costs related to the Senior Credit Facility in addition to the $0.6 million it had previously recorded related to the original credit facility. As of September 30, 2012, the Company had $1.6 million included as a portion of other non-current assets. The Senior Credit Facility bears interest at either LIBOR or the base rate plus in each case the applicable margin. The base rate is equal to the higher of (i) the lender’s prime rate, (ii) the federal funds rate plus one-half of one percent and (iii) LIBOR plus one percent. The applicable rate is generally determined in accordance with a performance pricing grid based on the Company’s leverage ratio and ranges from 1.25% to 2.50% for LIBOR rate loans and from 0.25% to 1.50% for base rate loans (weighted average interest rate of 1.72% at September 30, 2012). The agreement governing the Senior Credit Facility is subject to certain customary limitations, including among others: limitation on liens; limitation on mergers, consolidations and sales of assets; limitation on debt; limitation on dividends, stock redemptions and the redemption and/or prepayment of other debt; limitation on investments (including loans and advances) and acquisitions; limitation on transactions with affiliates; and limitation on disposition of assets. The Company is also subject to financial covenants which include a funded debt to adjusted EBITDA ratio (as defined in the Senior Credit Facility, with adjusted EBITDA generally calculated as earnings before, among other adjustments, interest, taxes, depreciation, amortization, and stock-based compensation) not to exceed 3:1 as of the end of each fiscal quarter, and an interest coverage ratio of not less than 3:1 as of the end of each fiscal quarter. The Senior Credit Facility is secured by substantially all present and future assets and properties of the Company.

 

8


Table of Contents

Quidel Corporation

Notes to Consolidated Financial Statements

(Unaudited)

Note 7. Line of Credit (continued)

 

As of September 30, 2012, the Company had $60.0 million available under the Senior Credit Facility. The Company’s ability to borrow under the Senior Credit Facility fluctuates from time to time due to, among other factors, the Company’s borrowings under the facility and its funded debt to adjusted EBITDA ratio. As of September 30, 2012, the Company had $19.0 million outstanding under the Senior Credit Facility. As of September 30, 2012, the Company was in compliance with all financial covenants.

Note 8. Stockholders’ Equity

During the nine months ended September 30, 2012, 135,295 shares of restricted stock were awarded, 17,165 shares of restricted stock were cancelled, 197,109 shares of common stock were issued due to the exercise of stock options and 44,290 shares of common stock were issued in connection with the Company’s employee stock purchase plan (the “ESPP”), resulting in net proceeds to the Company of approximately $3.0 million (excludes $0.6 million included in prepaid expenses and other current assets as of September 30, 2012). Additionally, during the nine months ended September 30, 2012, 231,704 shares of outstanding common stock were repurchased for approximately $3.4 million, which primarily included shares repurchased under the Company’s previously announced share repurchase program, but also included 31,304 shares repurchased in connection with payment of minimum tax withholding obligations for certain employees relating to the lapse of restrictions on certain restricted stock awards during the nine months ended September 30, 2012. There was approximately $22.1 million remaining under the Company’s share repurchase program as of September 30, 2012.

Note 9. Stock-Based Compensation

The compensation expense related to the Company’s stock-based compensation plans included in the accompanying Consolidated Statements of Operations for the three and nine months ended September 30, 2012 and 2011 was as follows (in millions):

 

     Three months
ended
September 30,
     Nine months
ended
September 30,
 
     2012      2011      2012      2011  

Cost of sales

   $ 0.2       $ 0.1       $ 0.4       $ 0.5   

Research and development

     0.2         0.3         0.8         0.8   

Sales and marketing

     0.2         0.2         0.4         0.3   

General and administrative

     0.8         1.0         3.4         4.2   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 1.4       $ 1.6       $ 5.0       $ 5.8   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total compensation expense recognized for the three months ended September 30, 2012 and 2011 includes $0.9 million and $1.0 million related to stock options and $0.5 million and $0.6 million related to restricted stock, respectively. Total compensation expense recognized for the nine months ended September 30, 2012 and 2011 includes $3.0 million and $3.6 million related to stock options and $2.0 million and $2.2 million related to restricted stock, respectively. As of September 30, 2012, total unrecognized compensation expense related to non-vested stock options was $5.0 million, which is expected to be recognized over a weighted-average period of approximately 2.2 years. As of September 30, 2012, total unrecognized compensation expense related to non-vested restricted stock was $2.0 million, which is expected to be recognized over a weighted-average period of approximately 1.0 years. Compensation expense capitalized to inventory and compensation expense related to the Company’s ESPP were not material for the three and nine months ended September 30, 2012 and 2011.

The estimated fair value of each stock option award was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants.

 

9


Table of Contents

Quidel Corporation

Notes to Consolidated Financial Statements

(Unaudited)

Note 9. Stock-Based Compensation (Continued)

 

 

     Nine months
ended
September 30,
 
     2012     2011  

Expected option life (in years)

     5.52        5.22   

Volatility rate

     0.46        0.47   

Risk-free interest rate

     0.83     2.05

Dividend rate

     0     0

The weighted-average grant date fair value of stock options granted during the nine months ended September 30, 2012 and 2011 was $6.51 and $5.73, respectively. The Company granted 621,705 and 519,337 stock options during the nine months ended September 30, 2012 and 2011, respectively. The weighted-average grant date fair value of restricted stock granted during the nine months ended September 30, 2012 and 2011 was $15.49 and $12.86, respectively. The Company granted 135,295 and 207,532 shares of restricted stock during the nine months ended September 30, 2012 and 2011, respectively. The grant date fair value of restricted stock is determined based on the closing market price of the Company’s common stock on the grant date.

Note 10. Industry and Geographic Information

The Company operates in one reportable segment. Sales to customers outside the U.S. represented $15.9 million (16%) and $13.8 million (11%) of total revenue for the nine months ended September 30, 2012 and 2011, respectively. As of September 30, 2012 and December 31, 2011, balances due from foreign customers were $1.7 million and $4.8 million, respectively.

The Company had sales to individual customers in excess of 10% of total revenue, as follows:

 

     Nine months
ended
September 30,
 
     2012     2011  

Customer:

    

A

     16     15

B

     6     12
  

 

 

   

 

 

 
     22     27
  

 

 

   

 

 

 

As of September 30, 2012, accounts receivable from customers with balances due in excess of 10% of total accounts receivable totaled $8.1 million while, at December 31, 2011, accounts receivable from customers with balances due in excess of 10% of total accounts receivable totaled $5.5 million.

Note 11. Commitments and Contingencies

Licensing Arrangements

On September 27, 2011, the Company entered into the Second Amendment (the “Amendment”) to Quidel/Inverness Settlement Agreement dated April 27, 2005 (the “Agreement”), as amended by an addendum dated June 19, 2006, with Alere Inc. (formerly known as Inverness Medical Innovations, Inc.) (“Alere”).

 

10


Table of Contents

Quidel Corporation

Notes to Consolidated Financial Statements

(Unaudited)

Note 11. Commitments and Contingencies (Continued)

 

The Amendment, which was effective as of April 1, 2011, amended certain royalty and other provisions in the Agreement and enabled the Company to “buy-down” and “buy-out” its future royalty obligation under the Agreement for payments totaling $29.5 million. Under the Amendment, the Company made an initial cash payment of $13.8 million to Alere in September 2011 in connection with a buy-down of the Company’s royalty obligations for the period beginning July 1, 2011. In addition, the Company exercised its buy-out right for any remaining future royalty obligation by exercising the Royalty Termination Option (as defined in the Amendment) in January 2012, thereby terminating the Company’s obligation to pay future royalties under the Agreement in exchange for a fixed cash payment in the amount of $15.7 million less $1.0 million of specified third quarter 2011 royalties. This amount was paid in February 2012.

In conjunction with Financial Accountings Standards Board Accounting Standard Update No. 2009-05, Fair Value Measurements and Disclosures (Topic 820), the Company assigned $28.8 million to the licensed technology and $0.7 million as a one-time charge to cost of sales. In determining the fair value allocation between the intangible asset licensed technology and the one-time charge to cost of sales, the Company assessed the past and estimated future revenue streams related to present and future products that use the patents that are subject to the Amendment. The effective life and related amortization of the licensed technology will be based on the higher of the percentage of usage or the straight-line method. This percentage of usage will be determined using the revenues generated from products covered by the patents that are subject to the Amendment. The terms of the Amendment provide for an estimated useful life of 3.5 years for this asset. The Company recorded $1.9 million and $5.7 million of amortization expense included as a portion of cost of sales for the three and nine months ended September 30, 2012, respectively.

In addition to the royalty agreement noted above, the Company has entered into various other licensing agreements, which largely require royalty payments based on specified product sales as well as the achievement of specified milestones. The Company had royalty expenses relating to those agreements of approximately $0.2 million and $0.4 million for the three months ended September 30, 2012 and 2011, respectively, and $0.6 million and $1.5 million for the nine months ended September 30, 2012 and 2011, respectively.

Legal

The Company is involved in various claims and litigation matters from time to time in the ordinary course of business. Management believes that all such current legal actions, in the aggregate, will not have a material adverse effect on the Company. The Company also maintains insurance, including coverage for product liability claims, in amounts which management believes are appropriate given the nature of its business. At September 30, 2012 and December 31, 2011, the Company had $0.8 million accrued as a liability for various legal matters where the Company deemed the liability probable and estimable.

Research and Development Collaboration Agreements

The Company has entered into various collaboration agreements which provide it with rights to develop, manufacture and market products using the intellectual property and technology of its collaborative partners. Under the terms of certain of these agreements, the Company is required to make periodic payments based on achievement of certain milestones. These milestones generally include achievement of prototype assays, validation lots and clinical trials. At September 30, 2012, total future milestone payments which may become due under the terms of these agreements are estimated at $3.9 million in the aggregate. These costs may fluctuate based on estimated development costs and activities and are expected to be paid at various dates through December 2013.

 

11


Table of Contents

Quidel Corporation

Notes to Consolidated Financial Statements

(Unaudited)

Note 11. Commitments and Contingencies (Continued)

 

During the three months ended September 30, 2012, the Company entered into a master collaboration agreement with a third party for the development of molecular diagnostic assays over a five year term. In connection with mutually agreed upon project plans and timelines for each molecular assay, the third party is expected to reimburse the Company a portion of total product development costs. As of September 30, 2012, the Company and the third party have executed project plans for several assays under the master agreement. Reimbursements of development costs are recorded as a reduction to research and development expense and recognized at the lower of cumulative cash received, or to be received, or a proportion of actual costs incurred as a percentage of total costs expected to be incurred for all projects in the agreement. Accordingly, the Company recorded a receivable from the development partner for the first payment in the amount of $2.5 million as a component of prepaid expenses and other current assets as of September 30, 2012, the earned portion of $1.3 million as a reduction to research and development expense for the three months ended September 30, 2012, and the unearned portion of $1.2 million as a component of other current liabilities as of September 30, 2012.

Note 12. Lease Obligation

During 1999, the Company completed a sale and leaseback transaction of its San Diego facility. The facility was sold for $15.0 million, of which $3.8 million was capital contributed by the Company. The sale was an all cash transaction, netting the Company approximately $7.0 million. The Company is a 25% limited partner in the partnership that acquired the facility. The transaction was deemed a financing transaction under the guidance in ASC Topic 840-40, Accounting for Sales of Real Estate. The assets sold remain on the books of the Company and will continue to be depreciated over the estimated useful life. In December 2009, the Company amended the terms of its lease agreement which had no significant impact on the Company’s financial statements. The amended terms include a new ten-year lease term through December 2019, with options to extend the lease for up to three additional five-year periods. The Company will amortize the lease obligation over this new term. The amount of the monthly rental payments remains the same under the amendment. The combined carrying value of the land and building subject to this lease, net of accumulated depreciation, was $2.3 million and $2.4 million as of September 30, 2012 and December 31, 2011, respectively. In addition, the Company has the option to purchase the general partner’s interest in the partnership in January 2015 for a fixed price. The Company has determined that the partnership is a variable interest entity (VIE). The Company is not, however, the primary beneficiary of the VIE as it does not absorb the majority of the partnership’s expected losses or receive a majority of the partnership’s residual returns. The Company made lease payments to the partnership of approximately $0.8 million for each of the nine months ended September 30, 2012 and 2011.

 

12


Table of Contents

Quidel Corporation

Notes to Consolidated Financial Statements

(Unaudited)

 

Note 13. Fair Value Measurement

ASC Topic 820, Fair Value Measurements and Disclosures requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed by the Company in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

As of September 30, 2012 and December 31, 2011, the carrying amount of the Company’s Senior Credit Facility approximates fair value because it has a variable interest rate that reflects market changes to interest rates and changes in the Company’s leverage ratio. As of September 30, 2012 and December 31, 2011, the Company used Level 2 inputs to determine the fair value of its Senior Credit Facility. As of September 30, 2012 and December 31, 2011, the carrying amount of the Company’s cash equivalents approximates fair value. Cash equivalents primarily consisted of funds held in a money market account. As of September 30, 2012 and December 31, 2011, the carrying value of cash equivalents was $10.9 million and $46.9 million, respectively, and was determined based on Level 1 inputs.

 

13


Table of Contents
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

In this quarterly report, all references to “we,” “our” and “us” refer to Quidel Corporation and its subsidiaries.

Future Uncertainties and Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially from those that may be described or implied in the forward-looking statements. As such no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation, seasonality, the timing of onset, length and severity of cold and flu seasons, the level of success in executing on our strategic initiatives, our reliance on sales of our influenza diagnostic tests, uncertainty surrounding the detection of novel influenza viruses involving human specimens, our ability to develop new products and technology, adverse changes in the competitive and economic conditions in domestic and international markets, our reliance on and actions of our major distributors, technological changes and uncertainty with research and technology development, including any future molecular-based technology, the medical reimbursement system currently in place and future changes to that system, manufacturing and production delays or difficulties, adverse regulatory actions or delays in product reviews by the U.S. Food and Drug Administration (the “FDA”), compliance with FDA and environmental regulations, our ability to meet unexpected increases in demand for our products, our ability to execute our growth strategy, including the integration of new companies or technologies, disruptions in the global capital and credit markets, our ability to hire key personnel, intellectual property, product liability, environmental or other litigation, potential required patent license fee payments not currently reflected in our costs, potential inadequacy of booked reserves and possible impairment of goodwill, and lower than anticipated acceptance, sales or market penetration of our new products. Forward-looking statements typically are identified by the use of terms such as “may,” “will,” “should,” “might,” “expect,” “anticipate,” “estimate,” and similar words, although some forward-looking statements are expressed differently. Forward-looking statements in this Quarterly Report include, among others, statements concerning: our outlook for the remainder of 2012, including projections about our revenue, gross profit, expenses, and net earnings; projected capital expenditures for the remainder of 2012 and our source of funds for such expenditures; the sufficiency of our liquidity and capital resources; the future impact of deferred tax assets or liabilities; the expected vesting periods of unrecognized compensation expense; and our intention to maintain our emphasis on research and development, to introduce new products, and to continue to evaluate technology and Company acquisition opportunities and the source of funds for such investments. The risks described under “Risk Factors” in Item 1A of this Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2011, and elsewhere herein and in reports and registration statements that we file with the Securities and Exchange Commission (the “SEC”) from time to time, should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date of this Quarterly Report. The following should be read in conjunction with the audited Consolidated Financial Statements and Notes thereto beginning on page 3 of this Quarterly Report. We undertake no obligation to publicly release the results of any revision or update of these forward-looking statements, except as required by law.

Overview

We have a leadership position in the development, manufacturing and marketing of rapid diagnostic testing solutions. These diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. We sell our products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics and wellness screening centers. We market our products in the U.S. through a network of national and regional distributors, and a direct sales force. Internationally, we sell and market primarily through distributor arrangements.

 

14


Table of Contents

Outlook

We anticipate revenue growth over the next three months as compared to the same three month period in the prior year and a related positive impact on gross profit and net earnings. We will continue our focus on prudently managing our business and delivering solid financial results, while at the same time striving to continue to introduce new products to the market and maintaining our emphasis on research and development investments and commercialization for longer term growth. Finally, we will continue to evaluate opportunities to acquire new product lines and technologies, as well as, company acquisitions.

Results of Operations

Three months ended September 30, 2012 compared to the three months ended September 30, 2011

Total Revenues

The following table compares total revenues for the three months ended September 30, 2012 and 2011 (in thousands, except percentages):

 

     For the three months
ended September 30,
     Increase
(Decrease)
 
     2012      2011      $     %  

Infectious disease net product sales

   $ 21,622       $ 21,996       $ (374     (2 )% 

Women’s health net product sales

     8,741         8,145         596        7

Gastrointestinal disease net product sales

     1,584         1,719         (135     (8 )% 

Other net product sales

     540         689         (149     (22 )% 

Royalty, license fees and grant revenue

     511         559         (48     (9 )% 
  

 

 

    

 

 

    

 

 

   

Total revenues

   $ 32,998       $ 33,108      $ (110     0
  

 

 

    

 

 

    

 

 

   

The increase in women’s health net product sales was driven primarily by an increase in sales from our pregnancy products of $0.4 million. This increase was offset by a decrease in infectious disease product sales driven primarily by a decrease in sales from our flu products of $0.5 million. The revenue from our royalty, license fees and grant revenue category for all periods primarily relates to royalty payments earned on our patented technologies utilized by third parties.

Cost of Sales

Cost of sales was $14.9 million, or 45% of total revenues for the three months ended September 30, 2012, compared to $15.0 million, or 45% of total revenues for the three months ended September 30, 2011. The absolute dollar value of cost of sales was relatively constant for direct and indirect costs for both periods.

Operating Expenses

The following table compares operating expenses for the three months ended September 30, 2012 and 2011 (in thousands, except percentages):

 

     For the three  months
ended September 30,
             
     2012     2011     Increase (Decrease)  
     Operating
expenses
     As a %  of
total
revenues
    Operating
expenses
     As a % of
total
revenues
    $     %  

Research and development

   $ 5,085         15   $ 5,884         18   $ (799     (14 )% 

Sales and marketing

     7,776         24     6,487         20     1,289        20

General and administrative

     4,759         14     5,194         16     (435     (8 )% 

Amortization of intangible assets from acquired businesses and technology

     1,728         5     1,791         5     (63    
 
(4
 

 

15


Table of Contents

Research and Development Expense

Research and development expense for the three months ended September 30, 2012 decreased from $5.9 million to $5.1 million primarily due to a research and development reimbursement of $1.3 million associated with the collaboration agreement described in Note 11 to the consolidated financial statements. Excluding this reimbursement, research and development increased by $0.5 million for costs associated with the development of potential new technologies and with products under development.

Research and development expenses include direct external costs such as fees paid to consultants, and internal direct and indirect costs such as compensation and other expenses for research and development personnel, supplies and materials, clinical trials and studies, facility costs and depreciation.

Due to the risks inherent in the product development process and given the early-stage of development of certain projects, we are unable to estimate with meaningful certainty the costs we will incur in the continued development of our product candidates for commercialization. In addition, we have not historically tracked research and development costs by individual project. However, we expect our research and development costs to be substantial as we move other product candidates into preclinical and clinical trials and advance our existing product candidates into later stages of development.

Sales and Marketing Expense

Sales and marketing expense for the three months ended September 30, 2012 increased from $6.5 million to $7.8 million due to additional investments of $1.3 million in our sales organization including an increase in personnel, travel, training costs, and incentives related to Sofia instrument placements. Other key components of this expense relate to continued investment in assessing future product extensions and enhancements and market research.

General and Administrative Expense

General and administrative expense for the three months ended September 30, 2012 decreased from $5.2 million to $4.8 million primarily due to a decrease in the incentive compensation accrual of $0.2 million for the three months ended September 30, 2012 because of a weak 2011/2012 cold and flu season.

Amortization of Intangible Assets from Acquired Businesses and Technology

Amortization of intangible assets from acquired businesses consists of customer relationships, purchased technology and patents and trademarks acquired in connection with our acquisition of DHI. Amortization of intangible assets from acquired technology consists primarily of expense associated with purchased technology.

Other Income (Expense)

Interest expense primarily relates to interest paid on borrowings under the Senior Credit Facility and interest paid on our lease obligation associated with our San Diego facility. The reduction in the outstanding principle balance under the line of credit from $42.0 million as of September 30, 2011 to $19.0 million as of September 30, 2012 resulted in a reduction to interest expense of $0.2 million.

Income Taxes

As of the three months ended September 30, 2012 and September 30, 2011, our expected annual effective tax rate was 55.7% and 34.0%, respectively. We recognized a tax benefit of $0.9 million and $0.6 million for the three months ended September 30, 2012 and 2011, respectively. The primary difference between the September 30, 2012 and September 30, 2011 effective tax rate is due to the exclusion of the federal research and development tax credit due to the expiration of the statute. In addition, we reduced our reserve for uncertain tax positions resulting from a federal statutory audit.

 

16


Table of Contents

Nine months ended September 30, 2012 compared to the nine months ended September 30, 2011

Total Revenues

The following table compares total revenues for the nine months ended September 30, 2012 and 2011 (in thousands, except percentages):

 

     For the nine months
ended September 30,
     Increase
(Decrease)
 
     2012      2011      $     %  

Infectious disease net product sales

   $ 66,735       $ 84,894       $ (18,159     (21 )% 

Women’s health net product sales

     25,638         24,556         1,082        4

Gastrointestinal disease net product sales

     4,790         5,254         (464     (9 )% 

Other net product sales

     3,266         3,708         (442     (12 )% 

Royalty, license fees and grant revenue

     1,387         1,800         (413     (23 )% 
  

 

 

    

 

 

    

 

 

   

Total revenues

   $ 101,816       $ 120,212       $ (18,396     (15 )% 
  

 

 

    

 

 

    

 

 

   

The decrease in total revenues was largely related to a weak 2011/2012 cold and flu season. This had an adverse impact on our infectious disease products, including influenza, Group A Strep, RSV and DFA respiratory. This was partially offset by stronger sales in our women’s health product line driven by increased sales of our thyroid products of $0.5 million and increased sales from our pregnancy products of $0.4 million. Revenues in other product categories remained relatively constant period over period.

The revenue from our royalty, license fees and grant revenue category for all periods primarily relate to royalty payments earned on our patented technologies utilized by third parties.

Cost of Sales

Cost of sales decreased 8% to $43.7 million, or 43% of total revenues for the nine months ended September 30, 2012, compared to $47.6 million, or 40% of total revenues for the nine months ended September 30, 2011. The absolute dollar decrease in cost of sales is primarily related to the variable nature of direct costs (material and labor) associated with the 15% decrease in total revenues. The increase in cost of sales as a percent of total revenue is primarily due to a shift in product mix as flu volume was lower in the nine months ended September 30, 2012 compared to the nine months ended September 30, 2011 because of a weak 2011/2012 cold and flu season.

Operating Expenses

The following table compares operating expenses for the nine months ended September 30, 2012 and 2011 (in thousands, except percentages):

 

     For the nine  months
ended September 30,
             
     2012     2011     Increase (Decrease)  
     Operating
expenses
     As a %  of
total
revenues
    Operating
expenses
     As a % of
total
revenues
    $     %  

Research and development

   $ 20,433         20   $ 19,559         16   $ 874        4

Sales and marketing

     21,989         22     18,996         16     2,993        16

General and administrative

     15,812         16     17,135         14     (1,323     (8 )% 

Amortization of intangible assets from acquired businesses and technology

     5,165         5     5,342         4     (177     (3 )% 

Research and Development Expense

Research and development expense increased from $19.6 million to $20.4 million for the nine months ended September 30, 2012 primarily due to an overall increase of $2.3 million for costs associated with the development of potential new technologies and with products under development. The increase was partially offset by the research and development reimbursement of $1.3 million associated with the collaboration agreement described in Note 11 to the consolidated financial statements.

Research and development expenses include direct external costs such as fees paid to consultants, and internal direct and indirect costs such as compensation and other expenses for research and development personnel, supplies and materials, clinical trials and studies, facility costs and depreciation.

Due to the risks inherent in the product development process and given the early-stage of development of certain projects, we are unable to estimate with meaningful certainty the costs we will incur in the continued development of our

 

17


Table of Contents

product candidates for commercialization. In addition, we do not currently track research and development costs by individual project. However, we expect our research and development costs to be substantial as we move other product candidates into preclinical and clinical trials and advance our existing product candidates into later stages of development.

Sales and Marketing Expense

Sales and marketing expense increased from $19.0 million to $22.0 million for the nine months ended September 30, 2012 due to increased costs of $3.0 million for additional investments in our sales organization, including an increase in personnel and corresponding travel and training costs. Other key components of this expense relate to continued investment in assessing future product extensions and enhancements and market research.

General and Administrative Expense

General and administrative costs decreased from $17.1 million to $15.8 million for the nine months ended September 30, 2012 primarily due to a decrease in the incentive compensation accrual of $0.9 million because of a weak 2011/2012 cold and flu season.

Amortization of Intangible Assets from Acquired Businesses and Technology

Amortization of intangible assets from acquired businesses consists of customer relationships, purchased technology and patents and trademarks acquired in connection with the acquisition of DHI. Amortization of intangible assets from acquired technology consists primarily of expense associated with purchased technology.

Other Income (Expense)

Interest expense primarily relates to interest paid on borrowings under the Senior Credit Facility and interest paid on our lease obligation associated with our San Diego facility. The reduction in the outstanding principle balance under the line of credit from $42.0 million as of September 30, 2011 to $19.0 million as of September 30, 2012 resulted in a reduction to interest expense of $0.7 million.

Income Taxes

The effective tax rate for the nine months ended September 30, 2012 and 2011 was 40.0% and 34.0%, respectively. We recognized a tax benefit of $2.5 million and a tax expense of $3.4 million for the nine months ended September 30, 2012 and 2011, respectively. The primary difference between the September 30, 2012 and September 30, 2011 effective tax rate is due to the exclusion of the federal research and development tax credit due to the expiration of the statute. In addition, we reduced our reserve for uncertain tax positions resulting from a federal statutory audit.

Liquidity and Capital Resources

As of September 30, 2012, our principal sources of liquidity consisted of $17.8 million in cash and cash equivalents, and $60.0 million available to us under our Senior Credit Facility, which can fluctuate from time to time due to, among other factors, our funded debt to adjusted earnings before interest, taxes, depreciation, amortization and stock compensation (“adjusted EBITDA”) ratio. Our working capital as of September 30, 2012 was $53.7 million.

Cash provided by operating activities was $5.9 million during the nine months ended September 30, 2012. We had a net loss of $3.7 million, including non-cash charges of $21.5 million of depreciation and amortization of intangible assets and property and equipment, and stock-based compensation. Other significant changes in operating assets and liabilities include an increase in deferred tax assets net of liabilities of $2.4 million, accounts receivable of $2.5 million, and inventory of $2.1 million all of which are related to the seasonal nature of our business. Prepaid expenses and other current assets increased by $2.6 million primarily due to a $2.5 million receivable as described in Note 11 to the consolidated financial statements. Cash provided by operating activities was $34.3 million during the nine months ended September 30, 2011. We had net earnings of $6.7 million, including non-cash charges of $17.9 million of depreciation and amortization of intangible assets and property and equipment, and stock-based compensation. The most significant changes in operating assets and liabilities included an increase in accounts receivable of $3.8 million and decreases in inventories and income tax receivable of $2.9 million and $8.3 million, respectively. The increase in accounts receivable and the decrease in inventory are related to the seasonal nature of our business, while the decrease in income tax receivable is due to a tax refund received during the nine months ended September 30, 2011.

 

18


Table of Contents

Our investing activities used $23.1 million during the nine months ended September 30, 2012 primarily related to the acquisition of intangibles associated with our exercise of a buyout clause under the Alere Amendment. During the nine months ended September 30, 2012, we exercised the buy-out right under the Alere Amendment, which allowed us to buy-out any remaining future royalty obligation for a fixed cash payment in the amount of $15.7 million less $1.0 million of specified third quarter 2011 royalties. In addition, we used cash for investing activities associated with the acquisition of production and scientific equipment, and building improvements during the nine months ended September 30, 2012. Our investing activities used $17.5 million during the nine months ended September 30, 2011 primarily related to the acquisition of licensed technology associated with the Alere Amendment as discussed in Note 11 to the Consolidated Financial Statements. In addition, we acquired production and scientific equipment, and building improvements during the nine months ended September 30, 2011.

We are planning approximately $5.5 million in capital expenditures for the remainder of 2012. The primary purpose for our capital expenditures is to acquire manufacturing and scientific equipment, implement facility improvements, the purchase or development of information technology and leased instruments under customer rental agreements. We plan to fund these capital expenditures with cash flow from operations and other available sources of liquidity. We have $4.1 million in firm purchase commitments with respect to such planned capital expenditures as of the date of filing this report.

Cash used for financing activities of $26.2 million during the nine months ended September 30, 2012 was primarily related to repayments under our Senior Credit Facility of $23.0 million, and repurchases of 200,400 shares of our common stock under our share repurchase program at a cost of approximately $2.9 million. Our financing activities generated $27.5 million of cash during the nine months ended September 30, 2011. This was primarily related to proceeds from the sale of our common stock, partly offset by repayments made under the line of credit, both of which occurred during the first quarter of 2011.

On August 10, 2012, we entered into an amended and restated $140.0 million senior secured syndicated credit facility (the “Senior Credit Facility”), which matures on August 10, 2017. The Senior Credit Facility amends and restates our $120.0 million senior secured credit facility dated October 8, 2008. As part of this amendment, we incurred $1.0 million in deferred financing costs related to the Senior Credit Facility in addition to the $0.6 million we had previously recorded related to the original credit facility. As of September 30, 2012, we had $1.6 million included as a portion of other non-current assets. The Senior Credit Facility bears interest at either LIBOR or the base rate plus in each case the applicable margin. The base rate is equal to the higher of (i) the lender’s prime rate, (ii) the federal funds rate plus one-half of one percent and (iii) LIBOR plus one percent. The applicable rate is generally determined in accordance with a performance pricing grid based on our leverage ratio and ranges from 1.25% to 2.50% for LIBOR rate loans and from 0.25% to 1.50% for base rate loans (weighted average interest rate of 1.72% at September 30, 2012). The agreement governing the Senior Credit Facility is subject to certain customary limitations, including among others: limitation on liens; limitation on mergers, consolidations and sales of assets; limitation on debt; limitation on dividends, stock redemptions and the redemption and/or prepayment of other debt; limitation on investments (including loans and advances) and acquisitions; limitation on transactions with affiliates; and limitation on disposition of assets. We are also subject to financial covenants which include a funded debt to adjusted EBITDA ratio (as defined in the Senior Credit Facility, with adjusted EBITDA generally calculated as earnings before, among other adjustments, interest, taxes, depreciation, amortization, and stock-based compensation) not to exceed 3:1 as of the end of each fiscal quarter, and an interest coverage ratio of not less than 3:1 as of the end of each fiscal quarter. The Senior Credit Facility is secured by substantially all of our present and future assets and properties. As of September 30, 2012, we had $60.0 million available under the Senior Credit Facility. Our ability to borrow under the Senior Credit Facility fluctuates from time to time due to, among other factors, our borrowings under the facility and its funded debt to adjusted EBITDA ratio. As of September 30, 2012, we had $19.0 million outstanding under the Senior Credit Facility. As of September 30, 2012, we were in compliance with all financial covenants.

Our cash requirements fluctuate as a result of numerous factors, such as the extent to which we generate cash from operations, progress in research and development projects, competition and technological developments and the time and expenditures required to obtain governmental approval of our products. In addition, we intend to continue to evaluate candidates for acquisitions or technology licensing. If we determine to proceed with any such transactions, we may need to incur additional debt, or issue additional equity, to successfully complete the transactions. Based on our current cash position and our current assessment of future operating results, we believe that our existing sources of liquidity will be adequate to meet our operating needs during the next 12 months.

 

19


Table of Contents

Off-Balance Sheet Arrangements

At September 30, 2012, we did not have any relationships or other arrangements with unconsolidated entities or financial partners, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.

New Accounting Standards

In September 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2011-08, Intangibles—Goodwill and Other (Topic 350): Testing Goodwill for Impairment, (“ASU 2011-08”), to allow entities to use a qualitative approach to test goodwill for impairment. ASU 2011-08 permits an entity to first perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If it is concluded that this is the case, it is necessary to perform the currently prescribed two-step goodwill impairment test. Otherwise, the two-step goodwill impairment test is not required. The provisions of this ASU were effective for us for fiscal years and interim periods beginning after December 31, 2011, and the adoption did not have an impact on our consolidated financial statements.

In July 2012, the FASB issued Accounting Standards Update No. 2012-02, Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment, (“ASU 2012-02”), to simplify the testing for a drop in value of intangible assets such as trademarks, patents, and distribution rights. The amended standard reduces the cost of accounting for indefinite-lived intangible assets, especially in cases where the likelihood of impairment is low. The changes permit businesses and other organizations to first use subjective criteria to determine if an intangible asset has lost value. The amendments to U.S. GAAP will be effective for fiscal years starting after September 15, 2012. Early adoption is permitted. We are currently evaluating the impact of our pending adoption of ASU 2012-02 on our consolidated financial statements.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to customer programs and incentives, bad debts, inventories, intangible assets, income taxes, stock-based compensation, restructuring and contingencies and litigation. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

A comprehensive discussion of our critical accounting policies and management estimates is included in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2011.

During the quarter ended September 30, 2012, we entered into a collaborative arrangement with a third party. ASC topic 808, Collaborative Arrangements, defines a collaborative arrangement as an arrangement where the parties are active participants and have exposure to significant risks. We are accounting for the joint development and commercialization activities with the third party as a joint risk sharing collaboration in accordance with ASC topic 808, Collaborative Arrangements. Payments from the third party are recorded as a reduction to research and development expense in the accompanying consolidated financial statements due to the nature of the activities.

Determining the fair values and useful lives of the intangible assets acquired in connection with the Alere Amendment described in Note 11 requires the exercise of judgment. While there are a number of different generally accepted valuation methods to estimate the value of intangible assets, we used the discounted cash flow method in determining the value of licensed technology associated with the Alere Amendment. This method required significant management judgment to forecast the future operating results used in the analysis. In addition, other significant estimates were required such as residual growth rates and discount factors. The estimates we used to value and amortize intangible assets were consistent with the plans and estimates that we use to manage our business and were based on available historical information and industry estimates and averages. These judgments can significantly affect our net operating results.

 

20


Table of Contents
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk

The fair market value of our floating interest rate debt is subject to interest rate risk. Generally, the fair market value of floating interest rate debt will vary as interest rates increase or decrease. We had $19.0 million outstanding under our Senior Credit Facility at September 30, 2012. The weighted average interest rate on these borrowings is currently 1.72%. A hypothetical 100 basis point adverse move in interest rates along the entire interest rate yield curve would increase our annual interest expense by approximately $0.2 million. Based on our market risk sensitive instruments outstanding at September 30, 2012, we have determined that there was no material market risk exposure from such instruments to our consolidated financial position, results of operations or cash flows as of such date.

Our current investment policy with respect to our cash and cash equivalents focuses on maintaining acceptable levels of interest rate risk and liquidity. Although we continually evaluate our placement of investments, as of September 30, 2012, our cash and cash equivalents were placed in money market or overnight funds that we believe are highly liquid and not subject to material market fluctuation risk.

Foreign Currency Exchange Risk

The majority of our international sales are negotiated for and paid in U.S. dollars. Nonetheless, these sales are subject to currency risks, since changes in the values of foreign currencies relative to the value of the U.S. dollar can render our products comparatively more expensive. These exchange rate fluctuations could negatively impact international sales of our products, as could changes in the general economic conditions in those markets. Continued change in the values of the Euro, the Japanese Yen and other foreign currencies could have a negative impact on our business, financial condition and results of operations. We do not currently hedge against exchange rate fluctuations, which means that we are fully exposed to exchange rate changes. In addition, we have a supply agreement with a foreign vendor whereby we evenly share the foreign currency exchange fluctuation risk. We may, in the future, enter into similar such arrangements.

 

ITEM 4. Controls and Procedures

Evaluation of disclosure controls and procedures: We have performed an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”). Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of September 30, 2012 to provide reasonable assurance that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in internal control over financial reporting: There was no change in our internal control over financial reporting during the quarter ended September 30, 2012 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

21


Table of Contents

PART II OTHER INFORMATION

 

ITEM 1. Legal Proceedings

We are involved in various claims and litigation matters from time to time in the ordinary course of business. We believe that all such current legal actions, in the aggregate, will not have a material adverse effect on the company. We also maintain insurance, including coverage for product liability claims, in amounts which we believe are appropriate given the nature of the business.

 

ITEM 1A. Risk Factors

There has been no material change in our risk factors as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011. For a detailed description of our risk factors, refer to Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2011.

 

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

The table below sets forth information regarding repurchases of our common stock by us during the three months ended September 30, 2012:

 

Period

   Total number
of shares
purchased(1)
     Average
price paid
per share
     Total number
of shares purchased
as part of publicly
announced plans
or programs
     Approximate dollar
value of shares that
may yet  be
purchased
under the plans or
programs
 

July

     —         $ —           —         $ 22,081,000   

August

     —           —           —           22,081,000   

September

     —           —           —           22,081,000   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     —         $ —           —         $ 22,081,000   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(1) On November 28, 2011, we announced that our Board of Directors authorized us to repurchase up to an aggregate of $25.0 million in shares of our common stock under our stock repurchase program. Any shares of common stock repurchased under this program will no longer be deemed outstanding upon repurchase and will be returned to the pool of authorized shares. This repurchase program will expire on November 8, 2013 unless extended by our Board of Directors.

 

ITEM 3. Defaults Upon Senior Securities

None.

 

ITEM 4. Mine Safety Disclosures

Not applicable.

 

ITEM 5. Other Information

None.

 

22


Table of Contents
ITEM 6. Exhibits

 

Exhibit
Number

    
    3.1    Restated Certificate of Incorporation of Quidel Corporation. (Incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q filed on October 29, 2010.)
    3.2    Amended and Restated Bylaws of Quidel Corporation. (Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on November 8, 2000.)
    4.1    Certificate of Designations of Series C Junior Participating Preferred Stock. (Incorporated by reference to Exhibit 4.1 to the Registrant’s Quarterly Report on Form 10-Q filed on October 29, 2010.)
  10.1    Amended and Restated Credit Agreement. (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed August 15, 2012)
  10.2    Amended and Restated Security Agreement. (Incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed August 15, 2012)
  31.1*    Certification by Principal Executive Officer of Registrant pursuant to Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  31.2*    Certification by Principal Financial and Accounting Officer of Registrant pursuant to Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  32.1*    Certifications by Principal Executive Officer and Principal Financial and Accounting Officer of Registrant pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101**    XBRL Instance Document
101**    XBRL Taxonomy Extension Schema Document
101**    XBRL Taxonomy Calculation Linkbase Document
101**    XBRL Taxonomy Label Linkbase Document
101**    XBRL Taxonomy Presentation Linkbase Document

 

* Filed herewith.
** Pursuant to applicable securities laws and regulations, we are deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and are not subject to liability under any anti-fraud provisions of the federal securities laws as long as we have made a good faith attempt to comply with the submission requirements and promptly amend the interactive data files after becoming aware that the interactive data files fail to comply with the submission requirements. Users of this data are advised that, pursuant to Rule 406T, these interactive data files are deemed not filed and otherwise are not subject to liability.

 

23


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: October 26, 2012       QUIDEL CORPORATION
     

/s/ DOUGLAS C. BRYANT

      Douglas C. Bryant
     

President and Chief Executive Officer

(Principal Executive Officer)

     

/s/ RANDALL J. STEWARD

      Randall J. Steward
     

Chief Financial Officer

(Principal Financial Officer and Accounting Officer)

 

24


Table of Contents

Exhibit Index

 

Exhibit
Number

    
    3.1    Restated Certificate of Incorporation of Quidel Corporation. (Incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q filed on October 29, 2010.)
    3.2    Amended and Restated Bylaws of Quidel Corporation. (Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on November 8, 2000.)
    4.1    Certificate of Designations of Series C Junior Participating Preferred Stock. (Incorporated by reference to Exhibit 4.1 to the Registrant’s Quarterly Report on Form 10-Q filed on October 29, 2010.)
  10.1    Amended and Restated Credit Agreement. (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed August 15, 2012)
  10.2    Amended and Restated Security Agreement. (Incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed August 15, 2012)
  31.1*    Certification by Principal Executive Officer of Registrant pursuant to Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  31.2*    Certification by Principal Financial and Accounting Officer of Registrant pursuant to Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  32.1*    Certifications by Principal Executive Officer and Principal Financial and Accounting Officer of Registrant pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101**    XBRL Instance Document
101**    XBRL Taxonomy Extension Schema Document
101**    XBRL Taxonomy Calculation Linkbase Document
101**    XBRL Taxonomy Label Linkbase Document
101**    XBRL Taxonomy Presentation Linkbase Document

 

* Filed herewith.
** Pursuant to applicable securities laws and regulations, we are deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and are not subject to liability under any anti-fraud provisions of the federal securities laws as long as we have made a good faith attempt to comply with the submission requirements and promptly amend the interactive data files after becoming aware that the interactive data files fail to comply with the submission requirements. Users of this data are advised that, pursuant to Rule 406T, these interactive data files are deemed not filed and otherwise are not subject to liability.

 

25

EX-31.1 2 d398839dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Douglas C. Bryant, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Quidel Corporation;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 26, 2012

 

/s/ DOUGLAS C. BRYANT

Douglas C. Bryant

President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 d398839dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Randall J. Steward, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Quidel Corporation;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 26, 2012

 

/s/ RANDALL J. STEWARD

Randall J. Steward

Chief Financial Officer

(Principal Financial Officer and Accounting Officer)

EX-32.1 4 d398839dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

Certifications by the Principal Executive Officer and Principal Financial and Accounting Officer of Registrant

pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Each of the undersigned hereby certifies, in his capacity as an officer of Quidel Corporation, a Delaware corporation (the “Company”), for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

 

   

the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2012 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

   

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: October 26, 2012

 

/s/ DOUGLAS C. BRYANT

Douglas C. Bryant

President and Chief Executive Officer

(Principal Executive Officer)

/s/ RANDALL J. STEWARD

Randall J. Steward

Chief Financial Officer

(Principal Financial Officer and Accounting Officer)

EX-101.INS 5 qdel-20120930.xml XBRL INSTANCE DOCUMENT 0000353569 2011-03-31 0000353569 qdel:ClaimsAndLitigationMember 2012-09-30 0000353569 qdel:ClaimsAndLitigationMember 2011-12-31 0000353569 us-gaap:LineOfCreditMember 2012-09-30 0000353569 qdel:SeniorSecuredCreditFacilityMember 2012-09-30 0000353569 2012-08-10 0000353569 us-gaap:PatentedTechnologyMember 2012-09-30 0000353569 qdel:CustomerTwoMember 2012-01-01 2012-09-30 0000353569 qdel:CustomerOneMember 2012-01-01 2012-09-30 0000353569 qdel:CustomerTwoMember 2011-01-01 2011-09-30 0000353569 qdel:CustomerOneMember 2011-01-01 2011-09-30 0000353569 qdel:NonUsCustomersMember 2012-01-01 2012-09-30 0000353569 qdel:NonUsCustomersMember 2011-01-01 2011-09-30 0000353569 us-gaap:StockOptionsMember 2012-09-30 0000353569 us-gaap:RestrictedStockMember 2012-09-30 0000353569 qdel:SeniorCreditFacilityMember us-gaap:ScenarioPreviouslyReportedMember 2012-09-30 0000353569 qdel:SeniorCreditFacilityMember 2012-09-30 0000353569 us-gaap:MinimumMember qdel:LondonInterbankOfferRateLoansMember 2012-09-30 0000353569 us-gaap:MaximumMember qdel:LondonInterbankOfferRateLoansMember 2012-09-30 0000353569 qdel:BaseRateLoansMember us-gaap:MinimumMember 2012-09-30 0000353569 qdel:BaseRateLoansMember us-gaap:MaximumMember 2012-09-30 0000353569 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2012-09-30 0000353569 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2011-12-31 0000353569 2011-09-30 0000353569 2010-12-31 0000353569 us-gaap:StockOptionsMember 2012-07-01 2012-09-30 0000353569 us-gaap:SellingAndMarketingExpenseMember 2012-07-01 2012-09-30 0000353569 us-gaap:RestrictedStockMember 2012-07-01 2012-09-30 0000353569 us-gaap:ResearchAndDevelopmentExpenseMember 2012-07-01 2012-09-30 0000353569 us-gaap:GeneralAndAdministrativeExpenseMember 2012-07-01 2012-09-30 0000353569 us-gaap:CostOfSalesMember 2012-07-01 2012-09-30 0000353569 us-gaap:StockOptionsMember 2012-01-01 2012-09-30 0000353569 us-gaap:SellingAndMarketingExpenseMember 2012-01-01 2012-09-30 0000353569 us-gaap:RestrictedStockMember 2012-01-01 2012-09-30 0000353569 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-09-30 0000353569 us-gaap:GeneralAndAdministrativeExpenseMember 2012-01-01 2012-09-30 0000353569 us-gaap:CostOfSalesMember 2012-01-01 2012-09-30 0000353569 us-gaap:StockOptionsMember 2011-07-01 2011-09-30 0000353569 us-gaap:SellingAndMarketingExpenseMember 2011-07-01 2011-09-30 0000353569 us-gaap:RestrictedStockMember 2011-07-01 2011-09-30 0000353569 us-gaap:ResearchAndDevelopmentExpenseMember 2011-07-01 2011-09-30 0000353569 us-gaap:GeneralAndAdministrativeExpenseMember 2011-07-01 2011-09-30 0000353569 us-gaap:CostOfSalesMember 2011-07-01 2011-09-30 0000353569 us-gaap:StockOptionsMember 2011-01-01 2011-09-30 0000353569 us-gaap:SellingAndMarketingExpenseMember 2011-01-01 2011-09-30 0000353569 us-gaap:RestrictedStockMember 2011-01-01 2011-09-30 0000353569 us-gaap:ResearchAndDevelopmentExpenseMember 2011-01-01 2011-09-30 0000353569 us-gaap:GeneralAndAdministrativeExpenseMember 2011-01-01 2011-09-30 0000353569 us-gaap:CostOfSalesMember 2011-01-01 2011-09-30 0000353569 qdel:NonUsCustomersMember 2012-09-30 0000353569 qdel:NonUsCustomersMember 2011-12-31 0000353569 2011-01-01 2011-09-30 0000353569 qdel:ResearchAndDevelopmentCollaborationAgreementsMember 2012-09-30 0000353569 2012-07-01 2012-09-30 0000353569 2011-07-01 2011-09-30 0000353569 qdel:SanDiegoFacilityMember 2012-01-01 2012-09-30 0000353569 2012-09-30 0000353569 2011-12-31 0000353569 2012-10-24 0000353569 2012-01-01 2012-09-30 qdel:Segment iso4217:USD xbrli:shares qdel:Lease xbrli:pure xbrli:shares iso4217:USD <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 1 - us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock--> <!-- xbrl,ns --> <!-- xbrl,nx --> <font style="font-family:times new roman" size="2"><b></b></font> <font style="font-family:times new roman" size="2"> <b></b></font> <font style="font-family:times new roman" size="2"><b></b></font> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Note&#160;1. Basis of Presentation </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The accompanying unaudited consolidated financial statements of Quidel Corporation and its subsidiaries (the &#8220;Company&#8221;) have been prepared in accordance with generally accepted accounting principles in the U.S. for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation&#160;S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"> Certain reclassifications have been made to prior year amounts to conform to the current year presentation. The Company reclassified patent and trademark expenses of $0.3 million and $0.8 million from research and development expense to general and administrative expense on the Consolidated Statements of Operations for the three and nine months ended September&#160;30, 2011, respectively. The Company reclassified stock-based compensation expense of $0.6 million from accrued payroll and related expenses to stock-based compensation expense on the Consolidated Statements of Cash Flows for the nine months ended September&#160;30, 2011. For the nine months ended September&#160;30, 2011, the Company reclassified a reduction of other non-current assets of $0.5 million from cash provided by financing activities and from cash provided by operating activities to non-cash financing activities on the Consolidated Statements of Cash flows. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The information at September&#160;30, 2012, and for the three and nine months ended September&#160;30, 2012 and 2011, is unaudited. Operating results for the three and nine months ended September&#160;30, 2012 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2012. For further information, refer to the Company&#8217;s consolidated financial statements and footnotes thereto for the year ended December&#160;31, 2011 included in the Company&#8217;s 2011 Annual Report on Form&#160;10-K. Subsequent events have been evaluated up to and including the date these financial statements were issued. In the opinion of management, all adjustments considered necessary for a fair presentation (consisting of normal recurring accruals) have been included. Operating results for any quarter are historically seasonal in nature and are not necessarily indicative of the results expected for the full year. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">For 2012 and 2011, the Company&#8217;s fiscal year will or has ended on December&#160;30, 2012 and January&#160;1, 2012, respectively. For 2012 and 2011, the Company&#8217;s third quarter ended on September&#160;30, 2012 and October&#160;2, 2011, respectively. For ease of reference, the calendar quarter end dates are used herein. The three and nine month periods ended&#160;September 30, 2012 and 2011 both included 13 and 39 weeks, respectively. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 2 - us-gaap:ComprehensiveIncomeNoteTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Note&#160;2. Comprehensive (loss) income </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Net (loss) income is equal to comprehensive (loss) income for the three and nine months ended September&#160;30, 2012 and 2011. During the first quarter ended March&#160;31, 2012, the Company adopted Accounting Standards Update No.&#160;2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 3 - us-gaap:EarningsPerShareTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Note&#160;3. Computation of Earnings Per Share </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Diluted net income per share is reported based on the more dilutive of the treasury stock or the two-class method. Under the two-class method, net income is allocated to common stock and participating securities. The Company&#8217;s unvested restricted stock awards and certain unvested restricted stock units meet the definition of participating securities. Basic net income per share under the two-class method is computed by dividing net income adjusted for earnings allocated to unvested stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share under the two-class method is computed by dividing net income adjusted for earnings allocated to unvested stockholders for the period by the weighted average number of common and common equivalent shares outstanding during the period. The Company excludes stock options from the calculation of diluted net income per share when the combined exercise price, unrecognized stock-based compensation and assumed tax benefits upon exercise are greater than the average market price for the Company&#8217;s common stock because their effect is anti-dilutive. For the nine months ended September&#160;30, 2011, 1.9&#160;million shares were excluded from the calculation of diluted earnings per share (&#8220;EPS&#8221;) as their effect was anti-dilutive. </font></p> <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p> <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2">For the three and nine months ended September&#160;30, 2012 and the three months ended September&#160;30, 2011 there were no differences between the number of common shares used for the basic and diluted EPS computations as they were periods in which the Company incurred a net loss. Due to the fact that the holders of participating securities are not contractually required to share in the Company&#8217;s losses, in applying the two-class method to compute basic net loss per common share, no allocation to participating securities was made for periods in which the Company incurred a net loss. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The following table sets forth the computation of basic and diluted EPS for the nine months ended September&#160;30, 2011 (in thousands, except per share amounts): </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="68%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="88%">&#160;</td> <td valign="bottom" width="7%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Basic net income per share:</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net income</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,675</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Less: income allocated to participating securities</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(61</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net income allocated to common stockholders</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,614</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average common shares outstanding &#8212; basic</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">32,833</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net income per share &#8212; basic</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.20</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Diluted net income per share:</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net income</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,675</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Less: income allocated to participating securities</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(60</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net income allocated to common stockholders</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,615</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average common shares outstanding &#8212; basic</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">32,833</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Dilutive securities</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">356</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average common shares outstanding &#8212; diluted</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">33,189</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net income per share &#8212; diluted</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.20</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 4 - us-gaap:InventoryDisclosureTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Note&#160;4. Inventories </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Inventories are recorded at the lower of cost (first-in, first-out) or market and consist of the following (in thousands): </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="72%">&#160;</td> <td valign="bottom" width="8%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="8%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>September&#160;30,<br />2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>December&#160;31,<br />2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Raw materials</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,554</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,239</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Work-in-process (materials, labor and overhead)</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,708</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,632</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Finished goods (materials, labor and overhead)</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,647</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,783</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">16,909</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">14,654</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 5 - qdel:OtherCurrentLiabilitiesTextBlock--> <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Note 5. Other Current Liabilities </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Other current liabilities consist of the following (in thousands): </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="72%">&#160;</td> <td valign="bottom" width="9%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="9%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>September&#160;30,<br />2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>December&#160;31,<br />2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accrued liability for technology licenses</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">530</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">863</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Customer incentives</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,400</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,352</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accrued interest &#8211; income taxes</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">607</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">491</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Customer prepayments</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">48</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">202</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Current portion of note payable to state agency</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,498</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Unearned research and development collaboration funds received</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,222</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Other</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">953</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,720</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,760</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,126</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 6 - us-gaap:IncomeTaxDisclosureTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Note&#160;6. Income Taxes </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company&#8217;s effective tax rate for the nine months ended September&#160;30, 2012 and 2011 was 40.0% and 34.0%, respectively. The Company recognized an income tax benefit of $2.5 million and an income tax expense of $3.4 million for the nine months ended September&#160;30, 2012 and 2011, respectively. The primary difference between the September&#160;30, 2012 and September&#160;30, 2011 effective tax rate is due to the exclusion of the federal research and development tax credit due to the expiration of the statute. In addition, the Company reduced the reserve for uncertain tax positions resulting from a federal statutory audit. During the quarter ended September&#160;30, 2012, the Company was notified by the Internal Revenue Service that it is examining the Company&#8217;s federal tax returns for the years ended 2007 through 2010. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company is subject to periodic audits by domestic and foreign tax authorities. The Company&#8217;s federal tax years for 1995 and forward are subject to examination by the U.S. authorities due to the carry forward of unutilized net operating losses and research and development credits. With few exceptions, the Company&#8217;s tax years for 1999 and forward are subject to examination by state and foreign tax authorities. The Company believes that it has appropriate support for the income tax positions taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors, including past experience and interpretations of tax law applied to the facts of each matter. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 7 - us-gaap:DebtDisclosureTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Note&#160;7. Line of Credit </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On August&#160;10, 2012, the Company entered into an amended and restated $140.0&#160;million senior secured syndicated credit facility (the &#8220;Senior Credit Facility&#8221;), which matures on August&#160;10, 2017. The Senior Credit Facility amends and restates the Company&#8217;s $120.0 million senior secured credit facility dated October&#160;8, 2008. As part of this amendment, the Company incurred $1.0 million in deferred financing costs related to the Senior Credit Facility in addition to the $0.6 million it had previously recorded related to the original credit facility. As of September&#160;30, 2012, the Company had $1.6 million included as a portion of other non-current assets. The Senior Credit Facility bears interest at either LIBOR or the base rate plus in each case the applicable margin. The base rate is equal to the higher of (i)&#160;the lender&#8217;s prime rate, (ii)&#160;the federal funds rate plus one-half of one percent and (iii)&#160;LIBOR plus one percent.&#160;The applicable rate is generally determined in accordance with a performance pricing grid based on the Company&#8217;s leverage ratio and ranges from 1.25% to 2.50% for LIBOR rate loans and from 0.25% to 1.50% for base rate loans (weighted average interest rate of 1.72% at September&#160;30, 2012). The agreement governing the Senior Credit Facility is subject to certain customary limitations, including among others: limitation on liens; limitation on mergers, consolidations and sales of assets; limitation on debt; limitation on dividends, stock redemptions and the redemption and/or prepayment of other debt; limitation on investments (including loans and advances) and acquisitions; limitation on transactions with affiliates; and limitation on disposition of assets. The Company is also subject to financial covenants which include a funded debt to adjusted EBITDA ratio (as defined in the Senior Credit Facility, with adjusted EBITDA generally calculated as earnings before, among other adjustments, interest, taxes, depreciation, amortization, and stock-based compensation) not to exceed 3:1 as of the end of each fiscal quarter, and an interest coverage ratio of not less than 3:1 as of the end of each fiscal quarter. The Senior Credit Facility is secured by substantially all present and future assets and properties of the Company. </font></p> <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p> <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2">As of September&#160;30, 2012, the Company had $60.0 million available under the Senior Credit Facility. The Company&#8217;s ability to borrow under the Senior Credit Facility fluctuates from time to time due to, among other factors, the Company&#8217;s borrowings under the facility and its funded debt to adjusted EBITDA ratio. As of September&#160;30, 2012, the Company had $19.0 million outstanding under the Senior Credit Facility. As of September&#160;30, 2012, the Company was in compliance with all financial covenants. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 8 - us-gaap:StockholdersEquityNoteDisclosureTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Note&#160;8. Stockholders&#8217; Equity </b></font></p> <p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2">During the nine months ended September&#160;30, 2012, 135,295 shares of restricted stock were awarded, 17,165 shares of restricted stock were cancelled, 197,109 shares of common stock were issued due to the exercise of stock options and 44,290 shares of common stock were issued in connection with the Company&#8217;s employee stock purchase plan (the &#8220;ESPP&#8221;), resulting in net proceeds to the Company of approximately $3.0 million (excludes $0.6 million included in prepaid expenses and other current assets as of September 30, 2012). Additionally, during the nine months ended September&#160;30, 2012, 231,704 shares of outstanding common stock were repurchased for approximately $3.4&#160;million, which primarily included shares repurchased under the Company&#8217;s previously announced share repurchase program, but also included 31,304 shares repurchased in connection with payment of minimum tax withholding obligations for certain employees relating to the lapse of restrictions on certain restricted stock awards during the nine months ended September&#160;30, 2012. There was approximately $22.1 million remaining under the Company&#8217;s share repurchase program as of September&#160;30, 2012. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 9 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Note&#160;9. Stock-Based Compensation </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The compensation expense related to the Company&#8217;s stock-based compensation plans included in the accompanying Consolidated Statements of Operations for the three and nine months ended September&#160;30, 2012 and 2011 was as follows (in millions): </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="80%">&#160;</td> <td valign="bottom" width="3%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="3%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="3%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="3%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Three&#160;months<br />ended<br />September&#160;30,</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Nine months<br />ended<br />September 30,</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Cost of sales</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.2</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.1</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.4</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.5</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Research and development</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.2</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.3</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.8</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.8</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Sales and marketing</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.2</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.2</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.4</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.3</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">General and administrative</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.8</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.0</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3.4</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4.2</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.4</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.6</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.0</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.8</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Total compensation expense recognized for the three months ended September&#160;30, 2012 and 2011 includes $0.9 million and $1.0&#160;million related to stock options and $0.5&#160;million and $0.6&#160;million related to restricted stock, respectively. Total compensation expense recognized for the nine months ended September&#160;30, 2012 and 2011 includes $3.0&#160;million and $3.6&#160;million related to stock options and $2.0&#160;million and $2.2&#160;million related to restricted stock, respectively. As of September&#160;30, 2012, total unrecognized compensation expense related to non-vested stock options was $5.0&#160;million, which is expected to be recognized over a weighted-average period of approximately 2.2&#160;years. As of September&#160;30, 2012, total unrecognized compensation expense related to non-vested restricted stock was $2.0 million, which is expected to be recognized over a weighted-average period of approximately 1.0 years. Compensation expense capitalized to inventory and compensation expense related to the Company&#8217;s ESPP were not material for the three and nine months ended September&#160;30, 2012 and 2011. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The estimated fair value of each stock option award was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants. </font></p> <p style="font-size:1px;margin-top:24px;margin-bottom:0px">&#160;</p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="86%">&#160;</td> <td valign="bottom" width="5%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="5%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Nine months<br />ended<br />September&#160;30,</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected option life (in years)</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.52</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.22</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Volatility rate</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.46</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.47</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Risk-free interest rate</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.83</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2.05</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Dividend rate</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> </tr> <!-- End Table Body --> </table> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The weighted-average grant date fair value of stock options granted during the nine months ended September&#160;30, 2012 and 2011 was $6.51 and $5.73, respectively. The Company granted 621,705 and 519,337 stock options during the nine months ended September&#160;30, 2012 and 2011, respectively. The weighted-average grant date fair value of restricted stock granted during the nine months ended September&#160;30, 2012 and 2011 was $15.49 and $12.86, respectively. The Company granted 135,295 and 207,532 shares of restricted stock during the nine months ended September&#160;30, 2012 and 2011, respectively. The grant date fair value of restricted stock is determined based on the closing market price of the Company&#8217;s common stock on the grant date. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 10 - qdel:IndustryAndGeographicInformationTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Note&#160;10. Industry and Geographic Information </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company operates in one reportable segment. Sales to customers outside the U.S. represented $15.9 million (16%)&#160;and $13.8 million (11%)&#160;of total revenue for the nine months ended September&#160;30, 2012 and 2011, respectively. As of September&#160;30, 2012 and December&#160;31, 2011, balances due from foreign customers were $1.7 million and $4.8&#160;million, respectively. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company had sales to individual customers in excess of 10% of total revenue, as follows: </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="86%">&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Nine months<br />ended<br />September&#160;30,</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Customer:</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">A</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">16</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">15</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">B</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">12</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">22</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">27</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">As of September&#160;30, 2012, accounts receivable from customers with balances due in excess of 10% of total accounts receivable totaled $8.1 million while, at December&#160;31, 2011, accounts receivable from customers with balances due in excess of 10% of total accounts receivable totaled $5.5&#160;million. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 11 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Note 11. Commitments and Contingencies </b></font></p> <p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Licensing Arrangements </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"> On September&#160;27, 2011, the Company entered into the Second Amendment (the &#8220;Amendment&#8221;) to Quidel/Inverness Settlement Agreement dated April&#160;27, 2005 (the &#8220;Agreement&#8221;), as amended by an addendum dated June&#160;19, 2006, with Alere Inc. (formerly known as Inverness Medical Innovations, Inc.) (&#8220;Alere&#8221;). </font></p> <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Amendment, which was effective as of April&#160;1, 2011, amended certain royalty and other provisions in the Agreement and enabled the Company to &#8220;buy-down&#8221; and &#8220;buy-out&#8221; its future royalty obligation under the Agreement for payments totaling $29.5 million. Under the Amendment, the Company made an initial cash payment of $13.8 million to Alere in September 2011 in connection with a buy-down of the Company&#8217;s royalty obligations for the period beginning July&#160;1, 2011. In addition, the Company exercised its buy-out right for any remaining future royalty obligation by exercising the Royalty Termination Option (as defined in the Amendment) in January 2012, thereby terminating the Company&#8217;s obligation to pay future royalties under the Agreement in exchange for a fixed cash payment in the amount of $15.7 million less $1.0 million of specified third quarter 2011 royalties. This amount was paid in February 2012. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In conjunction with Financial Accountings Standards Board Accounting Standard Update No.&#160;2009-05, <i>Fair Value Measurements and Disclosures (Topic 820), </i>the Company assigned $28.8 million to the licensed technology and $0.7 million as a one-time charge to cost of sales. In determining the fair value allocation between the intangible asset licensed technology and the one-time charge to cost of sales, the Company assessed the past and estimated future revenue streams related to present and future products that use the patents that are subject to the Amendment. The effective life and related amortization of the licensed technology will be based on the higher of the percentage of usage or the straight-line method. This percentage of usage will be determined using the revenues generated from products covered by the patents that are subject to the Amendment. The terms of the Amendment provide for an estimated useful life of 3.5 years for this asset. The Company recorded $1.9 million and $5.7 million of amortization expense included as a portion of cost of sales for the three and nine months ended September&#160;30, 2012, respectively. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"> In addition to the royalty agreement noted above, the Company has entered into various other licensing agreements, which largely require royalty payments based on specified product sales as well as the achievement of specified milestones. The Company had royalty expenses relating to those agreements of approximately $0.2 million and $0.4 million for the three months ended September&#160;30, 2012 and 2011, respectively, and $0.6 million and $1.5 million for the nine months ended September&#160;30, 2012 and 2011, respectively. </font></p> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Legal </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company is involved in various claims and litigation matters from time to time in the ordinary course of business. Management believes that all such current legal actions, in the aggregate, will not have a material adverse effect on the Company. The Company also maintains insurance, including coverage for product liability claims, in amounts which management believes are appropriate given the nature of its business. At September&#160;30, 2012 and December&#160;31, 2011, the Company had $0.8 million accrued as a liability for various legal matters where the Company deemed the liability probable and estimable. </font></p> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Research and Development Collaboration Agreements </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"> The Company has entered into various collaboration agreements which provide it with rights to develop, manufacture and market products using the intellectual property and technology of its collaborative partners. Under the terms of certain of these agreements, the Company is required to make periodic payments based on achievement of certain milestones. These milestones generally include achievement of prototype assays, validation lots and clinical trials. At September&#160;30, 2012, total future milestone payments which may become due under the terms of these agreements are estimated at $3.9 million in the aggregate. These costs may fluctuate based on estimated development costs and activities and are expected to be paid at various dates through December 2013. </font></p> <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p> <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">During the three months ended September 30, 2012, the Company entered into a master collaboration agreement with a third party for the development of molecular diagnostic assays over a five year term. In connection with mutually agreed upon project plans and timelines for each molecular assay, the third party is expected to reimburse the Company a portion of total product development costs. As of September 30, 2012, the Company and the third party have executed project plans for several assays under the master agreement. Reimbursements of development costs are recorded as a reduction to research and development expense and recognized at the lower of cumulative cash received, or to be received, or a proportion of actual costs incurred as a percentage of total costs expected to be incurred for all projects in the agreement. Accordingly, the Company recorded a receivable from the development partner for the first payment in the amount of $2.5 million as a component of prepaid expenses and other current assets as of September 30, 2012, the earned portion of $1.3 million as a reduction to research and development expense for the three months ended September 30, 2012, and the unearned portion of $1.2 million as a component of other current liabilities as of September 30, 2012. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 12 - us-gaap:LeasesOfLesseeDisclosureTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Note 12. Lease Obligation </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">During 1999, the Company completed a sale and leaseback transaction of its San Diego facility. The facility was sold for $15.0&#160;million, of which $3.8&#160;million was capital contributed by the Company. The sale was an all cash transaction, netting the Company approximately $7.0 million. The Company is a 25% limited partner in the partnership that acquired the facility. The transaction was deemed a financing transaction under the guidance in ASC Topic 840-40, Accounting for Sales of Real Estate. The assets sold remain on the books of the Company and will continue to be depreciated over the estimated useful life. In December 2009, the Company amended the terms of its lease agreement which had no significant impact on the Company&#8217;s financial statements. The amended terms include a new ten-year lease term through December 2019, with options to extend the lease for up to three additional five-year periods. The Company will amortize the lease obligation over this new term. The amount of the monthly rental payments remains the same under the amendment. The combined carrying value of the land and building subject to this lease, net of accumulated depreciation, was $2.3 million and $2.4 million as of September&#160;30, 2012 and December&#160;31, 2011, respectively. In addition, the Company has the option to purchase the general partner&#8217;s interest in the partnership in January 2015 for a fixed price. The Company has determined that the partnership is a variable interest entity (VIE). The Company is not, however, the primary beneficiary of the VIE as it does not absorb the majority of the partnership&#8217;s expected losses or receive a majority of the partnership&#8217;s residual returns. The Company made lease payments to the partnership of approximately $0.8 million for each of the nine months ended September&#160;30, 2012 and 2011. </font></p> <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 13 - us-gaap:FairValueDisclosuresTextBlock--> <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Note&#160;13. Fair Value Measurement </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>ASC Topic 820, Fair Value Measurements and Disclosures </i>requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed by the Company in one of the following three categories: </font></p> <p style="margin-top:6px;margin-bottom:0px; margin-left:4%"><font style="font-family:times new roman" size="2"> Level&#160;1:&#160;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; </font></p> <p style="margin-top:6px;margin-bottom:0px; margin-left:4%"><font style="font-family:times new roman" size="2">Level&#160;2:&#160;Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; </font></p> <p style="margin-top:6px;margin-bottom:0px; margin-left:4%"><font style="font-family:times new roman" size="2">Level&#160;3:&#160;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">As of September&#160;30, 2012 and December&#160;31, 2011, the carrying amount of the Company&#8217;s Senior Credit Facility approximates fair value because it has a variable interest rate that reflects market changes to interest rates and changes in the Company&#8217;s leverage ratio. As of September&#160;30, 2012 and December&#160;31, 2011, the Company used Level 2 inputs to determine the fair value of its Senior Credit Facility. As of September&#160;30, 2012 and December&#160;31, 2011, the carrying amount of the Company&#8217;s cash equivalents approximates fair value. Cash equivalents primarily consisted of funds held in a money market account. As of September&#160;30, 2012 and December&#160;31, 2011, the carrying value of cash equivalents was $10.9 million and $46.9 million, respectively, and was determined based on Level 1 inputs. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: qdel-20120930_note2_accounting_policy_table1 - us-gaap:ComprehensiveIncomePolicyPolicyTextBlock--> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:times new roman" size="2"> During the first quarter ended March&#160;31, 2012, the Company adopted Accounting Standards Update No.&#160;2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: qdel-20120930_note11_accounting_policy_table1 - us-gaap:FairValueMeasurementPolicyPolicyTextBlock--> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In conjunction with Financial Accountings Standards Board Accounting Standard Update No.&#160;2009-05, <i>Fair Value Measurements and Disclosures (Topic 820), </i>the Company assigned $28.8 million to the licensed technology and $0.7 million as a one-time charge to cost of sales. </font> </p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: qdel-20120930_note12_accounting_policy_table1 - us-gaap:RealEstatePolicyTextBlock--> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:times new roman" size="2"> The transaction was deemed a financing transaction under the guidance in ASC Topic 840-40, Accounting for Sales of Real Estate. </font> </p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note Table: qdel-20120930_note3_table1 - us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock--> <table cellspacing="0" cellpadding="0" width="68%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="88%">&#160;</td> <td valign="bottom" width="7%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Basic net income per share:</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net income</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,675</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Less: income allocated to participating securities</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(61</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net income allocated to common stockholders</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,614</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average common shares outstanding &#8212; basic</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">32,833</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net income per share &#8212; basic</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.20</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Diluted net income per share:</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net income</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,675</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Less: income allocated to participating securities</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(60</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net income allocated to common stockholders</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,615</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average common shares outstanding &#8212; basic</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">32,833</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Dilutive securities</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">356</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average common shares outstanding &#8212; diluted</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">33,189</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net income per share &#8212; diluted</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.20</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note Table: qdel-20120930_note4_table1 - us-gaap:ScheduleOfInventoryCurrentTableTextBlock--> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="72%">&#160;</td> <td valign="bottom" width="8%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="8%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>September&#160;30,<br />2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>December&#160;31,<br />2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Raw materials</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,554</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,239</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Work-in-process (materials, labor and overhead)</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,708</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,632</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Finished goods (materials, labor and overhead)</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,647</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,783</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">16,909</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">14,654</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note Table: qdel-20120930_note5_table1 - qdel:ScheduleOfOtherCurrentLiabilitiesTableTextBlock--> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="72%">&#160;</td> <td valign="bottom" width="9%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="9%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>September&#160;30,<br />2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>December&#160;31,<br />2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accrued liability for technology licenses</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">530</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">863</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Customer incentives</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,400</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,352</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accrued interest &#8211; income taxes</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">607</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">491</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Customer prepayments</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">48</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">202</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Current portion of note payable to state agency</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,498</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Unearned research and development collaboration funds received</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,222</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Other</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">953</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,720</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,760</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,126</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note Table: qdel-20120930_note9_table1 - us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock--> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="80%">&#160;</td> <td valign="bottom" width="3%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="3%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="3%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="3%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Three&#160;months<br />ended<br />September&#160;30,</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Nine months<br />ended<br />September 30,</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Cost of sales</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.2</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.1</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.4</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.5</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Research and development</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.2</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.3</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.8</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.8</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Sales and marketing</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.2</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.2</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.4</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.3</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">General and administrative</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.8</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.0</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3.4</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4.2</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.4</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.6</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.0</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.8</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note Table: qdel-20120930_note9_table2 - us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock--> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="86%">&#160;</td> <td valign="bottom" width="5%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="5%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Nine months<br />ended<br />September&#160;30,</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected option life (in years)</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.52</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.22</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Volatility rate</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.46</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.47</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Risk-free interest rate</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.83</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2.05</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Dividend rate</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> </tr> <!-- End Table Body --> </table> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note Table: qdel-20120930_note10_table1 - us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock--> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="86%">&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Nine months<br />ended<br />September&#160;30,</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Customer:</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">A</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">16</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">15</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">B</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">12</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">22</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">27</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> false --12-31 Q3 2012 2012-09-30 10-Q 0000353569 33350305 Accelerated Filer QUIDEL CORP /DE/ 5500000 8100000 P10Y 1200000 3800000 15700000 1000000 329000 367000 2352000 1400000 1300000 700000 3900000 January 2015 61000 60000 594000 2611000 652000 13800000 2400000 2300000 5947000 5667000 0.10 0.10 3 0.25 1498000 207000 242000 P5Y 1600000 500000 600000 157000 555000 16563000 2500000 600000 800000 300000 478000 P5Y 3 3.0 5001000 4679000 4800000 1700000 14646000 17132000 4667000 4413000 15093000 229000 175030000 180059000 5800000 500000 4200000 800000 2200000 300000 3600000 1600000 100000 1000000 300000 600000 200000 1000000 5000000 400000 3400000 800000 2000000 400000 3000000 1400000 200000 800000 200000 500000 200000 900000 5342000 1791000 5165000 1728000 5700000 1900000 1900000 0 0 0 278894000 236777000 104726000 69080000 6788000 51045000 61332000 17842000 44257000 -43490000 46900000 10900000 0.001 0.001 50000000 50000000 33276000 33297000 33276000 33297000 33000 33000 47579000 14996000 43688000 14872000 5009000 1670000 4315000 1438000 108611000 34352000 107087000 34220000 202000 48000 0.0150 0.0025 0.0250 0.0125 The agreement governing the Senior Credit Facility is subject to certain customary limitations, including among others: limitation on liens; limitation on mergers, consolidations and sales of assets; limitation on debt; limitation on dividends, stock redemptions and the redemption and/or prepayment of other debt; limitation on investments (including loans and advances) and acquisitions; limitation on transactions with affiliates; and limitation on disposition of assets. 1000000 600000 2527000 -2392000 1222000 10681000 10681000 7040000 4648000 12063000 16485000 0.20 0.20 -0.03 -0.11 -0.02 0.20 0.340 0.400 5377000 5394000 P1Y P2Y2M12D 2000000 5000000 13800000 15900000 0.27 0.15 0.12 0.11 0.22 0.16 0.06 0.16 28800000 P3Y6M -27000 17135000 5194000 15812000 4759000 71013000 71013000 10113000 -1687000 -6248000 -1527000 200000 167000 136000 491000 607000 3438000 -574000 -2501000 -851000 -289000 -877000 3828000 2486000 -254000 2155000 -160000 -8267000 -31000 -2856000 2140000 521000 -844000 -1858000 -148000 73830000 64179000 1639000 485000 985000 286000 1639000 985000 5783000 6647000 14654000 16909000 5239000 5554000 3632000 4708000 151000 42000 35000 8000 2019-12-01 278894000 236777000 32926000 15429000 19000000 The Company was in compliance with all financial covenants. 2017-08-10 140000000 120000000 60000000 42000000 19000000 0.0172 27482000 -26228000 -17518000 -23147000 34293000 5885000 6675000 -1113000 -3747000 -676000 6614000 6615000 -1488000 -443000 -977000 -305000 1498000 1 11601000 -1244000 -5271000 -1222000 863000 530000 1239000 1970000 7126000 800000 4760000 800000 928000 952000 27000 27000 1720000 953000 625000 3407000 1000000 14264000 15359000 3254000 6903000 0.001 0.001 5000000 5000000 3246000 6380000 59221000 2960000 3000000 -907000 -1041000 115000 28086000 30535000 30000000 23000000 19559000 5884000 20433000 5085000 10323000 6576000 1500000 400000 600000 200000 29500000 15000000 800000 800000 7000000 120212000 33108000 101816000 32998000 18996000 6487000 21989000 7776000 5798000 5001000 207532 135295 12.86 15.49 0.00 0.00 P5Y2M19D P5Y6M7D 0.0047 0.0046 0.0205 0.0083 519337 621705 5.73 6.51 31304 185386000 186668000 44290 17165 135295 197109 22100000 231704 356000 33189000 33019000 33036000 33004000 32833000 33019000 33036000 33004000 EX-101.SCH 6 qdel-20120930.xsd XBRL TAXONOMY EXTENSION SCHEMA 0613 - Disclosure - Fair Value Measurement (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0402 - Disclosure - Comprehensive (loss) income (Policies) link:presentationLink link:calculationLink link:definitionLink 0612 - Disclosure - Lease Obligation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0611 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 06091 - Disclosure - Stock-Based Compensation (Details 1) link:presentationLink link:calculationLink link:definitionLink 06092 - Disclosure - Stock-Based Compensation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0609 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 0509 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 06101 - Disclosure - Industry and Geographic Information (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0510 - Disclosure - Industry and Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 0610 - Disclosure - Industry and Geographic Information (Details) link:presentationLink link:calculationLink link:definitionLink 0608 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0607 - Disclosure - Line of Credit (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0606 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0605 - Disclosure - Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0505 - Disclosure - Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 0604 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 0504 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 0503 - Disclosure - Computation of Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 06031 - Disclosure - Computation of Earnings Per Share (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0603 - Disclosure - Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0601 - Disclosure - Basis of Presentation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 0110 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 0111 - Statement - Consolidated Balance Sheets (Parenthetical) (unaudited) link:presentationLink link:definitionLink link:calculationLink 0120 - Statement - Consolidated Statements of Operations (unaudited) link:presentationLink link:definitionLink link:calculationLink 0121 - Statement - Consolidated Statements of Operations (Parenthetical) (unaudited) link:presentationLink link:definitionLink link:calculationLink 0130 - Statement - Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:definitionLink link:calculationLink 0201 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 0202 - Disclosure - Comprehensive (loss) income link:presentationLink link:definitionLink link:calculationLink 0203 - Disclosure - Computation of Earnings Per Share link:presentationLink link:definitionLink link:calculationLink 0204 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 0205 - Disclosure - Other Current Liabilities link:presentationLink link:definitionLink link:calculationLink 0206 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 0207 - Disclosure - Line of Credit link:presentationLink link:definitionLink link:calculationLink 0208 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 0209 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 0210 - Disclosure - Industry and Geographic Information link:presentationLink link:definitionLink link:calculationLink 0211 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 0212 - Disclosure - Lease Obligation link:presentationLink link:definitionLink link:calculationLink 0213 - Disclosure - Fair Value Measurement link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 qdel-20120930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 qdel-20120930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 qdel-20120930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 qdel-20120930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R39.htm IDEA: XBRL DOCUMENT v2.4.0.6
Commitments and Contingencies (Details Textual) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Dec. 31, 2011
Mar. 31, 2011
Commitments and Contingencies (Textual) [Abstract]            
Accrued in other current liabilities $ 4,760,000   $ 4,760,000   $ 7,126,000  
Commitments and Contingencies (Additional Textual) [Abstract]            
Agreement for payments totaling           29,500,000
Cash payment       13,800,000    
Fixed cash payment   15,700,000        
Contract value Discount   1,000,000        
One-time charge to cost of sales 700,000          
Terms of Amendment provide for an estimated useful life 3 years 6 months          
Amortization expense 1,900,000   5,700,000      
Royalty expenses related to licensing agreements 200,000 400,000 600,000 1,500,000    
Period for molecular diagnostic assays to be developed 5 years          
Earned portion as an offset to research and development expense 1,300,000          
Receivable from the development partner for the first payment 2,500,000   2,500,000      
Unearned portion, component of other current liabilities 1,200,000   1,200,000      
Claims and litigation [Member]
           
Commitments and Contingencies (Textual) [Abstract]            
Accrued in other current liabilities 800,000   800,000   800,000  
Research and Development Collaboration Agreements [Member]
           
Commitments and Contingencies (Textual) [Abstract]            
Future milestone payments 3,900,000   3,900,000      
Patented Technology [Member]
           
Commitments and Contingencies (Textual) [Abstract]            
Assigned licensed technology $ 28,800,000   $ 28,800,000      
XML 12 R33.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stockholders' Equity (Details Textual) (USD $)
9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Stockholders' Equity (Textual) [Abstract]    
Restricted stock awarded 135,295  
Restricted stock cancelled 17,165  
Common stock issued due to exercise of stock options 197,109  
Common stock issued in connection with employee stock purchase plan 44,290  
Employee stock purchase plan, net proceeds $ 3,000,000  
Proceeds from employee stock purchase plan included in prepaid expenses and other current assets 600,000  
Repurchase of Common stock Shares 231,704  
Payments For Repurchase Of Common Stock 3,407,000 625,000
Repurchase of shares in connection with payment of minimum tax withholding obligations 31,304  
Stock repurchase program, remaining authorized repurchase amount $ 22,100,000  
XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
Industry and Geographic Information (Tables)
9 Months Ended
Sep. 30, 2012
Industry and Geographic Information [Abstract]  
Sales to individual customers
                 
    Nine months
ended
September 30,
 
    2012     2011  

Customer:

               

A

    16     15

B

    6     12
   

 

 

   

 

 

 
      22     27
   

 

 

   

 

 

 
ZIP 15 0001193125-12-437971-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-12-437971-xbrl.zip M4$L#!!0````(`$(P74$^/T=E$58``&D^!``1`!P`<61E;"TR,#$R,#DS,"YX M;6Q55`D``QM4CE`;5(Y0=7@+``$$)0X```0Y`0``[%WI<]LXLO_^JM[_@-4< MY53IHN133F;+L9W9[-IQUG9VYKV:*A=$0A(F%,&`I&7-7[_=#9*B9,FW+%)A MOL0B0:`O_-#=N-[^_6;HLFNA`ZF\=Q6KWJPPX=G*D5[_724*:CRPI:S\_9?_ M_9^W?ZO5V._OST_8K\(3FH?"82,9#NC9*==?V:'RQUKV!R';.'S#NF-V?LZ. ME.<)UQ5C5JLEE;SG`7RK/%-;JVY-WIT*W8=WT@M"[MF"./DXW^.H?HC]NOA*;OD_;[0[)^J&_SQ[T@ZPOW#:EZUMJY:3:O% M+D+ALUUVP8>"'?$Q^\?EZ0D[=F080(6"?7"1XC^^P5T&U6JU.LUFQ]IF!Z>FY$U7NPR^\X)WE4$8^IU&8S0:U?%Q7>D^ M?-5L-Q*^*J9DQY7>USN*X^LN""LI?G.K_*A-I:V]O;T&O4V*(C]IR6\DE+JM MAHV$Q:2<#-1FR]JYBV93(OD`;*+/N9]^T.-!EPK'+ZB%6M.JM:V4;*A//D(J M^-:9?)`MO-TP+].B@9PG#RAI-7X_/;FP!V+(:[,-.&*F]D#8];ZZ;L"++/V@ M5\;>HE@[`=5T+GJ,Q-P)Q[YX5PGDT'>Q6GHVT*+WKC)C28%380U3$=K^H?)" M<1.R"T&&;"P?WMGQ<^F\J[SG+E)[$)SUKMH6="VH+28&2D)OD.$X_@6_0;7P MI">A!Q"18DH@"6>''_]5^:4)_]I;[:WMO;>-R6=)Q8VIFM_Z0DOE9-HA(8:_ M(#&U9AOD\[:1/$MJR'SSMA&S=`]_S0OAH[2N#ETNA\'5@>=^*VT9&EJ8(Z&']S(H/(+VD?',`N\3E@UM;]MS&UT0F9CFLY':`VL>J_6 M;KZ(UJPC8:,AE%I;MM:L&BCNI?O:B?3$%3PYU`(&PH*HRQ#[@=O2!?*,6E)5 M`D.@-2I1J(Z4JN1">%)I^,\&`W02S23<%EA%U',,=S%STZ6*I"ZK>1#ULF%S_`S^/91QKBZ%/?"4J_I%L<$/TI.A.)'7POGH@3SZLNL"=X$( M`=]/^9]*`XP'P31^).Q.N,V[67X"Q#N%WX/@V'-`3QE'*@I"!5'+U>5(%41G M1BTQW4%VQ(V?`2O+40B(7H='H/U?$K^_"6/MY&E:4'A.IIC17/+LQ35W!L/S MFF@.6%E[S5EEGWNRYJR':=//J?3D,!HF_?M$>0YX M-Q_A,]WE'@R4O1X\/@>;A7>\,"/F.??Z,^@<<_KR/7JAE1AAIK(D4:(D29`% M-1=^\[V8B^&T-)?GF`NNF+EM#3.@DW?C6*@PY.Z1"GI-#"N*,4Q!2FD,RT&H MO!G#J?($N(%D]K#!R[UU7^X&PD85_PH#*Y.Q+5PK8(8R+$K:>;N M(WCY9_I7K2+_@]+(%/%DPO491:(LC"A($B]O/6GS[\%-Y4&D*0+YH,6W:+)4 MY%9A(WXC_4)96;K*I[2RTLJ6O2HI;RL<7[H7-?/$7_-Y^KL<:+%@5J;,"S]C M.F9G^=,Q=ZE.N*[T^K28TP`<_CJ^\4%>19D;Q17?3N2*L][QT'?56(@+H:^E M+2X&7`O:>7"HAL@1+=\\<%UETU]GO7-AJ[XG_Q+.9Y+DH0IPR9#)&^("PQGK M,-("8:6RBD7U/=A*.>-0?`4*KNT!]?8C]!J4C\R4_7U!?T\$!O+*B.L[ZO)F MVY=+!G/@#*4GH=.`+*]%:3,+;"86&4AL6F#?D=6@A'"KP05W15'\P=/V5@4'!`H.5&DP9%Q0S+ECM M5J$M$]*::+Q='QY\OTEH<>0T"F?"`Y3Y%0[RI3$V=PY!4 M'%]LU8%ZIELS_,W_GJH]$IX:2F]1Q73?52?``#]85//M*MXV,AS,99B0?[[4 MZ-4#9/89WMZJP=#KPY\/J('R%L&".N;QO$AWMZI8J(]L#7B'UK%+SNFM.[3H M;CG1EQY[[RK[J[D7SF&?5"C2,LE(>J;[W)-_D;L+?G*@7.D8W]=S/@,/4'^< MAOD`6@+'FKOIB9/!D0QL5R%]EV#TIK&X!YSC%6`+^__/;K@/5!Z='5[^W^=C M-@B'+OO\Y?W)QT-6J34:O[4/&XVCRR/V.UU29]6;C`9YB91PM]$X_E1A&#&MAMRKL$#^!45:%?P:/^PF M?S0F?V$%SZ\]_7IY33RX=C^I>L@U:+@6*K]CM?R;_?AW5X6A&G::_DU:[_,( M0JOYF0_]_1^L[>:^5<=+'F7`5(]E380MH)M^^/=RL#V/@7V&_:XF/1P-.YL_ M/8^ARX%@W+;5T.?>&()G%GD\=FFGM@\_>HFI0PN)K2.WYOY)=JBT'P?3 MC'L.D_`VB+J!="37$*2SC7`@#*\DM-U6J[E_:%I-GUC[;]B`7PO6%<)COA8^ MH"M>CDD4:H=NR*0K./MF;L`=XQOA(X%8)*+X'[Z40*KO0K/P+33,OM0OZJRG M-/P.81@?9MB1'CP?3BBG^O$;=(6TN7XS8*%B'Z!81N/-VK^I_($.I>UF;:&) M5<``LY3<)T]Q6KG][N7-5LBX%#HD`-# M6MAXPQ%XAF8J(>^4+'8D(#P-(A MYE&H5D]Z@@TIB<`$9A'`Z0"[P8!Y8L?M9I5A4%1%HGUT2H#:\1TR"G!90*U+ MU^#:F=F?A&H2@!'5]I1DT&YU1%(>:^4:SK5PB:U4R""9^UIX@%P.>3!@'UPU MFLCE4=*H(T(\_K,J2Y!QKN@X_(PO`48B%136`!5>+;%53C=]Q=+;FI:>C2SY M6J&;33`1=W)`"*M,^%IY;WP-%W4-1UU,DR2/* M7,[B;WB')EO5&)^?TZ=:](6Q"QF0`-(!N9YT71`W=+S(#9_;@Z$U+6C@\80M M@@"&:A@K0'@$I(`J\1B4M!8.0`)#/@9HI8YEDV<0DT"@"2TB>4=0W4R+EFG1 M]))>I,F0,\)%,.G!(P/%V0Z1^`?6SG[P`*=D>I#$9@34.4LE?+V02"L9A]/A MR7FB MUE&.V#:RFC@*P?QQFHV`2;"7($(K^6AH5CZ,#P8UP+!YGXI6R;7@SI]1$)I/ M4:#0W]&/2(Q@3-+BK,?E]##(-JAT0"8(]7JH/!#K!^7R'*1 M^2+D?8NX!L>,S'$`]2L-%@A^"_$-XV*`01TJPZ.I'C,`/LIT;YEK+P)!H#7D MU\G!GC*#"7=UC1Z$GMSP!%XL>I`:U)"@`&AOCL%G40>B>%##.&.]":Y-#_/S MR9I+4CB0VDFUFQ)R'_Z=V:&:>MN:[W`@)9@(`F7'/A0@B(`HP5`$TH`F01H9 M`J@[!60\$3H+"`\R]N_F@2@S:;]8BAE?/F&!W4)N!O8PF$"(U:8W[3WHI>)K M,,O#0N-[VUA60B*360+"%N>.'I-?0NUK,<`)G&OQT0,?3&"Y=-+'ZXQ^'D4Z&:9[4@?A#-2=8D!WVP>:PDL8C!5%Y@>3$!YZ+^(6H,X7'_$* M;*Z>T2#-%&]59_1H+(]M7,+`;[-6J_FF,YV+0L=[SA?WN.`3&+K/SIA*1&_KGC2SN#)0I[S!21M`R31Q+H2PAE0SHCT_,/)D72CD'S?,,$) M'Z.O@IQE7,]0TAS,VR0B6H,U(U2B>9T,1#I1C MNML7H'[^^VJ6%""`FQ6RT+:!-X"KN`'$(I]C^E'ZQJT.T!&G('PJ&3/EDD7> MM0BP.IWNVDCJ&Q'D8+5VG%E;7!AGJ)!DH)6"%-'#:\AC0UA,%6;);9+`7(%' M"\6"HK#)W$QJ@N8.L?9,/2:LB7U\D1CCE`!3AHB+@7*AO4D4;7P]K!Y_C83L M#RBU?`UQ2Q^BC8@.8&@R'ZEA M%T9VS!`*;4N(#WRP70@*(D^G:\P7IPPIN(18>HC"XS<0Q7I@W6#MD4\)Q;A. M;+(/73XDW7'3="*T(>UI,^T2\XFPY^8;IW("#Z%KT>A`J$`^`: MU!+(>7*NT:KO31XGN<)8=91$B!7BW*N"U-(F"MC(S.T"8'<,-6EZ"/U$#5]' M-`^6SIGAG($9XQ=G^)`*`0$[3D#ZOCM.@/T62L>!!P@BE@SB$WY-G2,KQRJ* MGJ>;7FAF*LM!G/!*N<`N0E-8*/E'2#&68%XS6S@$]!2(840RY5U7,)K&`#;C MZ5=[RK@HDM:8QZ0XQT29)S4;E[O[ M@>@D?\3ZY*[L>QWFBEY88?3C7<46.$E>61"[7!)1_Q#2WD]"V MN_O3/&Y#Y]8'US$-1DPI^X-M"W"/*@NY`2R9[I:S^(W]N&/5FTTQ MG`;LFGGX/-1^GXYML[YWYSZ07)T5/PEW7O:C)T'&PW3=7I:N/Z5:SKEJG\K@ MCT^"Q/BGQACY>>UO5[=WMAY$@Z=&FOOO*N;_RHM*X?'XQY8)74LSYQ,1!)TT M8Y+-C2P*(-;4[)_I$KR<_6]L6RNW_C?/-/]YN8C%76`E`]+M_A;[;!3JS7?8 M[HI)\M/LF@ZWBQ/^<=9C38$I!^.QM;ER1/K.`:D-R."H"(.E5T6D%VKW29!4 M'"?JM]FIH<738&D>M;5OTG9KBEJY<:?:K>INNUWB5XE?I4MURZ6:I/6_%UQ: MM3?5K+>:)1B58%1X9VIIR?2[%IZ5Z?0RG5X..&4Z/;>18)E.SUO\M[&]>G^K M3*>7Z?1\X%.93L_!>&P5?CPN.B"5$6">G:@RG9Y?=VHMTNEY-?RC9.-<&1Z\ MFCUO;1?WF\V;R]9@S:,QBU-SNU9>)[,,@[L^>CA"8=*C]?_S/C- MS)D]=[&=KV-[-O&`2$,L;C`GN^FFP'''6+&B`WJRQ.(HAR=X:-S='9\%X*I1 M'%V M?^]LYW?W]T[KF;N_'[I[_)4+%8#<)_FVY6;UYVQ6GW_H!+W6K($E<)B["W9S MXI.OGVKF'O@\HYGRH($K65A'VNY5Z?:Q> M6^VBYTKSBDN_*?T5*JSY6N&9\VPC!:DJH]N$*;Y0UT(/`*7?K"ERY69>8+.Z MT]PM@*F7"G[JQ$]UN]TJ@()?=1)T:>CV`>^3&@B']16>,EB"VTIM?[NZO;E3 M`-LO%?QD1VUGM^@KS`H_B[2>BW)*.>9@:<#3-),SM%QU-&MM5_>:10AG2\4^ M4K&;U>U"Y)_6>OA;UT44I23SNQSEKJ42+[DBY9LCW,X97GIP:*[*/9&\*UW: M;K"N2U*V6(T]B.\'K$E9PN47^"%-K1EBZXS(9#&=+$-H_M>E&-*36YC=#.EW MK2\IUY;D;&W)7GX6:Q2,W')M2;FV9.75YD8UY=J2@LQR'.`5Y>`O)2.VN>P\ M%/;``P;Z8W@!!A2L[9;450?^6^TB;)THM?JX]G>WBSZ5D5>\.HP"D`R$&M+# M@4U>KRTRY69FSJIN-DN06F,%MZKMK7)=R6M[7!+=W:>/%Z((!DE%&#Z]"#SD\X'WAV>,2V)9K^JGWV\K2]#CJ2M0KI.JM MZN9>$8:U(OIH7SS!M0=A)H28\)<]H.T*CK@6KO+18V,T0=U5FA,*]B+/"?`T M"2&OU_:@I!Q9?JM5A!&_5/!W.ZJMA[-'RY)*-%NNL>]M%6&VJU3ODP>KG?)\ MOU4OJ%[/'46E',N=6>NQXF.SNI.#*Z?6;Q1E_6@_4++.2H8EWY<\IOU/RIX>^JHX,5LY^NHX&T\*IB6YUSB\AQC M/-T4A^](,*QH3];E0+!#-?2Y-T[S43O[`1.]GK#IQJ&0WS"-](3 M;`@-#*"8A^<*S]]DP=#B**6,"_G9B`=LLUEO_D2/VIOP5Y6XUR+P35ONN,XR M!-'!Q7T/J'7@F\RZ)]85GNA)VB_V8ZN^Q8!/%S/46/-T27'CX])T*MFN;Z8E MG\=,=0[1OI:@JS%S)(@.0,$60&8X$L*CANZHEJ2`52\N8\U3B`R8$]%D)#8@ M;FPW"N+92MI%)P!9N;LXNX\5V5HX(,BI>GP9)_SCBG"J,PH%FC;#O6[XKDIO M)HIR(AOOBQP(:DY?&W.)0`HZY+B)#]KRE4$#G$,((I>NN^V!33).$DCH-A MAO2U!*V%`QXRD`F(5]Q`%_*2QN?UDX1H4HH((PW<);8U!K$G5M5J-G?@H591 M?X`$-NOL*8B0W713L=!2.?*_[7UK;]M(LNA?(08S%PE@ M.R*I9^;<`1P[&?C<)/;:S@[VDT%3+8D3BM3PX<3[ZV]5=Y-LOD2J15F43."< MG5@26<^NKJJNKC*98'SDY!06FA_@1Z!<0#B!+9\RPPB#A0 M=^ID,L#W,:UPO1^&-Z6-S`54F&28FG*!?CN[.Q/!BDIM&I[W'+\+]#ITP@!V M[/_R M7@G%[7+T1F?*9W0=0(,NV!;:>E?OVE'.PWGH!PD5:N%N22^#LNIS%]TI8\GV M,&X3`SH:^E<5G;GD59%CY1/'@B5.YU3"S_QG!S8,?(*2S]T-6'WL(N$;A!M9 M2:WW^QU[FK/T$_]9_`/U][T%G8PC-L$BL MQG-I*PG'=4ZC=A*X:03^6I$_TMTFOE,!6Q>QZ'L^7WVXOE7X+HB[$?.O5^!/ M(ZOH%F'BQ_@]W4A,FBI@"Y;!3!Y#OQ'V.CMBT<*:+]B\E3?6VX0-\!5E@(V+ MRTOI&X82[&4G\$SFH=AIXN4X,::N0TX7ACVC_''HF#.3<@94'-XBOH81'#T5 M_?(L^<%]FM"(KCG$70`:]&%*@(O@G%`S@=L_:(>!V_`/=(D,?"7L]$OZ$9!# M-73N6=-DLR]9;)PG?*@D#438(C6<.2Q1&B^H9]K@-V0OQ'X03Z)+P2BB>-JN MP=T3^N->]&,U_G$B*_;;-S^RPRQC):&_`H:J9R/M-U29-0K]EFF",?<(H=[+ M'%N_QN%#V5KTLVY?%#.9M(8>8TK;6EKS*N<^L)VN*9O0$-B/CU`6P&$U&>R-B8/J&2^6_9 M7^8_H<5=URRVU$$!MX]BQ]1T-@,9H.G_G3Z=IB$TY0YBW)>C4-VPR9Y89W$C[?#$PBAA(GHB;QEU"6G\0+X83=-SL!=$!\ M0!]+`L!S8)/_&_V%:H2*<,I6.7C*F'VAW[[%`)Q%;B:![_3W*F!":>=I!N), M8X=\!OX?L)"'^R=)8H_6;U^X7N#+Y'H_15_B( M$VT#B_(30Y@5!HCXDM!/,,Z"A6R1&`VN-6=)6KF.DY@ZD?F],A=0 MG3-_H/3,A>20:9K+H$>.4MQ`A!#Z;1Q*#8, M=;RK`L]J(G!6'-!$CSCSXX_$!\+@7AM'K0K-(<02\1<6(8*HV(7H?IVE`@9[HT. M)$X451^<:)-!/'9]1J-9<+C19#"G[`?!C0ESC&0*#XQ.U&'Q[RG5PC,FKES; MID]-X+'>1'@L&O>>_-SR?;RSGCI*@,#"8JNX!SV^X!YK\XKJ2EQ'$)] M-V9*RNPLN)JV^TP(?\LJ],P%>OLK&[R";+;AX]W-33JW$!],4%X`7$P.T]DU M!&(M3E9DY=`IQ'3J3POG/H!3\*LN&-@W]$!F"J2E0^LHI(674T<88B)^2,78 MXJ:Z)$8.1=K^*D+(<71+P#V3UB1-5T]&O3Z71^28B=M$7CZ`/V?PE"5V ML^SHYQ)$4?Z&'9?!RD@XPC5!?&FR,Q4)6\A/&([CXFD3?XOP$A3?W#.6)\IC M&#!W/88().LQR2G`?*YI5NV$N`4/AI;ADB:8\3LT-\@E]]&VYCRN0IY$T5RD MF3Q'0Z7$](GV@!27(LM=._&CN25-5[,O+6SJ*P&3?D0'`HG(-.U,C725G\XN M#78$MEX696S/JFX1-C6V_MI[T4YR\#&8Z]F%$-/Z)SH#Z@[-_RZ M^[&Z"!,Q5[\=9]KE.$RXXW!*D55$>MJ?WTFT3U[$V22T.YA+9PD;6/?7[%8[%@X5'V''=%I4DAL^[!-.T M4&2Q#JA%\$1K;XO@<6_+%L%Z>WKN=NAVZ&YW!^+`N_P.]]OE]QZMO1`%4&M/ MO^5=?JGA%S\H;]G\^EHT[UEX7Y,-NI[(E'U*ZC6N[CWW\.Z:I^^/\?OKC?[* M&=]I_*O3^)IWAU[#-`#,Z="$/M:+Y/EU%&TS]GVCM'?6=?XY1JD>0K?93JJ; M2O409G)V4MU4JH,#D*I4Q+MG_^&VY%;5D;H26WK?G4_1B;>F>+L&:T!X#[3K`2J_,].M^C$V\GWDZ\78;C%8KW$"*' M0TQU_,FN7_)[JE@P[@=8#?E$.H>C\Z<[\4HC`HNS$^_QBE?O'(YC%F__(,*% MMQ(-CTEU'-F\VPIN?T"Y>DU1G)/P)]N5.GHYZ?`DM5_)MSW[%TO+<(_R; MX=J79?M`Y<;0;,01R>XK$4,H#[#C60DQ>@4Q!9S12E^FG6E;<:9._TK*O-`1 M.%753P?[CV-[XE3KO(@B[%+SZZ"`HJ@#&ITO@SBRESVFA(3];15#B1I3GT:- MJ=D(EGSKN12#Z%B-W1-=T&J0=_1%22J[)!?;7W$J+XKP-8V5!931=P43'E;];EG`"ZA'[6Q^V`;YO?3.W/ATF;D[&4( MAPEKZ4Z)G32`9!V@\-FZ]B/% M$?MK:#_R,8HAN#=G6S-"6X#2<.!ME5/7E@5RJ+5;@[/!(11O=?*5EJ]V"/*5 M\CSV;+G^[6+;=SI?!J>*=99JY[>6NEJ&XY;OZ`#DVW#MVIYLUZWE?S^=87XS M-1FQLV$[O\:T_[MYOW5&;&<"ULYZ^^\S54/`A^AO7?+II)VE>@E+=0A:W$GW MF*5[+&4M"Y(_SF3GI/34-'WTFJXYH#^C,_@V'@Q&Z<[/V?EU>#9060W&X&RD MYRI.A'%X$?"AAH/D!O2A@3HYT?51!DW9N64Q:D5HU.=9MFR!DKX%ZXK8I@[. M^A->(J2=C8=U&!?-Z?*;'?7SG3$!CV?.Y,_R0X M#&^UL,PK9^9Z2XK7L0Z(4WO*J;(9!]HU"$[MG2D1ZG2U),@K`O9,)TO.@UHS M%"Z>5DHGL1$ZF-EUZ*A&UV/U(CZ9XU(X4UAKM,!53*#=71+/IP-`P8VFZ_'; MV=T9/L?FGI,I-7/IHL@WZO"WMPDGF0'4S\;)6%15%7^`%H'6H'GDB3@AV;(Z M<>.Z/_KD)3&S7ZLG_'V/AHUC<'TZUY8.`P<,8:MQ!![1FK!?U;-1,K><5X'] MVC\;%Q0`II&449Z7\D3$`>)^I!WP?HRM0BPVC9F`(TY_`J,HQ]7>;TI6M"?" MT+[WB>M5AW"*_#GS(WOO3NS51\Z6[5;9>Y,U3%+5]U_!?*VINK0&]L<9Q_!CH^[:2"R4?S0 MJCCLX&UE"VYK=%OA#L6[_Q+WU[X5'FL7J(Z3N]H.2[+.;2\\K-$NR#!--W0" M'UOW$.N)DD5K(H1:"&S.DBJ:*"\,B%Y'21=>2;_%\I+QF1J75/Q86#;6$`1K MRS5VA&$A=H."1EYK"]4VJXEJLAXM*I&[<)=+*Z!U;P#_`K"TG#EQ3(OX2?7< MT=:EJ)-M2G*=@>2D";EBZE$&>Z5W+P)EF0UA`!GRV3.+0@]-P#&X*=1 M[:O6^SW^)OY,_?TMEEG]*[3`8+R[=SC[!_36E#KO.5 M9]E9W'J#/+#H.1$85F910HTE*[5[Q+)'Q9CB]9EPR4'\;^B(-9(3"F%XPNSI MN8TU<%>.>::\05-&//M9^0[^J(-57PD)7\C4,L&P7CF.^T3MG7]"'WNKO!'1 MQ->)*,I5R156AS5?)!=+,.IUAR7@9#9C)7[(`-A0,A)*=BS.QELL(!SQ6NKV5Z)J_Y7;7(V M4.)-\EOR8,([$?>E,<5>>D`L6'NL,S3\!64'?S5R-%U8"M0R);2$U1JUK,2= MS$%QH".!^FHH$3_6%:7G24ZZR?'6A(^XV3A(XO^&]G-.OEA(C`N)[ED92_&3 M>*:%)?/(9,Y[A0:-%`C^QB-+T`E\.Q,"\Y3R@GB,7Q==";CE/[JGU?GL5]>L M9:`+7!?8*0K,^LGK@F0>BQQ*VD?:"S1*V,Z,!#*;FTT,=B3-?X$K\BL MB&G-++HX+&^J_`.T!9%JQ'CAU0?+C]Z,"WAE6)0_G\BC%[.CO=6Z5U3)_PX= M0 M;W+:&YQ04BV$^PFOB/R;7A'Y0@STFA+O)/&D?.7-O;NR3&6L]=ZRI]_1Q\45 M8?@^!';H6FOC],K&7]G4A4`Q$G/AN+8[?X[:Y@J%UP`8R]M/D5<*J)0W)[2@ MW?6IOM`:YC-*'J[,Z/9*I-/"?1?#!L>/KRX2_""$K138UT%-+0P$`%T2E*)% M.TY6()(V"/@^W^=&?&7XW+(G33?Y4N*5\A!$$&/IBYU+>64^?4XP&+!Y3$,3 MS?'"P&Z;A$,(F(W&#PUXL1\^_@TV,N)W;!/8K:!D/Z,MEQ!$!!D6C1=8_V7, MXN:TB"T_0$C8^#5U46@!!@]6(W\,K"J6K>']+?@D].D_F+G`V:EH'$]M6@5* M@H4[Y:NVZ"D$1JD'@,(EI:37*.>CK\SIF%;*88P48VZ9V)66>4,2_$*(?D16 MXOW1C7S*S9PC2!?$,@MMQEQX2H?MDK:TXAL.VB;4M_35,6RAZTWI38SD(D9R M^T"TC=A#5Y13U/B6]W.>LJ6#=T+XKU.:FN]RN]D-C4.Y\T`1$+;L2+BQ5Q;O M68Y+5?\1E"2]C!?H_(E1P),!GD+H`&J!_8*#^M5'C7(X+,M81; M&;ITD"$N*$Z"?KX_,]AD351'_*`??[!E3_:T+IW$O=/3`-6S`24_"[29BT52 M^KO+#,%G,H=MOO7QM*AG%L8R3Z[]Q/S0:)F8MF$MF?]@PQKD[B0H5H#9.VJB MZ9Z*BHC_Y2XLV$'P=L!-`V?&\ZD-?41C#UOJF?+%<`R69LMA MO?@A+#\S]#S\B4UY:9@\/.4`C#DH/&!#3MA&ADW`%P;&=TDO<&,*6X8?;9;1 M%L<)3J\RP_9=!;U[C/J0$^`F84KRA%MD7&MT!S*X4QPM=-LR'ED;,<8IBB#S M6WUN1Y9Y8)"+9_\!()/7.*5J@*7W0]IO[GB;%M_1JG\._K[(AFBD9A0V%J M'/E*5L#"&1H;TQN(4\:H$]3T<`8K%947.1A?-^<^7.+N8>,JVX95B=<6<0D0 M+^">>N*A\\<* M72]%T**R;#KNLSYF;DK,1I398VD>7+'/L=U4SF3&ZQI,Z4VXB8.(`H6(8>20)$#)9<2'T<1W"&U2#G=M?K:;'94O8NR@<\$MDW_>O89\Y/D%50*:$*E M0"7Q[2@.`%VBF"K7R1E,ZT,%[B&HD\DD;<]P;=F$>GLTL\72`4C?HP'"HM)E M`7KDL]\9CG)ID;FK0#Q``T$6;T=_T3,=W[79?HR&`<^.BL:SP0N9IPI>9KY[ M"WT/GR]&U=ZS'NF>R-/$J6"?HHX/X'&ZS8XQ1>1/@#%!]D0MFTL;)>=9Z10" MYH05;?`;F!HP$&0:FW9NQ*.@96&M>*;#9,$'SWT0@55QT":RE@WPHB$V.D3T M,`EQ%7Z2N._S$*((QZ0)F?.["X6?]_1[IWVP=L(A$_*>=1H"3M\28.-'/T"_ MG1W+(!)\NT!Q\3/0*)?RZ+K?X[2ZZ+#0G(Q)C6-(^-8ZQ5Y%ID7=?.K6!:DI M9D+*G?IW@K_>R^AC=$J?BE-0[:A.BCXHU1S,=3BN@L=9U@SB*-Q8X45Q2HA2 M6G2`.HM/["A+J-%G0H\QH-#CX(ZNK(`XI]159=C@3PJ#D`FOUH@:\0&78#$3 MONNQAU$ZX8JE>6FJGV?",;(#7XC!84%K)F],)<#/&(CP1N%0F`O!8FX"0QV= MZ_N4RX&/TKV:IL(=ZM-&,233!I^="`%/!`4TT@Z9&/:7C>,RI>W,B. MXD9#.OC_Q]"R:;8M=9YC<='2%XPTI"1ZQ6;;X@-_S3146$C*_NBN^#. M*,G;)-/2&>C2NH(%R_U'`U+P6#`$'\G@@0-/$$3&(:5]<7/O`@.2K@L8I,[I M:7>_["%"JC<@-3^1XJ=>BS8,PV?JL,8(@!319K_Y]]7'MSFCY[C!B;(`/QZT MB=$.""P1LT<@#M:;A?_FU"S\7:QEH*8-0N'"T/JXN^+AK":_A MWZYIP]:(>RO45>EG2G')2?N]W;AF1G"/-%AW=4MHDJH9GD5FACZ9CXIV@0?: M]/0L"4#YWL8L91<_B M_H0.;8[;\7*INYXH]-_;RL`,[S2!=_]*,8PF%B&VX4G2(L7.\?0DS_0.HDPE#?6&;B:?KC"W!RS+L#*P*9U8HX;G0#RLYMG MR"2F@06# M5D`]^B)7'4OG(K'/;)JXYC)@%;V\9:SP:W[$R+^UG%)D;<+K'^A1S_IVOI01 M&QC<^A;=LP#:#()J7UD0FQ;F&!@\D.=D9=%,3N/$Q@S.TL0[ZO?2 M%8[*K_UA\DF^ESW+YF=&T,?'OTSD*A=YK33\6A]YRVA$R([=N+9E/K^G#=1I M3-&;Z+T'K#;4'HSX9P\K^K,'>G]4+;CFM_+(`NL,G\B5@V?M[+7L?X\PI-F2 M@>F+@;5X5R,JJA]2Q*^1=TB%PW9VHA?=S![]1=!:3P1H!? MEU@!37%,:VJ.1?TWIOWRLWK#8]#E2*GJBHT4H=B=42TIIEV="2VT8? M5;7VBHZ-CQ`@=DMZ+0N+TAM5W*MSE-?=Y6G?79Z4R4@^*=_#JQ1A6\-18VEO MI?;U?0$\8&/G:Z_<4M3:_4NYU;;MO@U'M75772E3MUYETOLS=-:QEN.:QEU\T]>_K7=<(4B>9>TN7H-PQ6H[:*%(1:+=%>PL=)1 MC=VXA6,;//`UEG++12M+X*]2)K'!9MXGP]'^F]-OV>7R8'K38SW-^\AL\1X7 MO'F$X066::W8-6^?F*%'CUB/5.U;T^/US5#=N_:_W5+]#[W):]>GNRWV*=EN MT]9)G`^]<&W@X+$:IA;LQVI_[Q;IE1NDU](K^3"=J+\(+C-,M?+ZE,@Z80C( M9F;CX0OZ47&UAO8[5A]8YI%:K=:X4[IV,M;USGYU]JMSJ7(N59RG>C5V:=_> M5.],ZW7&J#-&!^],[2R9S@\`NW1ZETYODV@/=I=.;X=]ZM+I+=B/6S![_94;I"X";+,3U:73V^M.'44ZO:V*3U,?>/VM"P]> M3)\'PP-7YH/?C%]?='#T6_&4Y7`[X[5CXZ6?J.-)9[^Z8*++;]0\VSYNR[3O MY$9WNMV9HY(I2[5]BOO(N-T M;2=PO><+-GG@=5X^[J^[?+R>1=O<-AX-VWO;>*1M>=NX[FWE%_[1`:`KY4MU MEZ.WN1Q=W(B.?NTI[_`7:"\H58\Q?>W@X;&+IK`'8$8RW<7V%M3BW1H_XF&F MQYJ*WG?,-#@9#`[A?E4GUTWEJNF'GIMKJUWZR_6^PPM/5YZ+?=*5-[&1.E'H M*$@V`NPTF^/U'*U)@_=/QGUQ@>@ZIV`90\:3H:Z=@`"?M%#MYU9MT^6 M8_D+,E7FKCOMC-N>=7]X,NR/#D#W.P%+.VJC\:%7-!W\J<5Q%H%T?&S!4;2< M9%IF+?<=S:K#DTGO$,+93K`;"K9_,CR(_--1;W_'>FC?'CH:?:VVJN+T`?.$!Q#CAN;]72TEJDUIT;J2;_7&:DC%K!VH@^ZFH>7 M]KCBP?#_)[JTI_X>W>@+C)^=7=NUV@][7;'#$8NW/]G_=)DC]\%6'ED9SW12 ML=JS-7=7I$4M7ZW7^U\M9+WHVI*QK,:=;W.]EWL>YRW73H^=K>&CJ/BHW\R:L'X MG>/;!?R_1TK)[/J'_^]\9TAF>LDTO>&LE=^I.["3"K[ MI'YG*Y M\#L_\%_=):/)NL:J#?-TFQM)$ZV]-Y+&O2UO).GMN>+3H=NANUW(=>"7BH;[ MO51TO_`(26A9P@L6M/`HNE1$G"D[NXH^*+\A]OINA.U9>%\MARB;B$S9IZ1> MX^K>\Y7![J[F_AB_OZN8KYSQG<:_.HVOF:IX#9>/,03&^DO?L(_VNLN^$]B] MLZ[0Z!BE>@B76SJI;BK50VA/UTEU4ZD.#D"J6Y40[,E_N"VI;3Y25Z(U%6&= M3W'DXNWJ.8]:O(=PZ:83[U&+=VV]TL$D,.XP<4&]#P#WG026,^]\C\[WZ,3; MB;<3;Y?A>(7B/83(X1!3'7\2AWB&37T-8[K$N6D!7MU^(IW#T?G3G7BE$8'% MV8GW>,6K=P[',8NW?Q#APMIDQZ%?SCK.&[4='SL^=GP\/CXVG'>6DU7+=O-] M%TBHG8]VE%(]A'OSG50W@S_HPN6CE.HAY+B..HPZULX,'2<[3G:J6SH"/6%K9I:9RKQSHZ>CS MB>'Y;_,<[,K/FDW-'<1LUDZ^TO(]B$DP4I['GBW7OUT;8CG;"IX5SPBZ0MG= MU_9W)W['+=]#&)C<<(7'GFS7K>5_/YUYA"1SPCL;]A(Z/M[_#9;?.B.V,P%K M9[W]=V.I(>!#]+_C9^;K?M\:^VU?&O MVJL\B]$&$Q/,_/-\2.JK5 MY5YWG%MR/EKW^1?^T0&@^QH/Z;KCW.XX]U!.%;OCW.XX]_4>YT:NT?N6!^@O M5KR]+5FE2$NO]#O2[3M$/Q'GPZO/&]=V>VZD-G MJW:KS)VI.F;IJOLOE-K65!WZ+=7C;`K2\7'WS54J]^16Q6$';RM;4%3:;84[ M%._^*_%>^U9XK%>Z.TX>PN5XV?-NZ3*(7`7#E%COSP'"%*%\LHUYO4*$F6'[ MY'_>Y9Y.7GH1>AY^:/FF8?^'&!Y@>FD`;K7>?WJJ:J>ZRB"4O2H!=NF:X3+^ M">L;\`D^\^M!^Y?.`)6^I@P2(K,!'/S?(DCQ:_)P&!(;\0[_][0W@0_2L%*O MRD.Z?U[5!*#V3O^5?C4^F[SQHQ-8P?,%?.X9]I4S)3__'WFN]VI)`O>_W5V*K#\= M_/+'8$`-^O^\JPVQ,01[P*&,>A0@.%:W07!)2QONB;>L:4!NU-Y_(EC"PZEW M(@;7LV\.V!2'3&]P&\&".FRWXCH$O[L.%J`_S*A^MHQ'O%QED:UY`=N,R`MY M1`1R+HR5%1CV!6#F68\A+(EG8OCD@V%^IY5NADEOMXJ4 M8%7)%UI4\A$9EE#S<&OIU,48@]PN/%-)1L834P2B%;BFT`I2P'I-U+KH($AM(N"R'E836-581HC5<"2'%3,P5PX6 MAEA/Z]9S/?9H^D`3,%=K@X4O0@.<-/AKP"&6O$^`"%H)RLE[F,&6[.)O+=-: M&2R",T./[FL?#-\R:^U-%2MSJ"8,V0BX!-*7EHV;6B-H]S9'FX-/(^ZA%00; M1O][Y=QX9&584[ZF?-`^T;&`/[_")L?_\&%1^DT0,YCT4]1LB],.*2S3]O76 M?ZBJNR:0>X#97WX#__#*]T,T,=\>R_^\O@1>27^3$^*X)1+9F M[U#<6V712%$"RP7<4,-?%%IL&2VG6US*V2V`(N#P&<)?$/R'T+(Q#/Y*8'>! MD"A6<@\V`-PTNO5V8$UO`-VTZT>?2KN'VSI\8-($ MU[,:7D/(U7,(!\.A+')?+,=:ALL;XJ'W:,P)97>SR8L;\$I$E#&7=:9&Z$IB ML$L:"KB^:QJ^ANCM7<\^_@Q@S\CJ1+49I4+/9^F=X2P_[H!W5SK!4\TR+?<0.X*6RI:;V>82X?_J"I?_<.?W4^)XY9 M+X=8$5Y-QLEJJ@281\Z_=M;%O9).E=8;Y;#*0]H8&SD'J*]MB`L_+_"^N#;X MK[;A75K&W($@RS)A(S>>_7OW`^%Q$;B\"\\-YXLOA@\!12I"B@.DNM'?'S># M*"W8/!(BA5$:XI+,"!C;Z2?+`8L">QAMT@QNC!T"9E?.6G=4)K4X%/=/:31$ M4CS7)&3JH\$2/"JP9+;A^];,PI@$GP=7)W[]N1E83]B(J@'/*I79W@J;$JI* M;UDG_*GPX1L1W;",SH;P$ZGG+P%7@"5E/X*1I1F(#\_P4G@*561]WEO2<+$L M:T2E'!X-4R)E]`;TQ&4'='RV3)3A])Z8"\>UW?GS[F4R'`SU(FHVQ*41>M9$ MKC4%)<:M:8=+2+5QAV/K>"5EG:J@I1'C%HNU\S^?_@V.(#WIAD?!7P3JL1>$ M!UL-+.=;0B.>:(&CSP'&(#<>H"AI*VEVAQG"=H=M;:ZLS1#?NSS_"-^>IR:& M-\B4<7VF;(?L/G@B>U2E[X4IT]!DODV-3%`^%25I*?NCL4CJQCAL24&SMA'/ M,Y(C5^(MKUDC&?")F7.\:0`J>->;O%M$B3@6A,3@J5I!=-3,-`BLR:,53(U; MU*HM0\]>$@O7!%B!8G34<>$^@?[.21-(JH#D66\-FH5`T]UVHK0#CU2Y?FV= M_>KU6,)[/9CM4*F7Z^H/1Q-I5)+=^BNIP90'6*$/W_R'.&%3ZU"N'VT9:Z%O MA6!\K"B%H#IJ",&&M$OM#_O#:H3J2[8A55-'JJ[)XX4.$CO*NS=^$A]$93;# MKWZ4[JT#K`FT:J[,OJIOA]:M^VS8&!(TI5@#+.XM0"D+:$MLZO%'TW*&JP8N MTRGO,W8#T?Z5PZ/-K3DSPJK--#K%D+9$I^9*`Y,YF$B@$YV1%X].:S`,&.2, M>BW0NT/W`?-Y#\!B6J-2R^X/VD8"=_YI34S:_7_@+ZJWX6IM(ZRTVF<3LEJG M<4!5X%DX*>6!!B>UJ-!:)YP[8MN6,Z>R^6)XWPE6U6PD&;UU)%%Q\("K'@G# M_=`@71S;.GPE#+#:.AH:LL!QZ7)[*&O$!.]IH:\G:W,;W+ZUL[T-WM.VLHZF MC8WPOI;-YL=?L??8GEU/DS#`_;:1T)#]U5M'V#%ZP)JD!]RZA;.]]6V=ODEX MP&WS6:KJ?/;$\W)\)0QPVW;MQBSPGDS5&L(:L<#MDY>4"=Y3YFL-&#5C&W\G!0&S>,;\-,1;N7.^E="U`:.6F?)F<`-L'/":PI7H&$O3JY M%/GQ)ZN0Y>7"JS#@+\,[R&!C_1OB4>O"FC!L;!?R?5"*"6D"N5W36\NP%!-\ M:*16+Y_CH+/62MP+J145\S7[+HS&8WZY./WBS8#5/+#7AZ/1J":PIDH6>OV1 M-BR`65P=4`]T/7*'D]ZX5Q!$4@[A5`MJ(TB6M,S!+$-]HQI/?T:JGJFIFEO/*UTL,;]'6'*ZE&S]_8; MJ1;N:X-1#:2+,6@(=RG_^[2O]R>]!E'?1H6[7G7/*@RXU$`BM\4O#&\:X]>V)U2\B,O95-R/M[S74!M$L9L6.T62^XWD8+%S/^F^F^4T5%PL<3ST^6>P5(IB%UP!B]3SBAA'# MBQV-<`OV[]%P/5(,UI8(U>82(#09-8!0G\)KM_#8#CAW9_G3=J7_GVHTTW>J/!IG+)!D@]3&0SM'V)Y.LFDJB M(.7V]?5A-L9JG`65_3;&(TT:!3%CV$B2O]=;JQ(B/#G$I%6%WOK8)6:2&J0. M]L2P2L72UZKV>LS018VN,S=RY;XWCMK&E8'9``E9)=+[4>?2!I"0:Z_3&_7& MV>VO>3Y4;3U]5IA>&PE^P^Y\^H2[7%/I/JV7$48QF"UQJ7E_:[PY*I?D,;AR M?(C9,*J+[J?>0CC!8HJDLU.-\!C/>Q_PV8?/KA&?($.\_!.;:^5#X>S]V3X- M=,`:)434QV\/=+&F877IZF'GK%;1E18,$.=,7>>!OO31<+X_7,]F\'&.\$I* MM=9),"VJYBA5FY=I5!]C/1&\)NX8V6Z7I5?Y[Q=$,>+V6G.\8XZG.DH`G[/; MZ`J[CJY$]]$5RU?\\/%O8@9*X"HF\0+#@KV;6@YL%6Q;2XL=$ODGBD5[%^$; M#7#SYXJ+/1#\]\*/%/@_VP+K^WOF0S!#<_CM"1)"I[NQ=RH0(2D^[07MSA2# MGE9D'YT"=W*?64_6E#A3>*%/NRP`662Y2MZ))">?X4?O@/H5MERBO9-0;:-FT-<;W*2^97]AJ8!/+SOFL`^2MOB^\L,*%HHQFP'O M01_@M_ATEC)_Y;)W)2PY*].Q(EW)ZI;818S0/;+>S72F,0],8S8;(I`KBR_! MXD50?;B#16=XEOMPXY$GRPU]^_F!C2`";T/F]L5&U,27I[E;\H$X9&9M7K90 MY'L,M%$A8B4PY1&4.Y#0](FV/7Y\C%3D(S6$E>YF!88.M@2TVP1C?1$A,P!$.NZ*Z!6 M"*@&+MC!2W[@@116"4AY_.IF2O((GH*'KK\`AK54KA`]5=TG`^M@V-,:PO`% M5:\8'PCQJ*<<>Q\8F;$S[!">OEX1CTHY*O;O`?`FB:[MS!$^ZX?S;_"'^G;MD[Y(\;]3]Y M2E\&]=:SK>1*S1\WVG^T+ZIV>>2,2][$'J)-,^\7AL/Y42.T;^;"[MXH?"E& M(VOJ,W7S>UZYW@$O0DJ&>W1DZU_6E/`H.C6+8Y/;())=%_7L'=$Z&.V(!MG. MD8-LI6'3-)2DY67<*.;GC>KB6I9>;Q;?F.$/UT[!/<_B,3.#MM)P_\.M2X/6 M,AJJ];^8#G4O=,@.VVD7US4I[1^VE8;ZVM]K&PVRVK\U'9\L`$`^0UR8NQH; M3U_%:<>VZX=U:I\?;B`D#/4ZI+US2>ST/YLS6IW`?GC M1O_/\$L=O))WI['YT["-Z=N.Y$&T'SSA!)H@'E30Y,7)#R`T< M#J5C^'IP,[CN>'@$[R"=S@O7FG<@@Z%L0=A`S60;=H:A7&9],%:U/7.PZC1E ME&E=O!F&KCO]8=E;=W0>J;U,^^WHS9O"JT=U77@L_8=KDUT;SN?_/I"9ZQ&A M2_@7RW$]8=P!,#+]%ES0P?,7$BSP(EI2;-%(E:::(>L%"6@'YV0MR:DZS-1U MOCK6R>UE0RUS'/OJ^"9K>D_5;`W+GEE'7X@-ZQLIT,DXJ!D0Z^$W-CBH`$`R M_F+KRI)AD?@R0+;"HV8MB3Z4QN/C3P-V>:I?Z=]4`V2#.-;L M&M$KD:`$CDU7N.G9"R"U*L?J("2]1PY&_=U@)!EJE*K8C#E6A-![(891J M1W#E9,9"-:%.I]IXDD5M/=1MD)03Z'B46X[-H%AB:V57YEC+KIS;&9I`-#,8*5*`':1D-@'?A$')V;>ZT*O0+B^#:,394@>#"LS+$6@(=3F6 ML]$8NT&\VMF2M:5C+>_ZU0&^/<9R7-9SNU(SV#Y!*`'A1S-*##O4H,I<"2!E ML9.SI&J_2D\W0(U62O"@SIDW;`L&6I6P2\$W@[?DWM^OLKW2:,=#ZIITI]3Q MH,H)R,+="D])\YI/SFR(9/HLZ2L)6"-%D$!CR5]]K&<75S74)O&L&2SVU5'6 MA9;`DP:331[3#/4<5B*,^@C(QH79ZP/2"$CI^*0IZ+)!GY9SLFL@T%2:K53Z M14FV$M"-LKT(+ML8G_$LV%^0*>UA`6OE>H9M_KTGLG5GU<%HG#WWJ(39()(U M[<>PGW4:99&L-0"ZJK_(,!?M)&^7@5LS63F<]+(:6PGWUOCQ!9Q_SX+7-*LX M6F[Y5(%L#L6:%?6#,CEMBN)?KO?]RKGQ7)/XS;)1'V;ZLM:`V2"2=8^Z>UEG M2`))=G["XJ7(YC5BR'.9PV)8$AA)[^MYF3:$D=2.HVH3@'0S;0K3J-Y;!9PSG6?EA^`JVB$E>P;J: M0&PYH_TP+#I-GC0P?8L+@J)2@#OP/$<^U6Z%P)V"BD.L1H.R;OEBP-"R\% M2Q!8IQM,%>;E\#.XN\[\GGA+[.O37/N*?NX&7#&<[7"I:63SUJPF+@'_S5_$ MFB_P%MD3\8QY[%/@=>0:VHK2P1F'7$WK-O8::6F$:R"3I@!;EQC^`CQJ[%4U M_?#\S<=#,]8T"/3A'"]7-W?Z->J/TZYJ??B-X"UYVCC4,N?(#:/-'-+&V7VJ MC@9J+<0+$&@$<=F63&HF`=,PVO'91+/\UL%1T^O@70"_$;SE1N*-,PG"+9!. M*AJ;X.=P.,IAED"H"UR^T#A;HRT%7O(<>)1?`0V27EDKG&EJ7Q?Z^9-AV7@X M=>\*;=9YR";=:BBO%VJ_'+UJ'&0)V*(Y3`$):U2[#A89(ES'C=8G>T^#!U=X M.)G91LK`R6`EO4#[?7UW6,FMVTDF@?$RC*JT)KV!'%9!?-K<5(^__B2K23D8 MU4@T/,7G:XC>-N:2L=\F`KHCK+WM+?#:)UCS^'+XG,OKG6W!*<9+(TY9"VQZB> M*">9*2@;821Z:9$[N(/*?1E8]??\NL"V+_P=Y3E=`$@"'>ER,VF,[D)GZCTW M;X_5D5:P8,N@-8)8W752X&?4P^N&S4KP:?/`5>B9"\/'@XXD;FXD7M?2$50U MU*VPE"N[Z&>^>X[`(CWP(?6`7>`ZLUH9.ZF7?-%"7F)N_L`GX"L2S M];Z-A$Y];=A?CW`6[#982O8QT3-=0K;%,=7B!N=6%7;7D4V89^]QU0??"-I2 M/!Y.>GHS2'N\'_Y+SP^N![A99*6G"&^/[.YF"9=AN7YHKRQVFPX4;@X[/L1W MBZDF$:+O&@>VABLU@(D%42]#G@Q$61K9^-R&A]%L`Z)F0O8&1V!9T8Q$L*!" M"J.QRK[^,+M&JF`VB&3-BPBLF>]62+HF(5/:8`87%F+0N',\F&B9JXR58+?! M4BX\G`RSK&P`1;8*OP&SO"L'.U%:3RB5XD;3Z`[X5]&@MM)NV)N3-P!USIO\ M'>);SAHAY*"JN:-"HM-)-M39#(?F")"\[=GKER^8K?`O:$S9K/NK9@ZN-P"> MP[KX9PWP,]Q[Z:>-U&8R$!7E2&9RYP*!!Y(K9+&=[D3=_)(!.&KP4IBYUT,];Q MN+][[.1DV^OK^AXY5W7JV,O4RFV$'8ZM)=-H#M2Y:8;+D+9*N20SR[2V3^_V M="W+O"J8S>%8TZ4=9$K+-D:1MD%X;FJUTG$367.2`E$;O-1R!/C]9L!+^8W9 MJ;%-DUX!/MM[L@;X/T/#@ZV2$!]]=8LUR2R829)>/U\,KUH0VJ1$$];`3..( M#A"]Z?=HF-_ODZG*?WJN[T>>4BV=!1D:SL.E1>;NAI=6I%?0"F(,K^#*Z,ZJK.@)&>1)\/JDA:I+0B$>E M];1,A_8B4!LB(^M`Z;J:N:'>`#*2AVCJ6!V^&%^JPAMM,MF8+\2V,;9UIF"C MOY.R0WA9O1E/)AGVE,*3PDM6A8;]3!?SAO&2;)XVR?0>?2EN58T!&(TDI5B8 MV6HDZ3G*JGHAJ(W1D;O#T\M4]J(_',#6FN/F3;@U=FK/Q\.5Y74GU(0NCYBC6`F$,SOJ3 MXQ5&_+YSWP^7#!/<+Y%/EQ9>\W2FN9OJTM,PJS>B!E'>)X`> M-P&'Z?::$[I_^>-F@%.E)Y<9%NP$I[W07MK>!2@??AGMB_"F=>S?K@VOH5U$ M0,N^6`[V0-G:?K"^%KW^:,H::.&EF"^V%/0P%D56PR.!LUL>SV&H`TP+]:B;$\]X9G`[5-W*-S\SZY MWKWQ\R\K6&!3#\N9PP>-Y`8+EYFNZKU^A@<;HI$AI/'FI.IXH&9(L(KUR]`##C+%8"R.!N*PFPO\_A6MJFQ"JGUL"YK!='-,-B`G M2:W0G[&]W/5FQ,HVQ9&D2!VIPT%-BM8BLR51^6U/EJ!L/E4*DPVH$8MT/_XD MGFGY#8EF,E)[DYJ4%&)10$5R*?'&<^>>L8S[42:74Y+?%-1X2!W8LUKUW"*7 M029-TST.:@F]9_&2C=QMR>*##AV<)<&,KP&7QBNS2[$.-+R+5.Y.ROGT[Y#U MQM[8>2F^C*1G1D5)8E.#I.M9V6N:(D57,\>C&^+1'!&UCIW+J.BI+:%"9B5P M$O0:6K570=2BHM??.16YI^3:\)60H(TSY;H;8=$4`2^Q&G9+P`L``00E#@``!#D! M``#E74MSX[@1OJU-]K9%DY"$&HK0 M`J1MY=<'`$F)#[PHD1+AU!S&DM#-K_'AT6@TP"^_OBT"YP5@`E%XWAL=#7L. M"#WDPW!VWHM)WR4>A#V'1&[HNP$*P7DO1+U?__77OWSY6[__^^7#G>,C+UZ` M,'(\#-P(^,[SRGEX<*Y1&((@`"OGR9W-`,Z>XHR&1^S?Z/3TG\X56JXPG,TC MY\/5QX)4OY\^X](E5">5XP\[/AJM?[FG,*>0_WA&M0Z./P^.AZ-C9W1\-AR> MG9PX%_=)V0"&/YZI&H<:&Y+SWCR*EF>#P>OKZ]';,PZ.$)Y1R>')("O82TJ> MO1%8*/UZDI4=#7Z_OWOTYF#A]F'(JL?;2#$U(CEJ\NF`_TJ+$GA&N/P=\MR( M5[\6ER,MP3[ULV)]]E5_=-P_&1V]$;]'Z\!QOF`4@`G)D,G_=)TR?!'Z7\,(1JO;<(KP@J/N.4SO;P^W M:_A_QI!J./+08L!^&JBE![N"NW0#5OF/60\'2\! MYF89X)#)-0KHRB7SFP"]UL23$VN`'@*IR@D&A"HW;#)"H9VA7*'%$H,Y"`E\ M`;=TE%L`/12A4"-0XL2P\?2KBT,ZWI()P(]S%QN"4HCO#.\V?*'UCC`$!BVG M4'CG1X^C.K4E1KZ&),68!(SZDTZ=<(3KWAC/JW!GU)J7P[LT:4%+& MSP&<&59716!G"#%CSC.M/)-^EKU>VC"M%&_;"ZN%2R+?AH=>'I-;3N+M7HLH:*6H=L M/MB9Z=E7'=?H3?7TM>3DF]:S6KHE<,;M5B/>+KQZ(X%62[M@1SO"'+6[<-K" M;S15U?2BJO8TI19O-DX[<9D',0<1],P6-W+9EB*X-1$:*6DV@GF'"$E\G@D* MH/&R7JV@E75UW:9HHB,%2NO5BP->V]3/^E$`3(N"T`=^!IGIWG*7(E4+(Z9A M.'3Z3E8^_Z<;^DXB[(A".8UA+>UA%,&-1@S>NCW2O^FP0RC!/M^<2V6=1-CY M\%OHQM0Q!?['9)N(X@R05\`6L`TJA(O,I]#X+M34)<]\*RHF_9GK+ODVW``$ M$>AV(*_P%X@)I"??+O(-+T+:5(M[E3 M8T\I^]1MRK+@V(I"EU!4+-)M2HI84PH^=YN":S`%U"#_R7U+[--V&J5$MPE2 M0D_Y^J7;?.7BCYN>+^T[PK+=YD@".F5G-.PV/1,,EB[TO[ZQD`&@4:2W:;.R(2,R(Y[$Q.,Z`([6DWH0H8OUZA_M&1+'?E4I1;I`'5BSE2@[7`C MOB'DO\(@D/"R^;FC'&P`VN$SW(:1&\X@'9?7L^C7-R^(63ZOA@LST8[R9`;> M#C\B-S1_1Z&GG)HD93O*D@2M)0Y$;K^;CL:B1##I:^+98!6`#R`@`79C3N7@9P% MW!E888>W2ALACH'_@%9NH"=/6MH"RJ38[7!SN2-AW,NDI2T@2HK=%J<)A;,G M@!?7X#G2>K.RPEWAR=S?D!ABQS"8B\7FC->RIQ>SCD>]278L*=/A/A?`U;*I M%K&.2;4YE@RFYERHP<(6X[5MLLJ1:%6F:JQ2R@I0K:#I_QPO=A@FOB0CK-7KE+&+FR MO09I:0L8DF*W8^G\P/)H0^!G)P*I8Q0O8AZXH=XN]*#,ES`1M(`^$S/:=NJK M6=/LFS_2M?T$X>309N709`2D7IWOFHH3C.XC&TR)6$1TF M4EUA1.O&&5NT[<#W95#*B&\X35YVQ4ZJ,,N7/U;FRV^4.&CJ;-0X'^*#9LY3 M)I+%+#O%(1FR2V4.EQ3'GG]#&V)R`"JFX^ZF(B_!%&&06YC?PY"WE-LP`A@0 MEOI2U)(TU7L0S9'/$CM)5"^#]"W"O$84878P?JC&[`EAZIUZ@@I5#JH)S(6E*9D`)B.SK) M`R"`5@4[)W9-NWF`>'9P:JAT%:^4Z3Q5&OQV!,L>04!USJ@-]R[^`=B(H69- M)=!YRE3@[8B9?0,A'=@#:L&%OX`A)!$;YE^`FC2M5.>9TUI@R>[W@D4J_IM> MA7;A41<7LZW@8LJX+%1M*-QY,DT-L60O_#L*4='=4O=&1?G_YT6_J3W`;]^D'"V3[WGG*O4RAM/9W4 MV'IB6ARNYM!;3^*[:2:`UC)S1##;,KP&R?^R&%$M%0?Q+T'$T$TP>J',^I>K MWPCSEM)#7#/T[`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`X,YNB(>NZH,G?DI#GJDGSC/48<$]@`K,P?7,*I1@::PW3C M0LROB[^GCZ(/S2]\-L`J6U+>J:[;4?-Q"XI/2>B7FAHWZ&X>F+KJ`I5 M/V]%5:*K!0MRWI$,K\JCV@\R::M70RNV[_U?$\2`K*HWO;*0=/'G0]UCQ!'< ML(O6YL#/KFP=3]F=A_BELE54P*V2.LBBN%JKQ4T`(^1VG$5?F_(?A'^P$R/( MH\MV8^I44MVF3H7:ANR&2H,66=K08 M\3?B0]:P1M5-O#J\M-U'*EOYLE"2\89^BU2($4L#234@M]<+E)BEH]%I9?M< MBWWO+25][DB`OM+D]>A'[6R$RC(J=+VV7G[%7F;@8L:%S@!M_L4^,%^Z`0O@ M/,X!8!=',7=L#B+H50&/>(U++X%/%3F))N=#0=?'PE7P+;1^T0N4U=8<*ZV1 MOTUYGW85$CK92:3$IYQ0F**%I"+$GUT_<$P[4?6*[X,F+YG MVH7HA_\!4$L#!!0````(`$(P74&GJ:WN!1```.4L`0`5`!P`<61E;"TR,#$R M,#DS,%]D968N>&UL550)``,;5(Y0&U2.4'5X"P`!!"4.```$.0$``.U=7W/C MMA%_[TR_`^N\)`^R+%^3U&[?_M9J_7[UU'4\ZDY&0$+'98!"\)S>U'EZ#[ M,'5>T&``;#ZJTSDY%O^==D[_Z5S3\93AP3!TOKW^+M6KU8K?<84"/B;O%[WL M]+@S^\7'Y/5<_-/COSL<-0G./WK,]\*+HV$8CL_;;?'G,66#]NG)R??MV8]' M\Z8!7K1[?W\_?O\T;]EI_W[??7:',$(M3((0$1?B7JD>R=$_M>=(YN.+OPLT M_UAK'P/JG)V=M:-?>=,`GP<1L"YU41C-4.X;'&D+\5=KWJPE'K4ZIZU/G>./ MP#OB+':<&9,9]>$)^DZ$XCR#\19A]F_D3^">OVW"0+"G*%"=,9)H$7-U`4ML M_7SQ$T;^^XB.(1^"N9,>M#S,WR_6Y2,G?E$2^V(43,(V;]J.V[0S!Z@:]>)5 M+8^.$"X(>;WW#O%"'TW\<&/`\^Z5(XXXTQK!J`>L(-ITUZJ1(M\OAB_J$*/B M;J7SRUR"G1OH8X*%T7"^%6Z'1TSNGQ%AUX\]<435R!@7C@ MS:D2K][(QXD'Q:'H?_+#R8].R[G!@>M383/X'Q%2VG=FW9UOXP&<>(3O9B[< M'+)/W11.7WB0E&4R/V)A'P6]B(_-A71#NSL;H\_H2(NK,0:JIH(R#QC?`BZ4IITA^TMUNHG4W[F/U#]P>Q M(6O&4-_$*ZH&[IO4XEL(^;H_)I[\\0P$4Y9^RWV\#*4`Y;8N&],SN%SXO&+0 ME)V,S7=2]S(I4#4LCZ]=2CQ*[D@(K(?(ZV._#^P)A="EB`1RSFIU*P^EV&MK MH,IL5N7JL>X"9RT=TU?L=EZ-5LO*0W/(9!='(9O`\B$E(9?`SWZT MZ;HX"F`@_D=3`>_($!B.BGZ=/F7.>$>X($5G+*)4$@2AR,!$@27O*_<7^`]H(%O=B@Q@;O8H&7!@ M(P'V-Q`'0L"[?`/&4241RV90M[?!6>P#XQ)VBXE86JYI$`8/L&I( MDQ#;5%&9W@06FX+/8@6?E07)YDQJ2(RR4PN`ZX@[!F_A< MS3^/QCZ=`CP#>\,N/`\1@S6:+WT_OEGAL?\$+AT0_+]H>X.I%SG+JC1"1>\R MN(Z52\]57/XC9%NUG%?^6BO*/RJ5S/2Z7#4_+3PIV)BTNJOE#CE:#D%+ M?E4O,Q<7X'@>^\_(A^R3;HIVYOQ/"(!;[.$E\6[@#7PZ%CN MYI9L\/F8`P[N'K%7$#>VZ!"5W\T815^``$,^AW;IC?C2(#*J(7X#';(T^YHO MWMJ524^Z!579(6OJM*JUZJEXX;IE.T`N:%E&:U)\N^-+OG&U)C&X.Z9HFN;5 M9*)=U9/-)J.)FU2VG>CFU,&5_A8CY:$5\:K*^$>Z&/74>#%JR2QL+.4!:OLN M5Y8[CV8,[,JM6P![3:-CYS":N\#'A>,+J,@8UDF\KC2':":6M9L2:IM#VG&@MW,-J[S2TK MV3.J<=^*9L=#RMS8%F1^H.2-^U$P\[V"%QHB/_F["%8^T/`_$"[#F$GOSD+$MY3%CT0[V:4XNP:Q?]Q>CC3K]!CR=?=EB(@IZ<[%4S]/-8;^ MA3<,@SLRDZTOC`:E+WZJ-^T)WU;N/(E^%%?7++Y7NA.>:J"H'[\_(C=.]*G;*0\ MW-`Y6;4"\Y$<1#QG.9:3&,RNH_^2]DUIX*.@"T* MQ3$9/,\RN[K'9S"'H9(`%58RJZ%E);Y;SVSZ\T?K]%I8X7MH>ERBO.X0 MM5@K'OLI2,KU6=&^O-3_?.1'DGV-CZQ1^0A>WFD^@D0C\\6P(0HVI2(B3W56EAV;A&T]-4BBQBCF%>"TDLEK6H-O;S#4DQ6B3 M7"^R^:1:4_>IR8C&T-15H;:JU10WW+W0U(N4)9K*]I8:LMSOJ>EW-WVOQN9& M39]&2V_,.#1;TFQ+S<=^2]^3[4T45Y;3Z9QTME$W\^F=9J_01'4/.*J[MWK= M+*>E;1H>*/DU6'!('F;-;M=$6DW$*+/GHA3WQ'281.F/@"5S`;T*@HB_.9Y(C:5N>[J^_X):OJ.GU+DOA]?J5 MA_.>+TVCR6@Y@8_]3:%O/%1]TQK1LGHE4?=V9]-$@9NDJH&DZC4=C7`X^P(- M\:XI$9$7("Z&($_CUA0N,5:DE@JKP,7M[7CJ6)M*3)`S9RE(J05K;UN?*5]$V=C M5,8`E5Z1LD>)AWA]A$="VKIN#Q$3Q``-Q%#_IH;>`.?CH40 M7U.?(Z%L=N''@,'LN@\YUHV&,>^7%5<'N?U;$1IK7#`-95@>^)6+7"WIV4@L M[3[BW*Q:M7%&N6VQSUNPK!%P[!&5+;Z>.%V4:?N+I.974`!//;\ M.%"8IZQK5Z)'_9WE`!;II[@-*H+70^[K"T,DX)LZ<59*=?14WD27#<0 MN`Q'M_4K#(UV;RMREUKSECI:JDN>A;5>!ZA_EHMW-KK]2MC2?XBLH2CK&P%(ULW3`X0;SE*JIZ6Q MIXW6B!7QLZ9>J!"16TFI-25%I3ED46H;BE;@'[,6X0+]+K3:6%9SF%HJ3%9-F&)9F@R(*MKTK6[FTN?40+3>\1>(;R=$"_[ M@']>8_,)M<+"F*JCUYXF:]):104SE?.2S&+]BGX.P]#NKSN4@)=@_2V#/RM;:!=*BT,(2HX/3R>HEUP1="6S+4[R_8&#B,I6IGM>C-X9Y6N_(>!(& M77$]3$?I_RA[F'>""@AEIJ71FR_[?*`BLII)>-9TVOW]P(.SLGOK^62`N\6$ M/\/(?PY1&,W)-8K<_-P[5+8?UDB%45GHV"X6)UM\FA(M81[)13>1 M.TK\'H;Q::+HE471C62?#06B&YUM@C_U#_Z8N81IEU&3W$4V?B[^Z:$`^)/_ M`U!+`P04````"`!",%U!;PONXP5.```4.P0`%0`<`'%D96PM,C`Q,C`Y,S!? M;&%B+GAM;%54"0`#&U2.4!M4CE!U>`L``00E#@``!#D!``#E?7EOY,B5Y_\+ M['>([9V%JX%4=Y5[QC/=8\\B=96%44E:26V/82P,BHQ,TM%]6*`<;7RO8CW"\:+X\4[?O^_/^\2](;S(L[2/WSUX9OW7R&/MRC*PL,.IR4*?T/_[\/WW_\[NLCVQSS>OI;HW<77':ZSLZJ/ M\Z`@;1(^UMEOO_E0__*)B+6)V8\_D%:__>WOOOWM^P^_11]^^\/[]S]\]QU: M?^*T29S^]$*:001<6OSAJ]>RW/_P[;>__/++-Y]?\N2;+-\2SO???2L(O^*4 M/WPNX@[U+]\)V@_?_M>GVZ?P%>^"LS@MRB`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`"2"50S8"*&#%J1,B7F@-B27HF MS4J@=']>_HO+Q!,?NOW;HM^WW[%ZI:62*#^\)R8[/(1HN1+S8$UZ3RB`EPGP5:"Y>3WY;^Y5$#QK3L_ M+OJ-)3WWOFU-@RC1TEI]'1=AD/P%!_DU^4NAF:<]2CC-5@A]JMLG9"#:+95! MK=^<'%%ZQ!A@Y@-?9NQF1(<6>DY(!)?/BA8AX+SH26&<&=4&L.C6E3F84_/;T&9!CN#R6UQ-/' M"O7E5+,J,4]=DYM@N*%01%/$&QB MX:2L'R5.9UCUY[\]E61:TXWO?G,=IT$:QF2WS(I88Z=V8UUVM@V!1>><"]]B M,\]=J/[^E:5%EL01>[,\#Q+ZA$?F'\9E,:&]>OCT6Q<%$<4PT4Z)8*:47-3V MY.E2S#)-WG#^DA7X5C-;9%+T+\-/3U?/3Z????:9;"<;(_)H>E:'0*M9VJ.% MG*P*P?MS]H00=NI*A5&>S`/&\P/05+:3E=.ND)#9AZE]$12OZS2B_W/U\R%^ M"Q(B6;$N+X(\/Y(CR9^"Y'!Z\W3DA9GZ3L#:JF#%>*H:"ZY%89@=B$"/.,1$ MN)<$W^&RFE&J.:IE`5J9+&!T%B@-/=@Z992IOP14+"BO>58HQ>7RZ]8(V1]; MLA.N>D\5NTC?2/[F5$W$4@+LD,)->)F9[DK=_7_QZT>^\-P-J$O;=9YFS M9'*\\EWF"BO]%S\)F?4(P;BI8#1K4L M0+0U34,.M9L81>H_5E0??D8(3YA0>)L[,M^$F8[3.3" MK0U2J>926J@=1B-X=ZN1$$)-?8TPDB63TK(IWYRA%I_M`R1FQ)VS$_@T?\CQ M/HBCJ\][G!:87'KNRU><=ZZT"OQ6G#`JX`"JK1`6;%#J82U:;^I5G`ASUH+Y M+&>46^P3E>%D<04:CZEB99`8,SJQKWAB+[0Q''EA'S3:!1>_DMA,AY./OD+L M]`]S-[&1EU].]-JWY`Z0[7%>'A^(C"P8XN=#O*=O3.J+M)X%:LTWP^@N]FIZ MN%7>))-D*>0L;`W$@A[&H#1"_!5B3#R@ID$A,3$LIQ@?LRSZ)4Y4:)N?82;\ MJ7CMR2U^@YK(W?Y[7UW\O/@,'2C7DK?.D@@4D[M!?8.^^APF!^H:8IB/=JQ0 M=U)[6-TKJID/[L9J*YOD.BA8J]T?9KV>!D'+;(/>U?Q(-/`UG#*U[A-W9(YJ MS^(*6AAUT0K>U@\I(91":(3IS1]^6TNS]`SX$NHN=#W?:W+H6Z;V*@)[KU1? M*(%NDH8K)/C-47MEA+XJWL;!2YS$98P+9 MLJ[PVI/:EA=J<7:3KS?_;F_6YS>W-\\W5T]H?7>)GI[O+_[SC_>WEU>/3[]! M5__GQYOGORR^=H_%U+#7]TYRD?;!):LEFIW+H8X!7)DLG`_5U!XHC)L;8M(P M+N^+Z"QUB\$OKT3A:O00'.E3F9U[VRDQK&.;7'292UN7$MJ932:-VA5LSZG! MW-?J&-UNVNXG!'`37564O>]?1HW0P!30M9NGW&^>X2OY3&5Q$5,=#,UHK> MF=U22C!3@D::_F0GQ*@DU"@BY,L;$%QE/6.R4O(5:E[_A"7A4U`>Z;V<##'+1P%+$.4AX/`AXTD1G[0=%R.B'05AH"$1GI_/B M@9$?AEN^[D:]T;.`WK6T,"07+BD]\*U+(Y,F4`*#VNEK!@PH)LMXO+'8O)3Z.++"W)D0.G(1%/\16T'$#)""Z3#92 M2K#P1970)^&*IV2+V_"4,LAB]JJ+3I7[D!&OT$U1D*,>5(*&(?(77/Y_^N;] M^P_D5)VC-\J&]CA'!;\8^X M#.(41U=!GA*E+=9A>-@=F)_))=[$8:RZOM@PPNB!/:2V2IBYH+3#5K+>?!., M"%>-$%)WK7XD45,V!86__29GV[\^=Z;W>M!TBP+1=AS$48U%7!&A!W M52@D9@DOPB"D`1YF]PP%&[AGCA:.2UP1I->.1B#+8!M?O'AB[KVG)A-3)])A\T2P5%K5&G''YH MDEPJLP;UK%#`^N.,HUMB:*W$`:LKW(+I,`*"P1\=Z4(PZ0>G]DDWVA)9ZT4\ MG^7952_J@]QR#JL+ZH)NUES^:(6BI)LEBT_Z8:[MIE*23%W7#4137)!X M6*&N]=[D>*6QX@1_HW2YS%BP0?J%68EF>"GTX0XS&HO?MY=>'4OCU47+`:Y! M-I<6#;D'&F-YS.]J"OQ=93`"_VXI/2C:*XJ2VA-=4%].%*3>Z(#V6"^=_T!W MDD&2=^:]RI$'<-*;[R(^E99V@:'5`0^N(`-J2TNU`?+R,1S#B5YX<>_@84AU M[66#<[V2&K(_*CAO!3D-!: M06\X/6":'KE05UB0DP(Y;VC$[KAO2.C`XC&4LBC>&."SIY)*ME406O@24C M&RRQ8/!B,:=BW6^8#CYEB?IZ>$(%-\$EPI[.ZQ8)0!B$I'_I9*`[.Z-#E!`N M^,%%WH(MW>\P2Y!"336[+"_C?[##"?T]/JT(0?_X3Q]6__S=OZWH__[N7]^3 M__WGU7*`< MN"V`='VW-0QP;MM&H21NSYR'3:^HX0)PW!XI?(M+;!F`9WZA:P`FTV8O7KHW$N-L>"#M_R ME=Q&`^CRP6O*NG4DO-^LPY\/<4[3)G5K="F&PY89*#S4"5HG6M2*$RQXU$&Z M?DBF\0I`!Q$%5:OHY5#$*2Y$"><2AZ]IEF3;7IC![+HW*6S!CGHEY?PQ9UD: M,GPQ7]F8K4#N]WT!+*P]H#%"EE)7>7Z-MK4%$]7QIX]TRQ]3;K-"-8NEE$"I MZ=1"=W+2]&RSX8&:[-:#VW#_Z\`@IX4K$:V31U94F?T,I0/. MX@KR:N*OD.``+:#.)-#;EWI48&719<*>5$!ODP#XXDCZ5\]]G[HBX1?5C)VY MP*=_

Y)K.*)U,^$""-V]XYWF0Y;J6._Q2G61Z71Z'#Y&K>;86G[OB$R]2^3^DBW0/YJ2Z(357@@5L4N+VX$:/M_OK"!!%YJGCS MJ-7^ZJ36PM5G`'OQIU?E@7 M(\QJ;0">*'!I-/B=T`"='&2"=DX+;8+E3PC]WONG`EQV37J*_&_SZ`?.#?88 M2P0SWC7-IQ=+&;46R,4,7%,(N]Q*\&<<;U_)56E-H`5;?'>@68_O-[UPG/.@ MB$,%9,G%QZ`R]S(;58DF9`FWU`0\%9EF=&9XF80(*@R2DF6O)@@R M3@[DK[8!I\ZM>+4>F&(K99F:(9\0Y?FQP1 MGZQ.%2;?UJ>36(ZVBY+&+T3)X46,CPR$)MZG30X=^].7Q2(.:(7:;)Y$!5D@ M,;H!0B::KX*I[S<70?%ZG62_F"([]2Q0R>?-,+IIZ-7T``GI3<)(4M-7+'0Z M42;$N+QP1B`79"K10YZ]Q1&.SH\_%M1SM'8V6M-8-IZ2V^#5,Z`A,$O70,@G MYC#'5L`<@09*VO<,>KAZ7#_?W'U$ZXOGFS_=/-] MCNC=C_QD]#5J_.V:%KU0V77T]T-E"'_.'C&=\7&".]:PYVP:I9ZG*ZB26/,- M6[>>UO3]P!7CF@N+I"!6W16UU.>B,Y2>FG#IS_2/(=7=?4MW&Y>`H.YU^?4) M;LSJSE#_)83\_"6N=9=X3V9"S`[CY-\)IO^@,6;F&Z$=*\Q:Y`*KO;;8\$&M M%?:R]>9QFW753<7`"DE2[YC%]7@R/#4SCW+47(H7O$E26\]Y0/3_(MM1KR.= M)JF(@6Z/6M$[]T8I)5C4NT8:>36SLQ=*36V2-;G*1VS^:Z^3])2XDKY-#KF/ M\"SJM?-)Y95WCE.\4=:U-')![1Y68+H;AY8%;L^P$*MO:WPE_X69^5HDQR^# MSR)(ERZRK6)@`/O&$$R"J^7V)7RWT;N*%3"?$)$JQT2?+S'_W]9IM2I;:T[" M:=T`F%^F(\03MTI+;KC8%S<)%6I74+V3J]KR=ZW1F$0#Z)UH@MXR6_>AJADO M+D-]M.LPS`[D]D=N?CA^HUYNU@,E8_5%\=2P]"K7YX-P0;84RG8N"G[4-``6 MS3,86PTB5X*`U"/J6YR2WF)E:@D#CR^:(P&B5YD6@P>ZTI/&5DE:C-XHAPT8 MI=2PVE![Z`_86!3<_FB(!IQ)5R2L7FB-4BY[_6F"37S<:!PALE<"*0TW`#\I]W62K^0Y8T;+IF ME]6RJ8>#JM]4;2ZFE],*;*NP5?--"FYZ%^.I.ZI6V5]()_5_RY-XS:S2,X^. M&`;<'@8>31N*89@`MF(Z1%EXH*]O,N.Y!\#)7](L/>L.Q#<^G33$M>`A.`ZZ MO-9\OIPN%(#LKJT5DS\&(JE@ZKO=GI-Y8`6R$]QTX7Z0XX%4F*O=/LF.&#_B MA"ZVMXWQS7IL=$WXHD9FF'J-4O/[HUPF&65ZEA^HKWYPI!'?;'W/.3-<[9`) M<"G44+2#JH;0K?I1!U(E'[-CD%"A7#>Q/J,OZJ>"I%>Z4RY_5$TNF5+!&RJMWP&N7G1]^(8:1_$HA@NEP9\#[.2::,]]RS*:),IQTD^:?21502# MQP%6TP56>:>)/-O8!`&0VH:\TDP+R!8:JFG%LP!(HZ3]'>;N3U=/O@9`NL,Q MZ&G=H&]!0>0$7H575;5JB/QD32F/#P0>?4.A:0-9N4'%"+HT`*.B[A#;JFG/ MO?@UTE6T_L-7U0"-:*N:0**-%6*MK'BY&M$0D!/#:*2,K8AYOM!L0P\*C)\7 MM%&A\W'G'+V0^;]3CMLA(=)I.HDVQ=X!EM)R/%)V4&\)T/[&A3X?G/!DL^QT$_#F4+'"'M@-4.2'5357*L%'#].4\ZPD MK(CQLLQR"-NM;F8^ MH,7-%E!G;3,Q09TF+`7K6[\J6C;%JCRIE'S%LO'0/])?$YX[='FS]5!8@H]7 MZVB#Y+R(,?NA3:W]DCUK28Y,%J-CU0J\ICF`5>F=11,^:*&UF/+W7%!5&RY[ M5_'>U3L9N6)_7;W:RD[P7\)->_3%Q_^;];@;M5>/MO93MK8%O1/&H*\[[[>; M>K[Z]W[KAM+Q6@V8*IP(NDXC^C_4H/X6)'01>8.^WW"$F`'B__TX^/5$[J_1A?KIS^BZ]O[/Z.;N^O[ MQT_KYYO[N^7MT",!MKB;K.ZHU8`7MF916_$AB$U5FCD);.7MMIBRLMOT=SCW MVU,9Y"LS"\R-#CD](I%K#"VN0M=D_G0X8XE.W5RWD+TNPTUI)LR7\-#8]7DR MK=KQX?Q(]JE#3@>JBGE6.Z*/:PH@+\)(V'4NA('M+)O_8)20?#3"``F.;C/MT%: MY7>^R-(B2^(HJ%)'/Y"!%T-XOZGNT4%2UX6A,U#;,#C_IP+2/!I,TO/@S MYH12]Y2'EJ=D3YKMAKPXC8Y"?1D789(5AQP_X\_E>:)^29R^FR]09S3#-9GZ M2/J`.IW/@\-.MQ8_SB\$MMW-"G4Z8O:GSOI"QJ3N##6]H:8[]%?:(6(]`BY" M]&!2'@U[[2D1S`(@%[6MOEV*Q;8F:#*C-J!Z=;:U3/`[6&V\DE*3[:8NL6BUK>O#\%A&[M)LKO MR](9Y"FY<]'G"E;DP[2(*LF!EE.#^)V%54&[_!*K%40ZDP[-EBRXZ[HG0))-+$0"( MN6\K[M&_>SWS&6T]+5@OJ#:,0`9`:T@=DYZ1:WESMZ5(BHQ5DF>^D4NOXK&Z MG8V[U9EJ/;7D`7A^M@52OS.;&)9]4+:3QF6V:):H15Z(IT8$\\H["H5?+[5U M3D>'@[>&`RSIH0G$29)#%3E$1E&]+*K*+CQ5J!\G[QX$\\E;Q^+-)#*0D*'(EP<]-1962C0)O4)$/1V6Z<'9..5"[ M43\.5;:(S]N(C8>OL:UZ/O_U@S%(`>1-@AWZIA#;6A.6/R;.`J^UM?$T0(VJ MBV)DK.45=R0X8XL(JA.8C-T.E76'HP-99H[K-/J(LVT>[%_CT!Q'[<@+4D'8 M#5BK3+`=X]*U@%VDDEAY.#MSL&X:L`PL7N858$J(VP9BW+0PZ%U@H.)H'_<< MF#U4'?5SGS6G7\ICMI%::`_T4^`"(/U<%YR`3;@P3!8XL(M+?E-(R=DBI3G` M<1JZN)HXM@$64N`.]"2^P+Z!Q2^'`Z23.<2*-G@FGG8K7EP(K5!:!+TX->+Q M?#4%Q#BT`!@>XRREV\R%")>9&9)_ALI;FH_+9'@\)8+1++FH;U#%!KKH50EK-K\55WI.@M+D\6VT[% M>TWJR!,J8`?6KK!TPA,NDY2S3`QIOWJ/9EG>Q;E5STY,=*.,-RS M7#OWFW:6&:H;AR#1O779<`&8ZNW!U#9Z,\NRQGE;>2P3DKVKF+^>^SW+9(__ M4G$9[?'C@>U;K("F]]-H?RI?N$ZCRS@YE#AR3$.BY/8CE80!G-C5!J*:;;>S MAV'.S;!"C)M9\RI^P$5B'+H&250AN7IX\DV5ABB0EVKCI"Q^J,@0Q?!1&4PJ M0,O$52=%7L9?U?M)P3/_G2+%OKMR`F@B3X.6N5C*L:ZC`Y>JNI MV_%]LSD![+[=*)!ZL.$TT*;8;Q5E+.^XTL'Z;!4.[&#V`R'P*P-IZ[,"]K1G>7 M;$"27V^,Z[\NM$:3^_1PL8!;KR:`AOAU6L9L)8O?\!,.#SG+XG7U.4P.$8YH M07#M`*QWV2%561DG:AMF_YUT8,1N/^^NGIX^@JP0K#B<.7X M*N'I_9&\12^XNB0X/Z2,-A]G:#JB75_B=Y4V=M(L"`V&E'P+.W]@98G3:]RIWK MJ*\F=F@%M8/7UT@W7`NHH!&(3N=JYE6=L-DW!7/&IRE/`%#AXF-.;="6Y5%. MB(&K6DA%;SR4;62>;?XKA516?U@A1@I\SG.6&W06LR3HZS#,#SAJY4ZO-%$Q MFTU,@'4IC%#$[';#,-LL-PHMSUI?<;1S[]?K.\2D=X8A`(BT^T?FLU_B\#7- MDFQ[)#^$."U@%_@J!.'J<["+4V:[N$E+3(:OK,17KO86G,!1*690O4@5>S3S MK[$V*%1S+JXHT9DV2&3FW6T(@E:V]1;?"@E.L2X`[R=/AS3*CV[;B9H'<#EL)K8(YMU+-"++MQ+.X-=.X@H",*/-H2B)2N;KZ"T@<\HPTY740#EJ],*+ MV6TI]6SS6BUF[Y6RHD2"%'0J#Y![G^-]E;)S2J>,JGFR?9"6XS=<2%^))500 M#A9*81LWBA[)PLX2BO[5W[6AA/%WU6D2Z?KU M)VH`CT&)>1K'0YQN[_2_48G;3GAS2K-XAANY`#)/$\QF+6*TZ*^<&BR!C8]BV^2G<9&;*A!* M*.V49\;;.*758UB=0XM#HY8<0*\LQ*_U2T.[K)X9!3'5,?7FZ/CE(#%JXW`H M(>,!/$"V1;\.0O;*S9WF[P]E409I1#9MQ=G1DA!?$U,']/,OS[!?RCXM@3WXKCPY:I&O$'X4R0]7IECW&1=5, M"\I:X^I64-T,$NWXHGY.2*LM+:BSF,RQH:D>#5D')]MP]/=#4>+HZB4NH^"1 MKB+2-PY;5HA'0C=8S>.@'=_"CX(N0EFN\T@T@*[.;YXOUX@U`?,`.`.\%0I. M\.6SX3,_!DX!\&0)4`"[(\:*%I%P@I)_P2 MH1'+=I&HG75%&YXM$^,AMAR20X'1LZ5B`,C>8A'+00*:G#X%G^/=82=]>%'0 MP)S.I8**P[=6PMG.UJP1Y4I9%QP)I*#NG$F=FF`9J),T'HFZB2< M;R:>B-3[ROQWV)DX4L8%X]UI'L>;HCC@Z)(5BGE@-6)XEIJKW3[)CA@SH@%N*-K7C&BF*% M1(,\'2H232+6)D@H_63P+UJY3U',1R%.R0$G3:G3"/GIE[A\15B,`"?6BKK/\.?C\9R(J3>!*!H3\0>3NP!'UA<%I(3LOCFL*2,='P*X5 M?`*\\VGW,("*O&2T'19L3%V\6DVQO_',C:PUU&X.1*NG@?V(:_7,-CQY5"'3 MZ2KNB!+MJLV;.HC]TAJAK*X@"QB6K5WL'LEU+(_#$D>,;/U+D-/1V^!8G31Y M3(,>[NI60V"UL3MAA]G;36"';.]-F]4&SUI=H;I=[[9XUU%H(>0;>$CC$Y,$ M,G#<&2!+KS*52E>-?2'JW($^6)6EF/U18P%R2A5F;7X1ZJM"WU/=@%)[J[CL MQ_L].S)G^<^CH`=/Y[4LEGVT9UHEIZY57)!`#?3D[< M:S['J@N7C!`HIY%2Y#J=D5'6V2:%5+C>&>%T%E`Z;R;!94:=,*VF@2#U82)T MQ99/!;F\"TV&6D#C=."4@!/BD9[@-8M!ZW>83]\34'QOI62S?>2V*+V[//T- M7+V9%%H_C0X%X!>5^VAHI)OWJRI]'ZKO"JZGLB,(_=M-B77:GATH\YXCO#KOWD!"JLNV;2#6@WY\S3\*X1LD?QV,0ACM^HD?4.J_8A!2W,QJ,57.PT5A+/MK6H M1)147&1TJ"%<(4(*L7'8RGP>)*Q:%_/+I5^&!@;B>)N.,[I/_1!7A_7B_"T. ML3P<<)TP6E,%C0U9``N]^PL[K6(TE"!^1DJ!*X]C`T23J;^LI$ MZ\^3@@5\\]L19#X9%VD+K;0+>L[A`I.Y\KI.HTMR%TVR/3U'7W%UTWO4V7`" M>=K9@ZH]\-S1S#;K[<271%4R+F9@:_&ABA%4-1:&M.!A%B>DS2W!]2G(?\+4 M*<9&>2%T1,G8$)9!B&:36-L(9S.M(J/S;4NIQ>Z M`P!KX>Q@FFL607V1!$41;V+^AYOT.DZ#-(R#Y*DD-R?FK:EX5)^K$\",8I,/ M52?7V&QC--\N.?6@V.9,Z)@YJ(IUNZ%9$>J.4-,3X'/_(L/UI=HXJB'`D7R$ MJ@53]5!AR0ST&\*LIX MQ[:@31#GZ(VTP886!^%K)ZT/3]SEW7&X2<]T?I2/US7!18<&MX:%WK9Q^9I% M69)MC\/.R-/V[-7!>8Y!-9RFYQS-I8_8$P_?#+G*:/]L$<2=!9!9QQH9_#R1 MSSRZ7]:"^&(>GA>;X:&'5IJD\1GG.U4UTCD[!%S^9AW"SJJWR-C-N]C--5B+ MK7&L5BOK&M&^P=:UI0:R1ELM6DF\P>A=G*(C#O+BZU_)>4Z@_%.6D&98[4VR MA%)9#GM/8?AEG/=-@0BR'C2RTOA^-H>#B?/%'/]?! M;@U$#EK]>M)1>(R+GZYSC$4AP8472&WWOX+ET6)X9UD<'<;URU@:]0.YX,)( M!4%4DJ8XZ*]K770;:4I]MJ'#49<1_16MCF*/N*0)BW`:T;%8\MS8[?=7L![J M!G364Z)N)+^,%5`Q=!!G0B$"6_F^^`7/@#'`DPK]-AB,KV]Q+:@C)D1JJB,+:1N81D3%T!Q&3N1%(M@OP:J M/YF$1J,[@T1G5VQF%+R^UR-D?B";<->[+'TC:Q:.V&FS>,[*(&G_3F/_[K+R M+[@\#8:]SO+J3Y1.]=BZM!!`.8M`AKK.?@0ZQK,=%!8?U-Z;HWU`?"T&OY*2 MNR>3I+O2L3A:(@PZXK(5-+\24?.T$'9+))`L3^!C+J[LO^!X^TK^<180D8,M MIBD=Z2!E&Y0W3;`Q.Z1YDX&@XW)>N:=_@<8]7NSL)B6;#MNTBOOR%>?/KT%: MW9(^DB;*XB;E`_OG:K36?+#8CY?DVE^;#Z8V`DXOWQ=F+)SK`XTV*L[Y9;X` MQ9&"U-:LGJ.G+VPRFP=M]+2T'RW_K-O:X9FS!"_OL:F_"UE)>YG!:Q?@15O* M`UIC>^K<09JBGS/U!1UZ-,/`S9;J:]%"I7,-$4"*+R\J9$TSBJ)0T&VB(H!7RYQF5)LQU9;3G:LSCXV3 M@X?.R0@Y>LQ@C8U#!FF$4=%24SMJ"E[\=)J!O#642YV\ER]9-7N#-:U.*D?) MM%<"4]H@#(!R02M$_[H))QMGIV*U*M5P#XQ)0"_9`Q7 MA`9D&M$<)G?!3G_%F*P;?ZE2;E%H_`'\2YNS6E<1@@SC=4BBUEIEG6V2285 M[G3.G$P.\&,Z/03=;SJB:\_:&GJ8*6$$(&:&M>2S31"=J+TJA(26KBO=^>+! M6;2W@';P&&W-MMP^ULM5VX:'H9K/YFL-HQ]S)2V6._IHIPB_(N?,75RR_9#F MTLY2ND7B-(QQ81&#Y<(-$(CE#JZ.QK)G738DRU4N6<)ST0!/`]]NPJ/PIH%,BT2<>?#QYEDJUE'$`AB"9-RBH6G'K^7#"-AF(5$VXLV28I#0=7XV MS:$O89T9B][O%0?TVXY8AFYHK%207`3%:V7\.CWJJLD`%A&-N/4:(:%9=@E0 M"M";!14EHJ3"^+BX![^CS$S6/:>!663<90X=9!&)EW$19H=4<526$@)JGE3DGM)UJ&#T32*"^GOS;&N"&E3+ MG.1^FU]N:RT;('A440.F%5GOZ*O0/RK/RQN",]W&+PE-4(=[!TM;)B!O*2LH MM?N4$X;9#*5&H7MN(2T&:IYO6!#G@0@G'8<"/*_#=4Q.G?@V?L/1J>SB<986 M6=0\4#JU`*,>`T`*71F!;C;%<8/3/Z)1[C/&WE>AUALZ;0/\B52#M4%J=%)T M;L6[>:H#:S%7;5!"S%<%++L@%2^R6Y()AMPIE$[OD2$7I4,Z`6![RCD`K+)2["/&;Y)73A MW;;FCSIS7Q^3;(>(-,<4R)9?(K=ZKS8-?OH[2P^3*RS^YM.$,:&&RR/7HQ%XLIH+YKU_N4\Q)N5[D%[&>)M= M!R$KZ"8M2*"EA$CJKA6ZR>(N)5LX;;M&!LER34Z9E!H)KFY9_<4;P,O.<5OZ(C&Z'AN&@=0< M($:L!6LB>,3+44O=?+J_`^BT3,!:;]L_+JN;_9XE+WF,A'GKP/CG.`A9SB:D M43LLI'Q^Q2AH2SJE"GS$*<2OY1-FG]1>2Q^PQ?9 M&TZ#OI>W"R.,X<\>DK#\N6.9S?1G)7RO2"=A0@T7S>98\Z&:$<)#9Q`<9J[, M-BC,,3G+U;R7$MIU8W*1&&M'U\ M#'[Y%)`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`N>5^JCO"=4*I;A$^THBN/7M.<=!<6ZUR_D1$P^5 M1+Y?Y[+M_C7&+>4B!%:LZE,F*PE948B"H,/Q&S6Y4(-WM[:S[.'?C@\BN8D# MH";IB073PLE0K"7JYQ^I6%'#RQ]I3HIQP^1/F0!7WN"*#M2R0=2'Q1V1*^.' M]_\+*.7*M,#8!]NQ#Q8*=D!_%/Y"3Z-7J"L_E?`);V7E`&T8@`)`C!#J.!!K MV6<[26B%[46%<&\/%O,DR)&@!PD.&29]WDA?**1?;L8_9L<@*8\?#T$>I"7& M1;NZYTY20\R%$48#["$)37#',IM&6`G??Q"/?S/C]3"&J1'JO+K M-&+)F,^[14]D2\;0EB`J.(\"W91X'M3,PC6@1\C83QC!&T.MUFA]S*H]MN,R M1W*>O_O\I.8-3"WI.?"'36M`A:9G1D6_:EA]U4)\U81]55;)J&P:!=SA5269 M/N9948@(`<46;\GK5YDL*3!3J2PMHMEV>5L(]B6S5HCQH@=%H,42V_Q05'5) MEB)+>DL&O,+T450O+;W M%19550XTFRH.NR(G_&N\;R(?GE^#4L0-/>(@N6(YKV2[KA,[P+%V`+SZ+.O` MN^P!UEFP?BQDTT(K'(2Q]8.BI:WT48GK6A%&IRH.AN@_AU8+:EW+/MG!I!^[.' MDZ*&%C3.8B;1X4^2G\@=\C4Y/E+U3!ZJ%U#',Z6B#;].EUJ@IG.F%<+%3YPJ M2"YGSZH-Q!M!HA6?CJ&V,+D1:Z]`L)RJ?0SB])9<+^]3BNA^0\[09`,LCS1_ M07E%=KZ])K>0+3.,05D\/4@[:#*!5%%I-O'1I:),DTIV/Y:;K^FI#EY0= M@R1.H_@MC@[4_C^KZ[E%O>CA*+JNV(!W/Q9L.B2K&NT&=K+ICM MV1*,V)<=46T5OC"1Z_1\BCM M3#-_@L:FQV6ZSO)'+)+7W6^H4WN6LCAW%9B*ECDIA8Q<'N0XFQ8("/1]:)U& M]'_HD?V-;/W4%[^\"/+\&*=;YJVH]'`H>*9Z]H\6^PH%)1(MI]*(U*<*0_@.W$6):EFB#N`@SHGLJ@[P$P/>"MW&:TN\W+TK-5CTK0D`C M+U7T9KT@U^9M'NP>\8[C6@/R/@[=@!J0_!4R.':'O=%-*S'0#-94%F@9XQZ#2EA[@XP$/`L`.:V&XEE=8_!9_CW6%WGN5Y]@M97B^"/?FE/"H. M(FY-P.>UM(4IRWCIBF^V$X8C($/6R>LZ'7'5!JH;0:(5Z`R:`U!6.9=/0`)> M`:1IF=9Y3H1FH>[GQX:DLC*PM$M5LJ6/-'R^N$D?V+WL)$DN^_$R*'$=;:BZ M."PM!=!U`V:PZTL*["C/=[59?%A[6JTJK-$2@H;2&)N1("I4*[`?Y%(%/O*"YTPDVMZRL8GHV&R:L&5QK!$).3G93-%= MD\]3:FLJCTV>_U[*.R]F,)>R53)!EHGP_Y/YO<`7LY_YI_D+59/_"SAU.([K MU,<-Y^Z_L'/&P.$=?<`8.:Y?_(KMU8+\:UYHI582N]5Q]@=0A2^(*JV,TJ5E M%L%+G.N?QMRD%[6+R:3+;!U:EGKD&_(=)O+'FT4W^"M)MM59?9SE?IN\W5U2"0N-):L\/Y#'M"K#C06W+O+Q' MM9MDFMBB*GT,::4V?K"<2+PE>F^IVQKI537"ZWHD6O8[C\^M/,5FS,=OY8`] MQ>=KYXEAGZ^VJK"TJ/7WP\KOMV2L+G>,>\ZJ2.33K),&ASH-'U3TKB6@)HS7 M$-Z$IGRS(3L?S]_*8`(4=#L##*(N:J0O0CKED\*9HNB9Y:IY$I!-&I M!?B"YI8@9>7)'='-ITA.&V0X_9$3$(___S^0>=Y[T'8?=V6&FN"L\ M,?F'XII-+1R`]()/VJR(\Y*3'N-#?ZW^ES:`6`L@L;`3P_N!'&EQ(38@YEDH MH9KP$'C;\@Q<1Q&[YP4)%?L0)+J$#Y:,`(=!)TCU@="*:]E#H8-()L?4=PT_ MJAKX>NXH.&L;7"?9\1"B_JK&G?*B1$`(JL%+56VA[%L@JJZ%Y3 MKJZFA-$X=X'5YO!%5&R$P(`WJ3IMJ-U95$,/=+\R`:BO6K:2SW?KTHC:=YJI ML^GZ=HQT@5&5?J47,?ITQ=,-L4*>RF3!"]8W$LZ?GW!`BZ'1YYH*++9=,<%BJ:Z68O;-[6:'F'!GAB:8G]3&N0_Q2F-R&IR4=]OAI9: M']P4P#%O).SZ,#BPG66/C*.$[,W1JK5V`GE:M@NRF+OQ##K/".P[(Q`,K8Z^ MR*'6IQ&8LFA;$L2[@E9Y(C=9GEE*FF+>1`Q1>LTD>E-=346Y<`$UO1A]6R.C MYV70:@ZP9/-C(20+03!7/)L"`V36@JPH:+DVFTE\VPG;*60TIS.'4KT5T8+6$VA)_SY\2XHR9F7IN@3?SZN/\3L`)TF=&$55:S[H3#AVDF!2&? M5UKI%YI(I^*:9LZJGCJTMK!CY7A1U5ZZM%'$6T4BO633+GK.>.(ZFCJU;AN) MQF$*^LTY',R^T,Y%1XT/S7"4&<_D1H=C4P]',.=PF-TY9QB/O?UXT`%!B@&9 MQS8E4Q15##'!';J&'\EGE2M@OMG1]OF)0T#QL7 MHH5`.G&'-P:Q_8R%WFP]0UM:>-L9)Z8RXSTU[8H6V[477VC&C*K1.E/J[C(%%F&'._;Z,P94P\2PQYDE=2:?/744/$NQN%;Z+; ME:0+Q[(;Y+#,W(DX#TR`^D008`W_0U%P=]6Z[O4@T[]6%Y\PT7@B?VDZ.R`,AS\+F*\#K' M*=[$JAAX)36,J=,@/-5U`^EB2FXE1V_:<&I$R$4,('I7<7P-D_]LD/PED;^* M#V0OV2^<">J^[X:A'G!:_N0MIH[BS(LVKK'-=%DJLS)(7.P6^@QNS[0Y^S1T M8]QZ>.L/6<[K.UA45S2R0+CXV,%H''WT]`N[^]@(T_9%Q<9L!Y,67QSL M-C,*SKZ!,W$EPZ&>3'/!F3+.LRO3'2[O-UVY9*Z!R'JIGY*Y1R6&%72X`"/>>&-:&B\^/0.F$\]/7J M(2!=A/$^H`_M[*[#3@CG01&',K".#0"H_R"(]4K@Q+WLHC!`--4AO6Z$/C-V MFD%-.X@U-*U*?<\Q5HF!E"HU!=1;7!0_B)-[T`:\[P`NZM9@5L4)/ZL52O1" M&YK2MFB+X#).#HIT4,Y->+RPG,!T7EHJ?C\7EXYPXY:7JBFO%Q@]W%_;$F/U M<>T6F8@W->4RHW"T(;WI,M'8<$%DK[`&TZ2S,+(LG-_"4IY^.@:EVQMS\YPW M[XPQI\1@5/=W9Q?KIS^BZYN[]=W%S=U'M+YXOOG3S?/-U=,/0!D]1GPBA2N> MS%%BO%+?I&^X*%V56LL%I]068$Z56L,"HM1&>=1*7;/ZI]0#4`FEOKG[T]73 MLT]*/>@3<:6.ZT\T4JFG>9>\"G):7[YXP+FHB!2'ZS22WQ>LN6#>*2W!B+@, M1Q2S*+Z5'/U"$!4'32_`2W:MN,6@RH$QP^'>+JV'.Y1&[.K8BMXE65%\C;#` MN"<8"]H8G):(RNDT7S@[;NMS\:K)8?3")+Y0"%NY9],$C:!RW_`V[3SI>\V7 MVD&"8[FLXRQ!.;.&;X0PE2&<%Y#X<9^E-T5Q("=*%G9:1U0H+JT#VX*Q#8T" MWC82#6IH<6O1""EEEH4<5S[+M4[5;U:\340;1:+5*O=M'5H%9E>9:QBR7M@) MK_"`#G08XM8PM$.(8![`O!N&Q6.C1%6"ZRQ_Q/O:H]^,M2YG0+V,&M9%IK>% M]]1X7-==7/<+X%)M[,\Y2]1V9#VSDV%1%3J2G0D%-1=TQ4^XQ4I4;`(YV;HA MD$XG'FG(>>'.LI=X@XDZ1X_X#:<'7"T7BDFH(H8YQ^I%%Z=8.YEGF^I*(4_G MB"!$%>6\%7<-T]M:ZA]3>C$C4M-L^.3;O?*[&V%+,E8\B>P&"6DQJZJ5;@YI M)'*=@=:(#W$:Y''VD..W.#L4R9'H:):3,[TT!L.>#:@FNR6O8M MHB^F6U_3E\H@4-([0L#5TAQ,U4DS=8 M00MD`M$)7ML];"2>S]BA$%%E%`!/ZBL$^3$M]CADV?"T*7TU]+!V,26`4X.8 M4?+9+6$R4=56HQ;UJ#R^BK/G]8%F"/X4)[@HLQ2+MR39QJLD!3AC&L2NSY4* MNF7/DEHA^M6.JR9&@!SEM#9)]5\N^GU-VXU%W(N&G],&^8H\IU?5S79#3 M*[E,/F>/U>,*=9UKGE;D7FTLBR.CY<0JFS)UGLA8EB7:!U MBGB#-)&Q:)+\-4*M1J&JV<\$7R1C"&B1%I1Q^&6F?H94>-@ML]+X@W_*Q:I; M`ZN%@,:TI7*KE)D'8!&R!5(O.":&91<7.VDD3BEUP3&6'_WY%7<6C(H;9,$8 M#XGE]"X)I+82[#DW<_&BOVWBO"C%1@ZS-,R+=$IUOR5+"EFIS@]Q$L7IEB77 M6(<$WB&A)I!+O,_)341M6'1AA[!+N\-K[-/VO`O;J5T%ZUM%Z49"SQ*B#9;' MYIX5KQ3-H'8[,%;?:7"R+'E5&W4*F*`%-)H;J-D^/SU2$]`I%Q%9H5]:W/<0 M)+HH4RLV"$.#/9S&Z&#F6=@`82N09>EE]*[B_GKN8%/S%7]B:("AF330].KG M`]GT$VIU6)<709X?B?HR(14&61,3C%76#HHPS;IAF,T^:Q2ZES>0QO>V.%8H M*)%@XE,+XLUJ`(Y*Y#>F#33`@R+#31MP2E'K]_GQ/$BH$]K3*\;EQSP[[(G( MNBJI=JPP"N("2ZC)$#RS*8LE`/6BNZ+5,2I6Q'B18(8ON'J5Q-N8B$`+X-WG M3*[K+*\QW^^9F4?];NK`#Q0Y[PJPCJ$?BFRVF>@"I6=KJWA9I4.4Y7P*,NM! MZWC`FP!_JSV!),&M?;JU9P=>$BWA]99%1USS+XUF(+KED7.OD&*.PM=T_92E M^/@IR'_"Y34-^M'&U:B(8>::7G0QL\PR@YR#6K>5ZYPUV&+LV@.><"]#>[!N" M( M*/O9!JL)OY^\BX7C\F>2OQ^@S3IB*HZA#Q'E6+ M"TP(^\)#1Q\Q=O7016* MO=YEA[2\WXB\6[5/.8TB)2=8^AM+_5BE.6C5*94-\*CF`-;@">#7B^V(MI9= M54<+VH\59RU25XXZ?]M#*Z``U0TW:6!%NI-;=>W:1=;)Z0>C'H(JIF+%(LUK M^-:E>Y=9$N><#(>3D>"3P6XT`#WC1.#>^5)Q37@'S+,0X*FCTR=5NGV1'C%EV"M'O`Y&F2:#TD.-]$$=5C%I![K_M MQ4:34&V.;B`N@?,-5W,+G+Z/A:^!LWM/A:Z<[VU?#A]O#UST9R+.@ M+71K_-6,7^=05?W[EL`E_TW^B_R#9A`B__'_`%!+`P04````"`!",%U!?VJ` MPGLJ``!&YP(`%0`<`'%D96PM,C`Q,C`Y,S!?<')E+GAM;%54"0`#&U2.4!M4 MCE!U>`L``00E#@``!#D!``#M/6MSXSARWU.5_Z!,/F3W@W?LF=N[F\UN4O)K MXHIMJ32>V^33%DQ"$C(4J>/#8]VO#P"2$BGB*9'"8Z92E9NUT&`_@4:CT?WK M?[ZNHM$+3#.4Q+^]N?CI_,T(QD$2HGCQVYLB.P-9@-";49:#.`11$L/?WL3) MF__\CW_^IU__Y>SL?RYG]Z,P"8H5C/-1D$*0PW#TO!G-9J/K)(YA%,'-Z`DL M%C"MOS*Z./^)_-_%AP__/KI*UIL4+9;YZ(>K'UM09V?5-RY!AN?$O7W]Z?4ZCGY)T@2'/W[^M![XI1_[RFJ'6Z*_OZ[$7;__G MX?Y3L(0K<(9BPIY@!T6F8<%ADC^\I;_BH1GZ):/P]TD`CT:]I$L$9G(\H`K_DFS669896ZX@@3O^V3.'\ MMS=_#V%T1AAY_N'].8'_U^M*PN,XO(ESE&_NXGF2KBC6;T9DWL^SNRWZ?R\0 MGN&G(%F])3^]%4._/1:Y2Q`1YG]:0IAG MC=BG'!LCX7LVF4_6,*7\5F`0#VX@A#19IC1)KZA>@6QY&R5?-5G7`.M!QS*$ MIYRF,,.3*YH=$^AH5*Z2U3J%2QAGZ`7>X9UB!>6H,(%Z0:4H"9O,;T`:XSTK MF\+TTQ)K@QI2`O"CT;N+7S#?DQ1!!;K!;\!$FBQ2LERC00US@*+L";[FA9H_)IUBV%VK^MJ1F]=VEI,@J\Q=K*%BR?I$]/014Q!DB?:"CK(0MF*/=%E3<2\*'04^:9#+Y/7TO71@6@O?IA MNGB)8`?PT731D\\PN+ND8;**$PV.LOIBIS;/J7BL84UZ\PWDY*OR60P]$'+* M>BL!'Q8]O95`.LNPR%X;%L`>G`_Q&U:GZ/E1I;U-B\'ZC;_=)EI7[]32) MD/*15#S!(&="73:JS%$ANFZ M853.I`CW5@O%BH/T!BJ#P4^+Y.5M"!&]?2/_H.B?G5]4]T__BO_T1_GQ&5P@ M\LTX?P0KN(L+3,D30_MDISK=1KQC^9VL8/H7X MNYB:\!KD(L[OC7-2!'LT5++XJW%9C#%R(4'P-@(+A@SV?G>*]WNX5SR_.#?. M])J86Y0%(/I?"-);_)=,8`*=D4X)@DM%+1+S&W(;Q=):U832&NNP6%ITU((Q MOSM7,=J=ZO#W"_Y0I\3")Z.6BODMO"3F%D4PO<*H+9*4[[WNC7)*%DP*:C&8 MW[TKUSI9K9*81I/HG5@V*7*:*XIBUI:N`N2@D,0$;4]^2C+[]>U^2*/O0,=> M!F0[LG%Q06(;VT0V_.^K),Z2"(4TM;>"'97`HQ\^QZ`($?[E1[T@1U/CYB![ MIL(JLK,%`.M2[6"49_5?]O6O^O,?6S0G\UL48\00WDN2#`EB(GJ@AYO1X42- MLPRS5H+^_B`31G.(%(C=\&@014C@'.*=*;PON+[F&P/]#;GI?0$0O)O(KD*8;O-[3N#5' MO(JPYL7-T=:FU!5I\50+QD&0%)C>&0P@IOTY@H\PK[C&LVTAB!,R%Y,@BJHZ M+.HZQ6F#:>6(MCW$"5&V41;%9QT6W76%^Q-X+1DC-5(AA!."%5(@BOTZ+.=& MUMIN:>+:*G.L$[+EX"Z,+CLLUFD*UP"%-Z\D005B9X-F3K:XQ1&R$J03(E>B M1!C+=E@!5$3MHE`YXCO:<\J3'$2V"&^:)FN8YIMI!,J8&CXEK$F8@.]'B4', MBU9LJ"+>NY_MEMT.3T\=X3O,\7B!L+>P]0EO7H.H(`%J MB0S50.V6KQH-GCK'#8?A,8D#X6;*&6NW=#E(^^H5EY0*O2';)59CV9O?:I7C MTWC3A?V`[M,@R1V`.KB+ES[JU'GJ,C48H'8G)`(PJ0&Z:L[1@F_EWJB.G4_! MAD1MU.X*]@=;(F^-JX)]"CR5[LUJ'24;"&H"F9PQEJ^:.=D?`7!)\/58I"]=MN8I$ZMDQ M+(D73S!=78.^+LXN[IN6P:N?AQ;MB4MW[#6]JB;=UO&XT*GC MT9KKQ]$/Q?>Z'L,&*S##)RE%-J1'P%WC*87X!1_8Q9105=H\C7>TR2_K!XV+ M?(FQ^L=N61#J0Q?(?3WHTN1IC(1%]EV6%5JRKP%\D7M-CZ=A$Q;)_,IIRE"^ M2)]5/LVWN$DC!JSI"RA!NJ@*2H3YFKG0J2$H]0&$$([+G[O[>YFXT"):N/=S M1WLA[[U=W[M$!8UJJ6H@7DB=M=N?(%5A^&@-KY/Z7J3FG;#BZFZ243(?[:8Q M':,I$PNWV$G",MS11JZL0$0**+W`N(#D^7_&KTC"'FK2["1\;]U9,9'W-(QR ME60TYZVJE"0KH,L?[HAP^01X&BXZ4I2FB1I(I#W&01(8PK(I:0X:G=?H(1GG.!B7X`Z1=($I+% MTA8!N")J$0V>QC0_PAC[IA$F>1RN4$R;W^7H!8J%+85R1>)20CR-8XY7Y)[] M'Z#,JQ@'^!"4DF='[8I;O(Q/16!7E$"5'G^#F&U>*3K?[@BXB[F?CZ>K.$.\ M*$\DI%,P1Y;,D8Z!)=UX.X)85*)F!NSA)B6MK,#[30[8I'AZN*X)%/O MI+!1T.$!Q13GVAJP7]J>I4R>?H#Y,@EW:R'/DSLI!HYX#2?EB9_OB;:LJ>SW M$L9PSGT7R!WME,(P\/D2MCEUV'[YK#A&D4%_JMJ&I/V+&XK"9^N M6DU\VP;JE^]UHBZU"G+167*"HQ92*$?40$I'O7G\[)G8::FQYE%-?$#E#W?N M?,HGI9(U4]0-<2G*_4,I]RHH4 M2:HE3;4A'%F"A32<+-Q[6I,DS;=OH^1K-Z?XO49.,9EE1*KO MO1D@A@[$!)-IFKQ@R867F\\920'8WC6.@QR]E*4.)'=O!TQDR8,`KO3VSM?: M]'EZ;^-8$.5P%9?'5WP3[3C\OZ**\#XE,Q@D<8`BV*+]*>EGP1CF4^XKVC!\ M\31=]QIB]`-$I8S_'4$J[EC%C50#-=J:<$!C;)??5^&$IRM>'0&!X56R(F=B MD<[P!G\+6L*CW=,$\;HGA=Z%H!3J6]`4*1.\35T+4E+A[1J6_]M@7%595QZ8 M49[@6U`D'7[XFJ3>Y4'=K!(S'J(7TJ]269U8H(8C9IH6(U8/%GW:?HL3R79= MVDER3HR_QN\A(H'Q21%:A/F9;LDB>IO6=<#:P('V2RN8)&I[L`/K!Z>8;I>> M:0K7`.V>`L4AO>>KRPO'X6,2U__!>MC6W[3N:4E_M&M[LXXN+WM-LK6=CBV< M>\JB0=RWXX?R&V@KJX9H"I^T1$2GKZFV72YL^V_KKB!=0)^4HTN=KQ7EF,OG M7M_/`W87W@P^*8F`3%_[Y3%82%RQ+1\/V7`$,_BD+0(R>^O^8IFVJ%^^'IW` MXL,MLPZU7KY@Y#"@?.+60^*3<"(/$I^$]'F:;8"WW.K2HRJ6@YF"#2;?3"-` M@P/DL20MD\;1%9T)+%QC%(RC52Q?@UH_H_3J?#QZ[$I"^CS-5*F7V=LDG<%UD09+TF5NWJA<+MF-1(`6+BH*QL#:A414 M^GE#B,FM:)_,[Y-X\033U3V*(7F+@2D2=#N6PKFO%@I$VG8OV--RD28!A"$M M[D%:6)#.BDJKA1S.?:U0(-+7"YXFZ8TUDX:2&%Q4T!*E6?S2&262?;WQ46?G MT4ZK#WJC0ZV?Y5P(^>,X)/]#0@$O("*V,X48KW`_J,U1&;TI7#KAZ%'65TJU M`_HQQF:3IAML(;39GI9B=&#=UX@.2;TY*&NJ:QC+-/]F-.*/=Q[J!"&J-Z>C MU(J;.+1%)SX5ZW5$>0:BFF=W\3Q)5Z7@)$_R5:%=T@IEHOS--"G+64X!XE5S M:@\Q*ET]!6:5%BZ)\/2)9BOII2-/_.'N",?$R:3!TTO4CP#%Y(78)"8=_R;S MUJ4@[P*5,$@5T.>7<3I\.%I_F,6\^G_74,=,)O$].H!B&R8%.`M5X=C<"6Y;)J9]RROWJ:B(Z3`T8WU32;+1F<$#3=$A MU[HK,)D_)CFL,IV?$GH,&B]@'&P$>X,(R$)Q'[!'B"BT[34:1\#D&1WQ MC9436Y2A7#BG*Q-C7YUNCCQG,"P"@MID7M>:;3V3_+Q.XMV%*NN>^?!I3$A< M4XFW0C^(0.O.]6*C5L^A5H9RS:A5LJ,O_F*[/*>[;*GR%@:94&4 M9$4*\7]0*%)!O@5GH@M)N@!Q559U5^B^++G:Q&TRKU84$.U*X$MNLWN:VTAS MEF-0WTGZ":O29<1/8^[_,R97DEYUJ=4PIG=35@A3`3>$2.W/HI6JFV5V` MWNTO0"VHT0_X[]F/(U1"F^B!11M[2M:3_4%F.L1TN$W"GS)#EX.9-%PV]]LM M8F3X>V911;VB[/Y9M5?!DBZ]G&.$I1N4<%G29D]D:=[@-+?)DYB88 M;]3.)#(0]<7ST]08=6)WAO6G?<-JCC:2^E5^?K-#2EI#6P!A)GNM@Y#,EL0@ M9@L52>713D\4$>*1436+A#+"GCL#^WG?P"CDJ`(=-6%--F58C+[9K3G_N[E=D]*@<;C)766/#$D`83;?6 MV;!$(.9[<@KEL5=*3T"(1U:%H>%^&8B=6?UEWZS(<-I]LP0PTH_G.5>V*=Y@ M,XV$FKC(+(D[VJ01B7G?;OW#0=\CTZ$7<@)M"_C2JP M[U$_47?=?2Z3Z)>Z(6G`VQT'U"#$-R/CMN7;&=H'IJ&=48+%*P7J*@\0BSLY!U)C&YU1XDU[VK>"UB M/3)QSI/LG5EWTEPHQ*@!8D#%*0XR1WI_D`E;+'&8S.])VJ;&Z58!SJ3%L?G? M-"D%`CRRHEN`4EJ)Z0&3C:ELOE[>F5(GJX6`C2CW]63!2$,!A'(,C1'0A2RIT)*FGJ\YO^%E%Y$;%;F6&%6D M[[O,?X=HL21?R:,]@B_2%SI`V5=:5\1Y`/SC1F]884]VZM"3,Q;RO8ZU5 MAQ?F7L7;J7;1?=7=7&4F6S3BD%U=A;Z!#DG&+5ZX\O%W_@/F<$1##J#L^\Y0 MCW%`QAS,A]@7^JKSBY$<1Q2&W*)-09JC`*T!28C^!(,BI84H6-[;(1/8(D+N MUGX(495TWQ_6MD>I*NM)AF`^;PA:!"VSV,,).)G0[[I2Y:9;O6:^`%.^6 MC>9<&KICYMBF4`8*.9)Z\+;?'Q]`DJ13K:5YC642'V$OMA/=$NT?I]6)NDB-*)ZGHYX.2BLJYOJ7UOJ?: M*<$2A@5I!2BYK*,,YCV!(>1+3?JN_(L5U03UJB->E`<=J>" M6]2JNHX:IBD#=:!@K!Y!?MH?-Q]7;(`F,V\]L,`M0A]3$F3E)^3P!CIB73ST MA[$EHY)\A$+YT9]-19K$ZM81%L6UMP2?)`>1#0*Z):_#\&+_,4G"LE<5>5J6 MOG3Z!+9X(8)R1)PB$H:YN3$JY]^3],M=3-_C9.IR%D$Y(F<1"PK' M6A]HT^?169%#,??MO'OU(LN3%4SOX@#CC;H>+'>4`X+BXFY= M48R^CB=5+Y>;5[!",97(78S]=9CEE:XRSR<*4`Y(6YD63S-&:T4?AR\`Z[I@ M\^6.=$3*7/S[BAM:)EG*GD]%'*8;=>>*/]X1*4NH.%W5&BN\4,4#@4M"EM+0 MVT/`YCV`<0&39C;9%&S(L9UOP\Q1#@B5B[NOA0ZN*]QG\`7&!4>BLL$."%9& M0BW?BWXROHV&@QL=.&7YW<)^G'9D#]\GNR\?3=M25;9.2_KIV;)3.=MQM2N(6 M!,29V]!K0<:Z*AAK=\=="?+\1=.$1&8@7L#Q*V+M;(W?3/G]4H6I&=[`E;]N M&6/P`R05)'@LKG\UQ>2.#K286F-GE]X^@%>T*E9L M=4DRWOHE2H(_7\JFA5*L%6,&B6:3&M-)FB9?\3^NP!K_UFDNQ%MR1!,8"UEJJ;IH0151Y^O- M+HL/97$3<5%N13CWE8)!E*]9.61=O8LQ:PI2D70&\;\0O($I71'J]TJ2-UG`6LE5(5T0OC(Q-L3I>>^'88S7DSVOE!:.A^'-,\I# M,".L9ZW?RJ!6R%)I6]:CR[KPIX:,:P4E#@=16"TIQ1BSYE;[ ME+Y1Y5^8B$;;&MB5(KX-^]BZ+=#:M3#4$Y(0R`%9"?&O1?:S^SX4N+JO-W\6/ M25R_2LLRV(FS'SN9%0)7]_J/H'0;P+%=->Z3.*S*-CR#^,MDCG%3R$I2`K/: M@U.BP-,[>1IP)%'(3P&,`<:&D44I&6M3T+V3J23!7;%=DIF*[26BG^-L#0,T M1S!D9EDJC#>9&2-4L):$^/B+8N"62&F:PA>4%%FTF<$UWBQ@R%PQU<&,RDRF M>BRY\4EQNT9IL_OE#?X1;R.21W=_W7]TUYSBWT;E)'8\O2MQD?6IHVH,V.VR2=0\3NWWS,9!YK4(-* M;P\Y`I;0'R>4T.SF%:8!RO2UAS.))UK#HMCBZ<4`GQ*W5!J2VZ- M`\SOE+D'"D>[HRM",GQ]2C$%&Q*&R["[-X/K:C&>S+$!K)*8,B7V($_T&JDM9CN*W=CYC+(?4YG,A:A^SQB'DI!`U/B^OA M[V[$IRE<8W.JRO%EV/MJMA<2)!<,\1DW-&DX^OVJ%AP6F'<;3.I'2.QLO43! M73Q/TE69>,5I5W5QWJT=7,XT`G$XVLTU:DQV:.,J;AU>,>[BJKRJL&8;C=_@ MTU:^^1T+K:I9?;EY`/^7I'4;B>RRNBDDARVXH)X9KWIB+[,:K&"J)^UNH_(C MJ+:K;%0;:T[)+M8@4UDF/>KSKE1>ESR[I/0(5IC@%I[<"E^"L:9DQE>R;:L$ M/M)V2:*C="V<[P7UI90A/;(L99K[*JHJ:>\VB=FU4GF#3(E":N^=MFX-I&UX MH2R1P]/71"Z'QB!WY-!`VN;WPB""V5/2(DR8YR,<;THZFFOQ+N]'2(T-YG.* MO4I8X4$=U-P)7D&'U?:AXS>$SBS]EVJ^-?&K#'V7]OP,;;GQCT.`C(!=/UN2 M=48_ M@$TGBW29VEQY+V=T=M?#GLM\WU[MWE[E&0%]?L?']:A7!MEU/=HWD?5%([FV MXB0G#/])"RYD^S?=H=2RRSZ[-+0?*G70?H$D@4^F-7(0OQ5&3K]UB2TV>5-=UZ_$#;B][';MLE;_KD4V> M>NX50R"GD&RU1;#2SA0!C:UE@]CA-DM-D7K%?C\N%"D37K!P.\A\>*=]T6*T MC+%R-%/LB@V6F.&O<&X^]GXW M[_SVI/#;O:)-GUW".9S6'5EQ2/(-2.8^]Q9AF,^84A6F1DLU+Q5,7F/7D]/#7O-ET01?M8XG[6`0[*G,7PI1WD,%<73^IC4 M.R^B#Z8,_#R=D]^NV`Q3#FCMLJ&LY.T&FG**/=T^O`PZZ9M`G\$D'6W(86J/ M+AQL7&7O@;L8\[2@RRGM$O"T!''E@WW$4^3975Q&BW^':+'$/!YC6P`+2'^\ MQDR_!2@EJ=+,.(4]N#DE&B:1W$ZX0WS%*78-K,G6X??'.Y=6:"O9YVN;)J5+ MP<RK*G)`=1\W<2>'U,\O^%^?Z5(6V71O]$QEUP#.6T2+AI#:?G MT;>FX]^G3JA,J?G#V^-F(>/D`PX)?<]+L'8H2OE;=.=6@W&#QT28M/RQ=A M`W2?LB^W@8Q&WF6G*X4\[_+B>\:ET8S+0PUCZVDT*KV0=SXP7R9A$B6+C?YS M@GZ_ZE&6YBG8Y>FU[X[+8MX]J_".W(J2+)LGF*[V`[E;00WT,><2$?17B):^ M#\1&G]6\+RG5+/M;@E_`VRIERC%WQPC$/"P%-M#^UO?C>!/KEY MLCN2X4,8F$GJQAS+"8U*&`<()C)>FQV@AF-N6B7S=9L=KPD%9&[)442 MQM")=-(?WZ`6&>'/%"Q/" M2.)E!Y+W!V6U??(,GO,V4PO:U,HO5L%:7%JD."/#'>+"]Y?:,YB2Y0'JJB!@ M-HUV"7F*]_N8!D>"94S=#NZS.OY0"\4FTM!:='R"_.GGU5FE+C>/(*_"TO6? M-YQU6`?8[F58AQ*[*CNU,:^PYJZXPM'6B$BJ@VRQ[9'3UT+*>5>(%P^T(@[: M/`UL&BP'1)57NKN.T]Q&3&M?DR& M?[!1>(^K`VV-"#HZM+,I#7(\O9,2^&?;6-3NQ*MW@&!.8"PG25_S%!YZ21I,?EO1X(]T6 M'X\J7Y\1\8^&GS,X+Z)[--<[-#?!G%4%=1)]?0")_;XT1_^@$IO,]Z,&#(V0 M`3BM"S+BA.^Q'-:"ZF3`+EO'&^2LI'D$V5>2B+-YWX`TAN&4Z"IICCV9S[%Z M/B7"5FRLK?VP>9R5^Q$TU\=BZ_VZ&0P@>B%W.;>8<0U2IB#-8_:%HQS&;9'+ MZ:O$^]X>KX\K7I::7B41EF>2EF)9I+"LSLN_8CYH&CONR<27SP<1-DSPI!=Y M;VN)/>`/!$4$TFL$%C$^L:``.R5@DSTEE[`B%89/RS0I%LL'D.4P95/-4H[,D;P22&)+?Z"U3=;74N&QB:==1 MT[FM1D>17F]*UNO+;4%6Y`<4P2S'1(GB\=RA-LI9&D/B$7.R".[P3U[N(IO-\^U#-#'B=B6Z\Y"]AEF0(HH:)PM:&=+8&T05A9,)K4.-&^(3 M]_]2`+)-:!Q]E(EOB!`?67DC;>,Y^XF(D`3K,D.8QM`M=:&>]/EC^]Y[@I9,S)(&QC?$>/MH8FH\0Z@U.3H5;^HSJL MG4ZA)A&N)$"-5_3L1?)^.,&2YN_&3L6ZFM>(>#3Q%TG%I@C&1QC#%$35?4!6 MUW!A"8@[U#U9<4D1)CL8D5M/U]RDJ@GG9-;XS;:-CNEA-/"UZY$I18S?3[7Y MJRE&=_2@Q52Y6VZ"K0_@E=22XC)V[W>CK&TC63-W#T-_'H-69;[XHFG_;J-H MVAC:<"$Z[!F4EHV?IDD`8:AS#MV#LV7/EQ4L5Z/&E6/1%5@CVKXESE/T7.0P MO-R0"S40;PBEY.DY(?:R32S+F3MT)@?D?A1]UIVF!@[\POR`M:`%Y8!&*-/B MR@.4^N"R1.LI3`/"]05\6H)\'/R]0!C+&031399W"TGJ@]LB7XT4%AWRK%OZ MAS7X![P@+J/-C#`EXN0KB,R%`^^4DAQ`GZ_I[Y0%-Z]K5.9LD=Y7K(+\[&'. M"9U-AFC1MRE4MU59ZK3`=%6USKE-TC)I;S*_(0DN&*F8>,:\':+7H.0DV4H#+_-LJB6Y>N_W]]IR20C.LNH,J:O)3#N6DFBQ MF!^2&&X>0/H%YK=%'+(?Q&\W*;P[P6G,X46 MI!5:H+E6*Q&FZ`3;79/*BQ<"-=L(805LM117:94692Y($/62G6+8OPW!*)/)#1#J[.`\H;J MGO,NK+]IK="&@Q?P0ZE6C';U6U:TH?,*CY64P.R0WG$JW:T_*J+88ALGY:=) M(.X%1+1T!B8Y33>8&90HWB6"!,C8G9Z&VK8N$R3TG,S-9@87?WU+$'X&&<3_ M\?]02P,$%`````@`0C!=07Z$WZ0X#0``?(H``!$`'`!Q9&5L+3(P,3(P.3,P M+GAS9%54"0`#&U2.4!M4CE!U>`L``00E#@``!#D!``#M75]OVS@2?S_@OH/6 M+]<"Y]A.=GO77+(+QTZ*`$X=).YAWQ:T1-OUY2[PD+23B[;/5.NBT/,Y\'A,TO6Z%L(^D3TOKM MU[__[>*G=OOWJX>1%W`_7&*F/%]@I'#@3=?>PX,WY(QA2O':FZ#Y'(M$JM?K MGNC_>A\__L<;\-5:D/E">>\&[W>XVNWX&U=(@DS@,Q\[/>EM2NY`K1DQA><@ MM7/ZH7/:[9UZO=/S;O?\[,SKWT6TTE_@)?+`-"8O6PNE5N>=SO?OWT^^GYUP M,0>N;J_S^]WHT="U(L+SYZF@9(=@DC@_H0+O/=&BC1T7P=(&H#%1;$W_"Y MF6(&J"">=X$8XPHIJ)_F6;]9K0B;\?@17FA$S@6G>`+LGO[QY>$VS].ZJ'.# MB/@OHB&^PTB&PGA\B!4B5$[PLP)?MCP27+9*T&U42)0(\(PP8I3M?NB=>6UO M2*1/N>:'!RW2,S*]E%#O72S6B^6^O^ADI64_%$+3&[-?S>^5P!+$&!^-X$7, M'9/8.'U$_9`>P+C5K)@O?IO@82?*$1US*6XAZ2WS/*?$)EA%6 M+B(K4#]W3[-`[&96!:&OHH\CA2CN]=I)?)-@K']@I?Z1!,/7P)J MNNF5I+4WPE[W(`R;]GAH>ZS4$)TM\"4-L$$OV],M.`VPD-=0J-:%J:.-RI&. M_#NWQXL%_L.+1#81TCK=01@>SP8"!R1W\M!2[@#G7WL3'2#*XS,O$M;`8H]^ M>HIN@I[SIS6*BQV@?-B/<&8NT(AJ(+%!,E8++`:A$&#BB*`IH?#=C?\C7!PT M#G!^R8)CQ'FQ/"\EL.ET*B"43O+L)(X!5A5\FHPN)Z8]@7%<9!M-SGM'0_EY M/XIM1#1-P^'[W3%/]K6C"=@]WU3ZW%6_,#)N/+M&@A$VE_=8/"Z0P&DHRA`Z MP-E;IDW)U(E7(M4#L9Z1VT!6%;*"1:;2#([(=I:WSN3"L,G:7@9F>12=\!V. M7H-:"K4K)(D9`Z^]UF8D:J32,IL69L-J&&_.Z[/@FBFBUJG) ML0@F*X45(3,AEVS^2_W4TW&1J/14W%NA4L:Y!Z/YPUH0U3L''Q<8*YFTEO0K MJ]][9BKT$9R#8]9$H[]T7AL*`0,F;-8R_'`3W2(\1%U@1 M?QN]"LL=X/2J@+,C^;WW+FS`RIVPCMT)_K. M9BNT@:<*/#F-J@RA`SAKZRH&KFEG58$<(+FXH?Q[3C/;%MG!.JO0RK1,SPAM MP"F==AP(5+]0F" M!IW<6>R]^6N7YVTSUXV/G8MHUN4SE^_++YPU2.3N`=A;]7=YW+K.WS@Y?__+ M_HX7EYL=>UP:1]MVA!7M`7,YO=2NK\;UKFWGM@WG+@A*;S5O8"B_H[7<5E8' M-`?M86U0*G7`T'FDT(5-M4.$#2J%IW)SS^&ZO.\\>=LXW'ZY0/%U`B[7E[Q` MX/\``/V/OJ/C`<\\

HFE5XX$%TU>T>J3EOY*Y4-&JFINIFZ]D]&#[E5-J][>4"[.9">6SOGAW;K3_1K4(C[AM!%A;]U$[X MVOI5NW?:/NN=/,L@T;&*"EL?5%,AX7N9"GL7Z)32(LNE=?BH=>A]>)$.Z9M_ MJNG!V><#59DA.37"0MF>([0R5RLEUQ85*&$4R&7L8*ID\J:]%55.EYU[E`), M2NN2Y=$_7O9U_.PO*G]^PV1^O4P!GX<,AE*5=4CS)0]%FOS4;B?W9TG/W"X& M+^,71C_[AJK^%`9[R(^3-1U;_RA''@5HRY8?3TT6^>D^%/Y"CX-F`[0B"E$]_[72-%>`LP]& M`))Y\_F1;PYF/Y8_`CRUN:/H@`]^5E>4^U\3N]UTD8'1[7#G*GG_*B86MP'' MD?2L5148_@+F;6-3.>NV]-F@\X+8]B,,S=D^$>\DSII8AK)FQMD/KN2;68VG M;@9#)>20UT%XA/?D:1M,\TI>.4Y&2;^JW&WHBTB#D$+-FL5"GQTHVZ9PM`) MJ0%_P@+-L=.L`H;C&K:WMEQ0!4L0UJPB)EW-F.'=*)!3<.P8D*@T^<[S=4T5 M'%O7,AET;@]2D:UFU0G&NU]D`D>F7\DO.S90!3?E6=JWF[AFH%A6FHOSZM(< M?QUC^T%@)MX1K6ZVA;=F#KC5JPN(ZE,*]VAMC-E&EYRB-YN`*4:,&?]-L%@2 M9H@'"_W7!+;C(0M%;=0WJ]!Z<5I/RV8USQ0>7>G,EH>BC-I!5;.:_XC8D.`Y M3U+)W>ZGJ/38'5#&R&P6E_0"B*]%U1L\YQ02)[:_[C9JN`MB-[OL^?"^`KE1PJHU[P%2? M%TR6@R8\/U^LY-D7?Z2FK@6[=%\HP7I,GO0WM+5WZ$\N-F.$390H17ND&5*' MG9MM;A,^X%*-9X^(;C.;HM*:@A:O[9FLQOSAI>!JK2L=8FNM.-1.TSM=(?_K M1""HB7[TE3@9.I"[ILY(NH$%6=UCH6?JT1Q/%DCU_6\A$1A:*J+74I\=WJR2 M5F&)$Q/(2E81[1LG4U0'EYU&MC</9 M];/2AY:W<%?C.7IJ&M?.\>PS5Q@>S/H8-S<3]/45 M(ZY9%/H? MY*V_9B;-+!3YD?6(*SE&UT<,0,!0V&F4E;!NML6UZIZ+*&4K2&&=9#7=1931 M\S.&]&77EH+9SUS*FAH9[0[J4ZJW>.L@JD>#Q"93'4T\4+OW?-WMQ25 M9JIKI"EKQI!0/2]0U?H-6UWM+^@O]<)B)JTM0UFWG#9265^$(U49XZR4-3,N MV?1?:IBRAP:J\]>U+F]ZER&>83`EV-15/86I_](T#0,#IHA]'<_`K(+-E:5(ZY9]W(0*4J4[0J'5@M.SVPH*BVO:$>N- MXCB(:V%?`@90N2;'X2G%XWGJU`J5@ZZF[1*Q`!"Y"@D- M(+J89+'O^^$R-$MH0[P2V"<[&70EEGI:G7>Q0L$<6BG2FG7(^4UMP+5D'C'W MYP)'!Q]W@^]!K'4+QM'D]`T7=YQB?8A>#`F:,^@YB0_=)%K+";_"L7V0,R]` MC?GB#DGH<1S/OC"\&[KURB.T65U6>%=ALDGE!2)J MV@>F9_FNERO*UQB;O#.9YKH'0=M,S''0=3>]>PW1QP^U%YWHA#;\_!]02P$" M'@,4````"`!",%U!/C]'91%6``!I/@0`$0`8```````!````I($`````<61E M;"TR,#$R,#DS,"YX;6Q55`4``QM4CE!U>`L``00E#@``!#D!``!02P$"'@,4 M````"`!",%U!E7A=B?4.```PQ@``%0`8```````!````I(%<5@``<61E;"TR M,#$R,#DS,%]C86PN>&UL550%``,;5(Y0=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`0C!=0:>IK>X%$```Y2P!`!4`&````````0```*2!H&4``'%D96PM M,C`Q,C`Y,S!?9&5F+GAM;%54!0`#&U2.4'5X"P`!!"4.```$.0$``%!+`0(> M`Q0````(`$(P74%O"^[C!4X``!0[!``5`!@```````$```"D@?1U``!Q9&5L M+3(P,3(P.3,P7VQA8BYX;6Q55`4``QM4CE!U>`L``00E#@``!#D!``!02P$" M'@,4````"`!",%U!?VJ`PGLJ``!&YP(`%0`8```````!````I(%(Q```<61E M;"TR,#$R,#DS,%]P&UL550%``,;5(Y0=7@+``$$)0X```0Y`0``4$L! M`AX#%`````@`0C!=07Z$WZ0X#0``?(H``!$`&````````0```*2!$N\``'%D M96PM,C`Q,C`Y,S`N>'-D550%``,;5(Y0=7@+``$$)0X```0Y`0``4$L%!@`` 0```&``8`&@(``)7\```````` ` end XML 16 R37.htm IDEA: XBRL DOCUMENT v2.4.0.6
Industry and Geographic Information (Details)
9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sales to individual customers    
Sales percentage 22.00% 27.00%
Customer A [Member]
   
Sales to individual customers    
Sales percentage 16.00% 15.00%
Customer B [Member]
   
Sales to individual customers    
Sales percentage 6.00% 12.00%

XML 17 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Computation of Earnings Per Share
9 Months Ended
Sep. 30, 2012
Computation of Earnings Per Share [Abstract]  
Computation of Earnings Per Share

Note 3. Computation of Earnings Per Share

Diluted net income per share is reported based on the more dilutive of the treasury stock or the two-class method. Under the two-class method, net income is allocated to common stock and participating securities. The Company’s unvested restricted stock awards and certain unvested restricted stock units meet the definition of participating securities. Basic net income per share under the two-class method is computed by dividing net income adjusted for earnings allocated to unvested stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share under the two-class method is computed by dividing net income adjusted for earnings allocated to unvested stockholders for the period by the weighted average number of common and common equivalent shares outstanding during the period. The Company excludes stock options from the calculation of diluted net income per share when the combined exercise price, unrecognized stock-based compensation and assumed tax benefits upon exercise are greater than the average market price for the Company’s common stock because their effect is anti-dilutive. For the nine months ended September 30, 2011, 1.9 million shares were excluded from the calculation of diluted earnings per share (“EPS”) as their effect was anti-dilutive.

 

For the three and nine months ended September 30, 2012 and the three months ended September 30, 2011 there were no differences between the number of common shares used for the basic and diluted EPS computations as they were periods in which the Company incurred a net loss. Due to the fact that the holders of participating securities are not contractually required to share in the Company’s losses, in applying the two-class method to compute basic net loss per common share, no allocation to participating securities was made for periods in which the Company incurred a net loss.

The following table sets forth the computation of basic and diluted EPS for the nine months ended September 30, 2011 (in thousands, except per share amounts):

 

         
    2011  

Basic net income per share:

       

Net income

  $ 6,675  

Less: income allocated to participating securities

    (61
   

 

 

 

Net income allocated to common stockholders

  $ 6,614  
   

 

 

 

Weighted average common shares outstanding — basic

    32,833  
   

 

 

 

Net income per share — basic

  $ 0.20  
   

 

 

 

Diluted net income per share:

       

Net income

  $ 6,675  

Less: income allocated to participating securities

    (60
   

 

 

 

Net income allocated to common stockholders

  $ 6,615  
   

 

 

 

Weighted average common shares outstanding — basic

    32,833  

Dilutive securities

    356  
   

 

 

 

Weighted average common shares outstanding — diluted

    33,189  
   

 

 

 

Net income per share — diluted

  $ 0.20  
   

 

 

 
EXCEL 18 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\Q9F(W,6(W-U]D,6(R7S1D-3=?.#)D.%]A8V)D M-C'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D)A#I. M86UE/@T*("`@(#QX.E=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I7;W)K M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-T;V-K:&]L9&5R#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN9'5S=')Y7V%N9%]'96]G#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D9A:7)?5F%L=65?365A#I7;W)K#I7;W)K M#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;7!U=&%T:6]N7V]F7T5A#I7;W)K#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN8V]M95]487AE'1U86P\+W@Z M3F%M93X-"B`@("`\>#I7;W)K'1U86P\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K M#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DEN9'5S=')Y7V%N9%]'96]G#I7;W)K5]A;F1?1V5O9W)A<&AI8U]);F9O#I%>&-E;%=O#I% M>&-E;%=O'1U/"]X.DYA;64^ M#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0 M#I%>&-E;%=O7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^4V5P(#,P+`T*"0DR,#$R/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^ M9F%L'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^+2TQ,BTS,3QS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q9F(W,6(W M-U]D,6(R7S1D-3=?.#)D.%]A8V)D-C'0O:'1M;#L@8VAA"!A"!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XQ,S8\6%L=&EE'0^)FYB'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D.R!N M;VYE(&ESF5D.R`S,RPR.3<@86YD(#,S+#(W-B!S:&%R97,@:7-S=65D M(&%N9"!O=71S=&%N9&EN9R!A="!397!T96UB97(@,S`L(#(P,3(@86YD($1E M8V5M8F5R(#,Q+"`R,#$Q+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)FYB'0^ M)FYB'0^)FYB'0^)FYBF5D/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\Q9F(W,6(W-U]D,6(R7S1D-3=?.#)D.%]A8V)D-C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2D\+W1D/@T*("`@("`@ M("`\=&0@8VQAF%T:6]N(&]F(&EN=&%N9VEB;&4@87-S971S M(&9R;VT@86-Q=6ER960@8G5S:6YE3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^)FYB&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X-3$I M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!O M<&5R871I;F<@86-T:79I=&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XS,3QS<&%N/CPO'!E;G-E6%L=&EE2!O<&5R871I M;F<@86-T:79I=&EE2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M/B@V+#DP,RD\6UE;G1S(&]N(&QI;F4@;V8@8W)E9&ET/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M/B@R,RPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$2!B>2!I;F-U'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQAF%T:6]N0V]N&)R;"QN&)R;"QN M>"`M+3X-"B`@(#QF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.C0E)SX\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/E1H92!A8V-O;7!A;GEI;F<@=6YA=61I=&5D(&-O;G-O;&ED871E M9"!F:6YA;F-I86P@2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@:6X@ M=&AE(%4N4RX@9F]R(&EN=&5R:6T@9FEN86YC:6%L(&EN9F]R;6%T:6]N(&%N M9"!W:71H('1H92!I;G-T2P-"B`@('1H97D@9&\@;F]T(&EN8VQU9&4@86QL(&]F('1H92!I M;F9O65A M65A'!E;G-E'!E M;G-E(&]N('1H92!#;VYS;VQI9&%T960@4W1A=&5M96YT2!R96-L87-S:69I960@ M82!R961U8W1I;VX@;V8@;W1H97(@;F]N+6-U2!O<&5R871I;F<@ M86-T:79I=&EE'0M:6YD96YT.C0E)SX\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/E1H92!I;F9O28C.#(Q-SMS(#(P,3$@06YN=6%L(%)E<&]R="!O;B!&;W)M M)B,Q-C`[,3`M2RX@4W5B2!Q=6%R=&5R(&%R92!H M:7-T;W)I8V%L;'D-"B`@('-E87-O;F%L(&EN(&YA='5R92!A;F0@87)E(&YO M="!N96-E2!I;F1I8V%T:79E(&]F('1H92!R97-U;'1S(&5X<&5C M=&5D(&9O28C,38P M.S$L(#(P,3(L(')E2X@1F]R(#(P,3(@86YD(#(P,3$L('1H M92!#;VUP86YY)B,X,C$W.W,@=&AI2X@1F]R(&5A2X@/"]F;VYT/CPO<#X-"CQS<&%N M/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA3PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!" M;&]C:R!486=G960@3F]T92`R("T@=7,M9V%A<#I#;VUP'1";&]C:RTM/@T*("`@/'`@'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/DYE="`H;&]S3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Q9F(W,6(W-U]D,6(R7S1D-3=?.#)D.%]A8V)D-C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\ M(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#,@+2!U6QE/3-$;6%R9VEN M+71O<#HQ.'!X.VUA6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)VUA2!S=&]C:R!O2!T:&4@=V5I9VAT960@ M879E2!T:&4@=V5I9VAT960@879E2!E>&-L=61E28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!B96-A=7-E('1H96ER M(&5F9F5C="!I6QE/3-$9F]N="US:7IE.C%P>#MM87)G M:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@ M/'`@#MM87)G:6XM8F]T=&]M.C!P>#X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/D9O6EN9R!T:&4@='=O M+6-L87-S(&UE=&AO9"!T;R!C;VUP=71E(&)A2!I;F-U&-E<'0@<&5R M('-H87)E(&%M;W5N=',I.B`\+V9O;G0^/"]P/@T*("`@/'`@F4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P M>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#8X)2!B;W)D97(],T0P('-T>6QE/3-$)V)O MF4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/C(P,3$\+V(^/"]F M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N M9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM M/@T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX] M,T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E M>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/DQE6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)VUA M3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C,R+#@S,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/C`N,C`\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@;F]W3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T* M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O'0M:6YD96YT M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O M;3XF(S$V,#L\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C8L-C'0M M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UEF4] M,T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T M>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@ M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL M93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^ M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T6QE/3-$ M)VUA6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C8L M-C$U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@/'`@3IT:6UEF4],T0R/E=E:6=H M=&5D(&%V97)A9V4@8V]M;6]N('-H87)E6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C,U-CPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/C,S+#$X.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)VUAF4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!" M;&]C:R!486=G960@3F]T92`T("T@=7,M9V%A<#I);G9E;G1O#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/CQB/DYO=&4F(S$V,#LT+B!) M;G9E;G1O6QE/3-$)VUA M6QE/3-$9F]N="US:7IE.C$R<'@[ M;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T* M("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED M=&@],T0W-B4@8F]R9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T* M("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT M9"!W:61T:#TS1#F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@8V]L6QE/3-$)V)O6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2`M+3X-"B`@(#QT3IT:6UEF4],T0R/E)A=R!M871EF4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ MF4],T0R M/E=O6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE MF4],T0R/C,L-C,R/"]F;VYT/CPO=&0^(`T*("`@ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@'0M:6YD96YT.BTQ+C`P96TG M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C8L-C0W/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@3IT:6UEF4],T0R/C$V+#DP.3PO9F]N M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4] M,T0R/C$T+#8U-#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE M/3-$)V)O7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@ M/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`U("T@<61E;#I/=&AE'1";&]C:RTM/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQB/DYO M=&4@-2X@3W1H97(@0W5R6QE/3-$)VUA6QE/3-$9F]N="US:7IE M.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[ M/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS M1#`@=VED=&@],T0W-B4@8F]R9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L M;&%P'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N M=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@/'1R/B`- M"B`@(#QT9"!W:61T:#TS1#F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@8V]L6QE/3-$ M)V)O6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2`M+3X-"B`@(#QT3IT:6UEF4],T0R/D%C8W)U960@;&EA8FEL:71Y(&9O6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C4S,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C@V,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D-UF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@F4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA&5S/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C0X/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE M/3-$)VUA3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@;F]W3IT:6UEF4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C$L M-#DX/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@'0M:6YD96YT.BTQ+C`P M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4] M,T0R/D]T:&5R/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ MF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/C0L-S8P/"]F;VYT/CPO M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@ M/"]TF4Z,7!X/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA&5S(%M! M8G-T&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A4 M34P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G'1";&]C:RTM/@T*("`@/'`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`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^ M#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#<@+2!U#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQB/DYO M=&4F(S$V,#LW+B!,:6YE(&]F($-R961I="`\+V(^/"]F;VYT/CPO<#X-"B`@ M(#QP('-T>6QE/3-$)VUA28C.#(Q-SMS M("0Q,C`N,"!M:6QL:6]N('-E;FEO2!D871E9"!/8W1O8F5R)B,Q-C`[."P@,C`P."X@07,@<&%R="!O9@T*("`@ M=&AI2X@07,@;V8@4V5P M=&5M8F5R)B,Q-C`[,S`L(#(P,3(L#0H@("!T:&4@0V]M<&%N>2!H860@)#$N M-B!M:6QL:6]N(&EN8VQU9&5D(&%S(&$@<&]R=&EO;B!O9B!O=&AE2!I2!L:6UI=&%T M:6]N6UE;G0@;V8@;W1H97(@9&5B=#L- M"B`@(&QI;6ET871I;VX@;VX@:6YV97-T;65N=',@*&EN8VQU9&EN9R!L;V%N M2!I&5S+"!D97!R96-I871I;VXL(&%M;W)T:7IA=&EO;BP@86YD M('-T;V-K+6)A6QE/3-$9F]N="US:7IE.C%P>#MM87)G:6XM=&]P.C$R<'@[;6%R9VEN M+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/D%S(&]F(%-E<'1E M;6)E28C.#(Q-SMS(&%B:6QI='D@=&\@8F]R28C.#(Q-SMS(&)O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/"$M+41/0U194$4@:'1M M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A M9V=E9"!.;W1E(#@@+2!U4YO=&5$ M:7-C;&]S=7)E5&5X=$)L;V-K+2T^#0H@("`\<"!S='EL93TS1&UA#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/CQB/DYO=&4F(S$V M,#LX+B!3=&]C:VAO;&1E2`\+V(^/"]F;VYT/CPO M<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O M;3HP<'@^/&9O;G0@&EM871E M;'D@)#,N,"!M:6QL:6]N("AE>&-L=61E'!E;G-E&EM871E;'D@ M)#,N-"8C,38P.VUI;&QI;VXL('=H:6-H('!R:6UA2!I;F-L=61E9"!S M:&%R97,@65E M&EM871E;'D@)#(R+C$@;6EL;&EO;@T*("`@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\Q9F(W,6(W-U]D,6(R7S1D-3=?.#)D.%]A8V)D-C'0O:'1M;#L@8VAA'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@ M+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#D@+2!U'1";&]C:RTM/@T*("`@/'`@'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/E1H92!C;VUP96YS M871I;VX@97AP96YS92!R96QA=&5D('1O('1H92!#;VUP86YY)B,X,C$W.W,@ M6QE M/3-$9F]N="US:7IE.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O M;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C M96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS M1"=B;W)D97(M8V]L;&%P'0M86QI9VXZ(&QE9G0G M(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM M/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#@P)3XF(S$V,#L\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3XF(S$V,#L\+W1D M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`- M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0S)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`- M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3XF(S$V,#L\+W1D/B`- M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@ M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0S)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@ M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T MF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0Q/CQB/C(P,3$\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$ M)V)O6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0R M/C`N,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C`N,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT M:6UEF4],T0R/C`N-#PO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C`N-3PO9F]N M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UEF4] M,T0R/E)E3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/C`N,CPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/C`N.#PO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT:6UEF4],T0R/E-A;&5S(&%N9"!M87)K971I;F<\+V9O;G0^ M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C`N,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T M6QE/3-$)VUA3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/C`N.#PO9F]N M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ MF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C0N M,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF(S$V M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*("`@/'`@F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@/'`@"!D;W5B;&4@(S`P,#`P M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@/'`@2`M+3X-"B`@(#PO=&%B;&4^(`T*("`@/'`@F5D(&9OF5D(&9O M2X@07,@ M;V8@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(L('1O=&%L('5N'!E8W1E9"!T;R!B92!R96-O9VYI>F5D(&]V97(@82!W96EG:'1E M9"UA=F5R86=E('!EF5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T960@=&\@;F]N M+79E'!E8W1E9"!T;R!B92!R96-O9VYI>F5D(&]V97(@82!W M96EG:'1E9"UA=F5R86=E('!E'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE MF4],T0R/E1H92!E6QE/3-$9F]N="US:7IE.C$R<'@[;6%R9VEN+71O<#HP M<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@8F]R M9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I M;B!486)L92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#@V M)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0U)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0U)3XF(S$V,#L\+W1D/B`-"B`@(#QT M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF M(S$V,#L\+W1D/@T*("`@/"]TF4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/C(P,3(\+V(^/"]F M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@8V]L2`M+3X-"B`@(#QTF4],T0R M/D5X<&5C=&5D(&]P=&EO;B!L:69E("AI;B!Y96%RF4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@'0M:6YD96YT M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@2!R871E/"]F;VYT/CPO<#X- M"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/E)I6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/C(N,#4\+V9O;G0^ M/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B4F(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@ M/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B4F(S$V,#L\+V9O M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@2`M+3X-"B`@(#PO=&%B;&4^(`T*("`@/'`@2X@5&AE($-O;7!A;GD@9W)A;G1E9"`V,C$L-S`U(&%N9"`U,3DL,S,W M('-T;V-K(&]P=&EO;G,@9'5R:6YG('1H92!N:6YE(&UO;G1H2!G2X@5&AE(&=R86YT(&1A=&4@9F%I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q9F(W,6(W-U]D,6(R M7S1D-3=?.#)D.%]A8V)D-C'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2!A;F0@1V5O9W)A<&AI8R!);F9O'0^/"$M+41/0U194$4@:'1M M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A M9V=E9"!.;W1E(#$P("T@<61E;#I);F1U4%N9$=E;V=R87!H:6-);F9O M'1";&]C:RTM/@T*("`@/'`@'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/E1H92!# M;VUP86YY(&]P97)A=&5S(&EN(&]N92!R97!O2X@07,@;V8@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(@ M86YD($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$L(&)A;&%N8V5S(&1U92!F2X@/"]F;VYT/CPO<#X- M"B`@(#QP('-T>6QE/3-$)VUA#MM87)G:6XM8F]T=&]M M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/@T*("`@/"]TF4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M8V]L6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T* M("`@/"]T6QE/3-$)VUA MF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3IT:6UEF4],T0R/D$\+V9O;G0^/"]P/@T* M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/C$U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/D(\+V9O;G0^/"]P M/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT M:6UEF4],T0R/B4F(S$V,#L\+V9O;G0^/"]T9#X- M"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/C(W/"]F;VYT/CPO=&0^ M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)VUA#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!" M;&]C:R!486=G960@3F]T92`Q,2`M('5S+6=A87`Z0V]M;6ET;65N='-!;F1# M;VYT:6YG96YC:65S1&ES8VQO'1";&]C:RTM/@T*("`@/'`@6QE/3-$;6%R9VEN+71O<#HV<'@[ M;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@'0M:6YD96YT.C0E)SX\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/@T*("`@3VX@4V5P=&5M8F5R)B,Q-C`[,C2!K;F]W;B!A'0M:6YD96YT.C0E)SX\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/E1H92!!;65N9&UE;G0L('=H:6-H('=A2!A;F0- M"B`@(&]T:&5R('!R;W9I2!T;R`F(S@R,C`[8G5Y+61O=VXF(S@R,C$[(&%N M9"`F(S@R,C`[8G5Y+6]U="8C.#(R,3L@:71S(&9U='5R92!R;WEA;'1Y(&]B M;&EG871I;VX@=6YD97(@=&AE($%G6UE;G0@;V8@ M)#$S+C@@;6EL;&EO;B!T;R!!;&5R92!I;B!397!T96UB97(@,C`Q,2!I;B!C M;VYN96-T:6]N('=I=&@@82!B=7DM9&]W;B!O9B!T:&4@0V]M<&%N>28C.#(Q M-SMS(')O>6%L='D@;V)L:6=A=&EO;G,@9F]R('1H92!P97)I;V0@8F5G:6YN M:6YG($IU;'DF(S$V,#LQ+"`R,#$Q+B!);B!A9&1I=&EO;BP@=&AE($-O;7!A M;GD@97AE2!T M97)M:6YA=&EN9R!T:&4@0V]M<&%N>28C.#(Q-SMS(&]B;&EG871I;VX@=&\@ M<&%Y(&9U='5R92!R;WEA;'1I97,@=6YD97(@=&AE($%G&-H86YG92!F;W(@82!F:7AE9"!C87-H('!A>6UE;G0@:6X@=&AE#0H@("!A M;6]U;G0@;V8@)#$U+C<@;6EL;&EO;B!L97-S("0Q+C`@;6EL;&EO;B!O9B!S M<&5C:69I960@=&AI6%L=&EE6QE/3-$)VUA#MM87)G:6XM8F]T=&]M M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!A2!A2!W:6QL(&)E(&)A65A2!P87EM96YT2X@/"]F;VYT M/CPO<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@2!A;'-O(&UA:6YT86EN2!F;W(@=F%R:6]U'0M:6YD M96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/@T*("`@5&AE($-O;7!A;GD@:&%S(&5N=&5R960@ M:6YT;R!V87)I;W5S(&-O;&QA8F]R871I;VX@86=R965M96YT2!A;F0@=&5C:&YO;&]G>2!O9B!I=',@8V]L;&%B;W)A=&EV90T* M("`@<&%R=&YE6QE/3-$9F]N="US:7IE.C%P>#MM87)G:6XM=&]P M.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'`@'0M M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/D1U7,@;W9E65A2!I'!E8W1E9"!T;R!R96EM8G5R M2!H879E(&5X96-U=&5D('!R M;VIE8W0@<&QA;G,@9F]R('-E=F5R86P@87-S87ES('5N9&5R('1H90T*("`@ M;6%S=&5R(&%GF5D(&%T M('1H92!L;W=E2P@=&AE($-O;7!A;GD@7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA#MM87)G M:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE MF4],T0R/CQB/DYO=&4@,3(N($QE87-E($]B;&EG M871I;VX@/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM M=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2`D-RXP(&UI;&QI;VXN(%1H92!#;VUP86YY M(&ES(&$@,C4E(&QI;6ET960@<&%R=&YE2!A;F0@ M=VEL;"!C;VYT:6YU92!T;R!B92!D97!R96-I871E9"!O=F5R('1H92!E65AF4@=&AE(&QE87-E M(&]B;&EG871I;VX@;W9E2`H5DE%*2X@5&AE($-O;7!A;GD@:7,@;F]T M+"!H;W=E=F5R+"!T:&4@<')I;6%R>2!B96YE9FEC:6%R>2!O9B!T:&4@5DE% M(&%S(&ET(&1O97,@;F]T(&%B2!O9B!T:&4@<&%R=&YE2`D,"XX(&UI M;&QI;VX@9F]R(&5A8V@@;V8@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E M;6)EF4Z,7!X.VUA#MM87)G M:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H\'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@'0M:6YD96YT M.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQI/D%30R!4;W!I8R`X,C`L($9A:7(@5F%L=64@365A M2!T:&4@0V]M<&%N>2!I;B!O;F4@ M;V8@=&AE(&9O;&QO=VEN9R!T:')E92!C871E9V]R:65S.B`\+V9O;G0^/"]P M/@T*("`@/'`@3IT:6UEF4],T0R/@T*("`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`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!! M8V-O=6YT:6YG(%!O;&EC>3H@<61E;"TR,#$R,#DS,%]N;W1E,E]A8V-O=6YT M:6YG7W!O;&EC>5]T86)L93$@+2!U6QE/3-$)VUA M3IT:6UEF4],T0R/@T*("`@1'5R:6YG('1H92!F:7)S="!Q=6%R=&5R M(&5N9&5D($UA6QE/3-$)VUA#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X M="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@2!A&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!" M;&]C:R!486=G960@06-C;W5N=&EN9R!0;VQI8WDZ('%D96PM,C`Q,C`Y,S!? M;F]T93$R7V%C8V]U;G1I;F=?<&]L:6-Y7W1A8FQE,2`M('5S+6=A87`Z4F5A M;$5S=&%T95!O;&EC>51E>'1";&]C:RTM/@T*("`@/'`@'0M:6YD96YT.C0E M)SX-"B`@(#QF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA6QE/3-$)V)O MF4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/C(P,3$\+V(^/"]F M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N M9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM M/@T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX] M,T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E M>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/DQE6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)VUA M3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C,R+#@S,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/C`N,C`\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@;F]W3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T* M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O'0M:6YD96YT M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O M;3XF(S$V,#L\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C8L-C'0M M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UEF4] M,T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T M>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@ M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL M93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^ M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T6QE/3-$ M)VUA6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C8L M-C$U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@/'`@3IT:6UEF4],T0R/E=E:6=H M=&5D(&%V97)A9V4@8V]M;6]N('-H87)E6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C,U-CPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/C,S+#$X.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)VUAF4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M M+2!"96=I;B!";&]C:R!486=G960@3F]T92!486)L93H@<61E;"TR,#$R,#DS M,%]N;W1E-%]T86)L93$@+2!U6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/D1E8V5M8F5R)B,Q-C`[,S$L/&)R("\^,C`Q M,3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C4L M-34T/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/C0L-S`X/"]F;VYT/CPO=&0^ M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D9I;FES:&5D(&=O M;V1S("AM871EF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/@T*("`@/"]TF4Z,7!X M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^ M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T3IT:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE M/3-$)V)O6QE/3-$)V)O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1";&]C:RTM/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@8F]R9&5R/3-$,"!S='EL M93TS1"=B;W)D97(M8V]L;&%P'0M86QI9VXZ(&QE M9G0G(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D M("TM/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@2`M+3X-"B`@(#QT3IT:6UEF4],T0R/D%C8W)U960@;&EA8FEL M:71Y(&9O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/C4S,#PO9F]N=#X\+W1D/B`-"B`@(#QT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@3IT:6UEF4],T0R/C@V,SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ MF4],T0R M/D-UF4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA&5S/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA MF4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE MF4],T0R/C0X/"]F;VYT/CPO=&0^(`T*("`@/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C$L-#DX/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT:6UEF4],T0R/D]T:&5R/"]F;VYT/CPO<#X-"B`@(#PO=&0^ M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0R M/C0L-S8P/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&AT;6PQ+71R86YS:71I;VYA;"YD=&0B M("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92!486)L93H@ M<61E;"TR,#$R,#DS,%]N;W1E.5]T86)L93$@+2!U6QE/3-$)V)OF4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/E1HF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T MF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q M/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L2`M+3X-"B`@(#QT3IT:6UEF4],T0R/D-OF4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C`N.#PO M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C`N,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE MF4],T0R/C`N,SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D=E;F5R86P@86YD M(&%D;6EN:7-T6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/C,N-#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE/3-$9F]N M="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@ M/'`@6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\ M+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$F4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^ M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O M6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6UE;G1!=V%R9$5M<&QO>65E4W1O8VM0=7)C:&%S95!L86Y686QU871I M;VY!6QE/3-$)V)OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT M:6UEF4],T0Q/CQB/DYI;F4@;6]N=&AS/&)R("\^ M96YD960\8G(@+SY397!T96UB97(F(S$V,#LS,"P\+V(^/"]F;VYT/CPO=&0^ M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V M,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0Q/CQB/C(P,3$\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@ M(#PO='(^#0H@("`\(2TM($5N9"!486)L92!(96%D("TM/@T*("`@/"$M+2!" M96=I;B!486)L92!";V1Y("TM/@T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G M:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/C4N-3(\+V9O;G0^/"]T M9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/C4N,C(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T* M("`@/"]T6QE/3-$)VUAF4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)VUA M6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/C`\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@;F]W3IT:6UEF4] M,T0R/B4F(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N M9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X@#0H\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2!A;F0@1V5O9W)A<&AI8R!);F9O4UA:F]R0W5S=&]M97)S0GE2 M97!O6QE/3-$)V)OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/DYI;F4@;6]N=&AS/&)R M("\^96YD960\8G(@+SY397!T96UB97(F(S$V,#LS,"P\+V(^/"]F;VYT/CPO M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V)O6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/C(P,3$\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X- M"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!(96%D("TM/@T*("`@/"$M M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@/'1R(&)G8V]L;W(],T0C8V-E M969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O M;3XF(S$V,#L\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B4F(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C$R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V)O M6QE/3-$ M)V)O6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/B4F(S$V,#L\+V9O M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE M/3-$)V)O6QE/3-$)V)O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'1U86PI M(%M!8G-T'!E;G-E'!E;G-E('1O(&=E;F5R86P@86YD(&%D;6EN:7-T'!E;G-E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\Q9F(W,6(W-U]D,6(R7S1D-3=?.#)D.%]A8V)D-C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\Q9F(W,6(W-U]D,6(R7S1D-3=?.#)D.%]A8V)D-C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'1U86PI/&)R M/DEN($UI;&QI;VYS+"!U;FQE'1U86PI(%M!8G-T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\Q9F(W,6(W-U]D,6(R7S1D-3=?.#)D.%]A8V)D-C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'1087)T7S%F8C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\Q9F(W,6(W-U]D,6(R7S1D-3=?.#)D.%]A8V)D-C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'1U86PI(%M!8G-T'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^5&AE($-O;7!A;GD@=V%S(&EN(&-O;7!L:6%N8V4@ M=VET:"!A;&P@9FEN86YC:6%L(&-O=F5N86YT'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'1U86PI(%M!8G-T'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'1U86PI(%M!8G-T'1U86PI(%M!8G-T&EM=6T@6TUE;6)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$&EM=6T@6TUE;6)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'1U86PI(%M!8G-T2P@87!P;&EC86)L92!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XP+C(U)3QS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'1U86PI("A54T0@)"D\8G(^ M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$65E('-T;V-K('!U'!E;G-E"!W:71H:&]L9&EN9R!O8FQI9V%T:6]N'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D(')E<'5R8VAA'1087)T7S%F M8C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E;G-E(')E;&%T960@=&\@'!E;G-E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-#QS<&%N/CPO'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'!E;G-E(')E;&%T M960@=&\@'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XP+C(\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^-2!Y96%R7,\7,\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XD(#$N-#QS<&%N/CPO'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E(')E8V]G;FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E8W1E M9"!W96EG:'1E9"UA=F5R86=E('!EF5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\7,\ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'1U86PI(%M!8G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^,2!Y96%R/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2!A;F0@1V5O9W)A<&AI8R!);F9O'1U86PI(%M!8G-T M'1U86PI(%M!8G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q9F(W,6(W-U]D,6(R7S1D-3=? M.#)D.%]A8V)D-C'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'1U86PI(%M!8G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$7,@=&\@8F4@9&5V96QO<&5D/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'1U86PI(%M!8G-T'0^,3`@>65A'1E;F1E9"!E;F1I;F<@9&%T93PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^1&5C(#$L#0H)"3(P,3D\'1E M;G-I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA'0^-2!Y96%R'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XP+C@\2!;365M8F5R73PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1U86PI(%M!8G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\Q9F(W,6(W-U]D,6(R7S1D-3=?.#)D.%]A8V)D-C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1U86PI(%M!8G-T3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\Q9F(W,6(W-U]D,6(R7S1D-3=?.#)D.%]A8V)D-C&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U XML 19 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6
Inventories (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Dec. 31, 2011
Inventories    
Raw materials $ 5,554 $ 5,239
Work-in-process (materials, labor and overhead) 4,708 3,632
Finished goods (materials, labor and overhead) 6,647 5,783
Total Inventory $ 16,909 $ 14,654
XML 20 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
Computation of Earnings Per Share (Details Textual)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Computation of Earnings Per Share (Textual) [Abstract]        
Shares excluded from calculation of diluted (loss) earnings per share ("EPS") 0 0 0 1.9
XML 21 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Other Current Liabilities (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Dec. 31, 2011
Other current liabilities    
Accrued liability for technology licenses $ 530 $ 863
Customer incentives 1,400 2,352
Accrued interest - income taxes 607 491
Customer prepayments 48 202
Current portion of note payable to state agency    1,498
Unearned research and development collaboration funds received 1,222   
Other 953 1,720
Total other current liabilities $ 4,760 $ 7,126
XML 22 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes (Details Textual) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Income Taxes (Textual) [Abstract]        
Company's effective tax rate     40.00% 34.00%
Income tax expense and benefit $ (851) $ (574) $ (2,501) $ 3,438
XML 23 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Comprehensive (loss) income
9 Months Ended
Sep. 30, 2012
Stockholders' Equity  
Comprehensive (loss) income

Note 2. Comprehensive (loss) income

Net (loss) income is equal to comprehensive (loss) income for the three and nine months ended September 30, 2012 and 2011. During the first quarter ended March 31, 2012, the Company adopted Accounting Standards Update No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income.

XML 24 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6
Line of Credit (Details Textual) (USD $)
In Millions, unless otherwise specified
9 Months Ended
Sep. 30, 2012
Aug. 10, 2012
Line of Credit (Textual) [Abstract]    
Senior Credit Facility   $ 140.0
Senior Credit Facility, maturity date Aug. 10, 2017  
Line of Credit (Additional Textual) [Abstract]    
Senior Credit Facility, adjusted EBITDA ratio 3  
Senior Credit Facility, Interest coverage ratio 3.0  
Amount available under the senior credit facility 60.0  
Amount outstanding under the senior credit facility 19.0  
Line of credit facility restrictive covenants The agreement governing the Senior Credit Facility is subject to certain customary limitations, including among others: limitation on liens; limitation on mergers, consolidations and sales of assets; limitation on debt; limitation on dividends, stock redemptions and the redemption and/or prepayment of other debt; limitation on investments (including loans and advances) and acquisitions; limitation on transactions with affiliates; and limitation on disposition of assets.  
Line of credit facility covenant compliance The Company was in compliance with all financial covenants.  
Portion of deferred financing costs included in non-current assets 1.6  
Senior Credit Facility [Member]
   
Line of Credit (Textual) [Abstract]    
Deferred financing costs 1.0  
Senior Credit Facility [Member] | Scenario, Previously Reported [Member]
   
Line of Credit (Textual) [Abstract]    
Deferred financing costs 0.6  
Senior Secured Credit Facility [Member]
   
Line of Credit (Textual) [Abstract]    
Senior Credit Facility $ 120.0  
Line of Credit [Member]
   
Line of Credit (Textual) [Abstract]    
Weighted average interest rate 1.72%  
LIBOR rate loans [Member] | Maximum [Member]
   
Line of Credit (Textual) [Abstract]    
Senior credit facility, applicable rate 2.50%  
LIBOR rate loans [Member] | Minimum [Member]
   
Line of Credit (Textual) [Abstract]    
Senior credit facility, applicable rate 1.25%  
Base Rate Loans [Member] | Maximum [Member]
   
Line of Credit (Textual) [Abstract]    
Senior credit facility, applicable rate 1.50%  
Base Rate Loans [Member] | Minimum [Member]
   
Line of Credit (Textual) [Abstract]    
Senior credit facility, applicable rate 0.25%  
XML 25 R40.htm IDEA: XBRL DOCUMENT v2.4.0.6
Lease Obligation (Details Textual) (USD $)
In Millions, unless otherwise specified
9 Months Ended
Sep. 30, 2012
Lease
Sep. 30, 2011
Dec. 31, 2011
Lease Obligation (Additional Textual) [Abstract]      
Partnership that acquired the facility 25.00%    
Amended terms 10 years    
Amended term lease extended ending date Dec. 01, 2019    
Number of extension 3    
Extend the lease options 5 years    
General partner's interest January 2015    
Land and building, net of accumulated depreciation $ 2.3   $ 2.4
Lease payments 0.8 0.8  
San Diego Facility [Member]
     
Lease Obligation (Textual) [Abstract]      
Facility sold 15.0    
Capital contributed 3.8    
Cash transaction, netting $ 7.0    
XML 26 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Balance Sheets (Unaudited) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Dec. 31, 2011
Current assets:    
Cash and cash equivalents $ 17,842 $ 61,332
Accounts receivable, net 17,132 14,646
Inventories 16,909 14,654
Deferred tax asset - current 10,681 10,681
Income tax receivable 136 167
Prepaid expenses and other current assets 6,380 3,246
Total current assets 69,080 104,726
Property and equipment, net 30,535 28,086
Goodwill 71,013 71,013
Intangible assets, net 64,179 73,830
Other non-current assets 1,970 1,239
Total assets 236,777 278,894
Current liabilities:    
Accounts payable 4,679 5,001
Accrued payroll and related expenses 5,394 5,377
Accrued royalties 229 15,093
Current portion of lease obligation 367 329
Other current liabilities 4,760 7,126
Total current liabilities 15,429 32,926
Long term debt 19,000 42,000
Lease obligation, net of current portion 5,667 5,947
Deferred tax liability - non-current 4,648 7,040
Income taxes payable 4,413 4,667
Other non-current liabilities 952 928
Commitments and contingencies      
Stockholders' equity:    
Preferred stock, $.001 par value per share; 5,000 shares authorized; none issued or outstanding at September 30, 2012 and December 31, 2011      
Common stock, $.001 par value per share; 50,000 shares authorized; 33,297 and 33,276 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively 33 33
Additional paid-in capital 180,059 175,030
Retained earnings 6,576 10,323
Total stockholders' equity 186,668 185,386
Total liabilities and stockholders' equity $ 236,777 $ 278,894
XML 27 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Cash Flows (unaudited) (USD $)
In Thousands, unless otherwise specified
9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
OPERATING ACTIVITIES:    
Net (loss) income $ (3,747) $ 6,675
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Depreciation, amortization and other 16,485 12,063
Loss on disposal of assets 27   
Stock-based compensation expense 5,001 5,798
Change in deferred tax assets and liabilities (2,392) 2,527
Changes in assets and liabilities:    
Accounts receivable (2,486) (3,828)
Inventories (2,140) 2,856
Income tax receivable 31 8,267
Prepaid expenses and other current assets (2,611) (594)
Accounts payable (877) (289)
Accrued payroll and related expenses (160) 2,155
Accrued royalties (148) (1,858)
Accrued income taxes payable (254)   
Other current and non-current liabilities (844) 521
Net cash provided by operating activities 5,885 34,293
INVESTING ACTIVITIES:    
Acquisitions of property and equipment (6,903) (3,254)
Acquisitions of intangibles (15,359) (14,264)
Purchase of business (1,000)  
Proceeds from sale of fixed assets 115  
Net cash used for investing activities (23,147) (17,518)
FINANCING ACTIVITIES:    
Payments on lease obligation (242) (207)
Purchases of common stock (3,407) (625)
Payments on line of credit (23,000) (30,000)
Payments on note payable to state agency (1,498)  
Issuance of common stock, net of cancellations 2,960 59,221
Other (1,041) (907)
Net cash (used for) provided by financing activities (26,228) 27,482
Net (decrease) increase in cash and cash equivalents (43,490) 44,257
Cash and cash equivalents, beginning of period 61,332 6,788
Cash and cash equivalents, end of period 17,842 51,045
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:    
Cash paid during the period for interest 985 1,639
Cash paid during the period for income taxes    200
NON-CASH INVESTING ACTIVITIES:    
Purchase of capital equipment by incurring current liabilities 555 157
Purchase of licensed technology by incurring current liabilities    16,563
NON-CASH FINANCING ACTIVITIES:    
Reduction of other non-current assets upon issuance of common stock    478
Increase of other non-current assets upon issuance of common stock $ 652   
XML 28 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-Based Compensation (Details 1)
9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Estimated fair value of each stock option award    
Expected option life (in years) 5 years 6 months 7 days 5 years 2 months 19 days
Volatility rate 0.46% 0.47%
Risk-free interest rate 0.83% 2.05%
Dividend rate 0.00% 0.00%
XML 29 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Inventories (Tables)
9 Months Ended
Sep. 30, 2012
Inventories [Abstract]  
Inventories
                 
    September 30,
2012
    December 31,
2011
 

Raw materials

  $ 5,554     $ 5,239  

Work-in-process (materials, labor and overhead)

    4,708       3,632  

Finished goods (materials, labor and overhead)

    6,647       5,783  
   

 

 

   

 

 

 
    $ 16,909     $ 14,654  
   

 

 

   

 

 

 
XML 30 R36.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-Based Compensation (Details Textual) (USD $)
In Millions, except Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Stock-Based Compensation (Textual) [Abstract]        
Share-based compensation expense recognized $ 1.4 $ 1.6 $ 5.0 $ 5.8
Weighted-average grant date fair value of stock options granted     $ 6.51 $ 5.73
Stock Options [Member]
       
Stock-Based Compensation (Textual) [Abstract]        
Share-based compensation expense recognized 0.9 1.0 3.0 3.6
Total unrecognized compensation expense related to non-vested stock options 5.0   5.0  
Expected weighted-average period of recognition for unrecognized compensation expense     2 years 2 months 12 days  
Stock options granted     621,705 519,337
Restricted Stock [Member]
       
Stock-Based Compensation (Textual) [Abstract]        
Share-based compensation expense recognized 0.5 0.6 2.0 2.2
Expected weighted-average period of recognition for unrecognized compensation expense       1 year
Total unrecognized compensation expense related to non-vested restricted stock $ 2.0   $ 2.0  
Restricted stock granted     135,295 207,532
Weighted-average grant date fair value of restricted stock granted     $ 15.49 $ 12.86
XML 31 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2012
Stock-Based Compensation [Abstract]  
Compensation expense related to stock-based compensation plans
                                 
    Three months
ended
September 30,
    Nine months
ended
September 30,
 
    2012     2011     2012     2011  

Cost of sales

  $ 0.2     $ 0.1     $ 0.4     $ 0.5  

Research and development

    0.2       0.3       0.8       0.8  

Sales and marketing

    0.2       0.2       0.4       0.3  

General and administrative

    0.8       1.0       3.4       4.2  
   

 

 

   

 

 

   

 

 

   

 

 

 
    $ 1.4     $ 1.6     $ 5.0     $ 5.8  
   

 

 

   

 

 

   

 

 

   

 

 

 
Estimated fair value of each stock option award
                 
    Nine months
ended
September 30,
 
    2012     2011  

Expected option life (in years)

    5.52       5.22  

Volatility rate

    0.46       0.47  

Risk-free interest rate

    0.83     2.05

Dividend rate

    0     0
XML 32 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } }
XML 33 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Basis of Presentation
9 Months Ended
Sep. 30, 2012
Basis of Presentation [Abstract]  
Basis of Presentation

Note 1. Basis of Presentation

The accompanying unaudited consolidated financial statements of Quidel Corporation and its subsidiaries (the “Company”) have been prepared in accordance with generally accepted accounting principles in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements.

Certain reclassifications have been made to prior year amounts to conform to the current year presentation. The Company reclassified patent and trademark expenses of $0.3 million and $0.8 million from research and development expense to general and administrative expense on the Consolidated Statements of Operations for the three and nine months ended September 30, 2011, respectively. The Company reclassified stock-based compensation expense of $0.6 million from accrued payroll and related expenses to stock-based compensation expense on the Consolidated Statements of Cash Flows for the nine months ended September 30, 2011. For the nine months ended September 30, 2011, the Company reclassified a reduction of other non-current assets of $0.5 million from cash provided by financing activities and from cash provided by operating activities to non-cash financing activities on the Consolidated Statements of Cash flows.

The information at September 30, 2012, and for the three and nine months ended September 30, 2012 and 2011, is unaudited. Operating results for the three and nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012. For further information, refer to the Company’s consolidated financial statements and footnotes thereto for the year ended December 31, 2011 included in the Company’s 2011 Annual Report on Form 10-K. Subsequent events have been evaluated up to and including the date these financial statements were issued. In the opinion of management, all adjustments considered necessary for a fair presentation (consisting of normal recurring accruals) have been included. Operating results for any quarter are historically seasonal in nature and are not necessarily indicative of the results expected for the full year.

For 2012 and 2011, the Company’s fiscal year will or has ended on December 30, 2012 and January 1, 2012, respectively. For 2012 and 2011, the Company’s third quarter ended on September 30, 2012 and October 2, 2011, respectively. For ease of reference, the calendar quarter end dates are used herein. The three and nine month periods ended September 30, 2012 and 2011 both included 13 and 39 weeks, respectively.

XML 34 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Balance Sheets (Parenthetical) (unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified
Sep. 30, 2012
Dec. 31, 2011
Consolidated Balance Sheets [Abstract]    
Preferred stock, par value per share $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000 5,000
Preferred stock, shares issued      
Preferred stock, shares outstanding      
Common stock, par value per share $ 0.001 $ 0.001
Common stock, shares authorized 50,000 50,000
Common stock, shares issued 33,297 33,276
Common stock, shares outstanding 33,297 33,276
XML 35 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Commitments and Contingencies
9 Months Ended
Sep. 30, 2012
Commitments and Contingencies [Abstract]  
Commitments and Contingencies

Note 11. Commitments and Contingencies

Licensing Arrangements

On September 27, 2011, the Company entered into the Second Amendment (the “Amendment”) to Quidel/Inverness Settlement Agreement dated April 27, 2005 (the “Agreement”), as amended by an addendum dated June 19, 2006, with Alere Inc. (formerly known as Inverness Medical Innovations, Inc.) (“Alere”).

The Amendment, which was effective as of April 1, 2011, amended certain royalty and other provisions in the Agreement and enabled the Company to “buy-down” and “buy-out” its future royalty obligation under the Agreement for payments totaling $29.5 million. Under the Amendment, the Company made an initial cash payment of $13.8 million to Alere in September 2011 in connection with a buy-down of the Company’s royalty obligations for the period beginning July 1, 2011. In addition, the Company exercised its buy-out right for any remaining future royalty obligation by exercising the Royalty Termination Option (as defined in the Amendment) in January 2012, thereby terminating the Company’s obligation to pay future royalties under the Agreement in exchange for a fixed cash payment in the amount of $15.7 million less $1.0 million of specified third quarter 2011 royalties. This amount was paid in February 2012.

In conjunction with Financial Accountings Standards Board Accounting Standard Update No. 2009-05, Fair Value Measurements and Disclosures (Topic 820), the Company assigned $28.8 million to the licensed technology and $0.7 million as a one-time charge to cost of sales. In determining the fair value allocation between the intangible asset licensed technology and the one-time charge to cost of sales, the Company assessed the past and estimated future revenue streams related to present and future products that use the patents that are subject to the Amendment. The effective life and related amortization of the licensed technology will be based on the higher of the percentage of usage or the straight-line method. This percentage of usage will be determined using the revenues generated from products covered by the patents that are subject to the Amendment. The terms of the Amendment provide for an estimated useful life of 3.5 years for this asset. The Company recorded $1.9 million and $5.7 million of amortization expense included as a portion of cost of sales for the three and nine months ended September 30, 2012, respectively.

In addition to the royalty agreement noted above, the Company has entered into various other licensing agreements, which largely require royalty payments based on specified product sales as well as the achievement of specified milestones. The Company had royalty expenses relating to those agreements of approximately $0.2 million and $0.4 million for the three months ended September 30, 2012 and 2011, respectively, and $0.6 million and $1.5 million for the nine months ended September 30, 2012 and 2011, respectively.

Legal

The Company is involved in various claims and litigation matters from time to time in the ordinary course of business. Management believes that all such current legal actions, in the aggregate, will not have a material adverse effect on the Company. The Company also maintains insurance, including coverage for product liability claims, in amounts which management believes are appropriate given the nature of its business. At September 30, 2012 and December 31, 2011, the Company had $0.8 million accrued as a liability for various legal matters where the Company deemed the liability probable and estimable.

Research and Development Collaboration Agreements

The Company has entered into various collaboration agreements which provide it with rights to develop, manufacture and market products using the intellectual property and technology of its collaborative partners. Under the terms of certain of these agreements, the Company is required to make periodic payments based on achievement of certain milestones. These milestones generally include achievement of prototype assays, validation lots and clinical trials. At September 30, 2012, total future milestone payments which may become due under the terms of these agreements are estimated at $3.9 million in the aggregate. These costs may fluctuate based on estimated development costs and activities and are expected to be paid at various dates through December 2013.

 

During the three months ended September 30, 2012, the Company entered into a master collaboration agreement with a third party for the development of molecular diagnostic assays over a five year term. In connection with mutually agreed upon project plans and timelines for each molecular assay, the third party is expected to reimburse the Company a portion of total product development costs. As of September 30, 2012, the Company and the third party have executed project plans for several assays under the master agreement. Reimbursements of development costs are recorded as a reduction to research and development expense and recognized at the lower of cumulative cash received, or to be received, or a proportion of actual costs incurred as a percentage of total costs expected to be incurred for all projects in the agreement. Accordingly, the Company recorded a receivable from the development partner for the first payment in the amount of $2.5 million as a component of prepaid expenses and other current assets as of September 30, 2012, the earned portion of $1.3 million as a reduction to research and development expense for the three months ended September 30, 2012, and the unearned portion of $1.2 million as a component of other current liabilities as of September 30, 2012.

XML 36 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document and Entity Information
9 Months Ended
Sep. 30, 2012
Oct. 24, 2012
Document and Entity Information [Abstract]    
Entity Registrant Name QUIDEL CORP /DE/  
Entity Central Index Key 0000353569  
Document Type 10-Q  
Document Period End Date Sep. 30, 2012  
Amendment Flag false  
Document Fiscal Year Focus 2012  
Document Fiscal Period Focus Q3  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   33,350,305
XML 37 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
Lease Obligation
9 Months Ended
Sep. 30, 2012
Lease Obligation [Abstract]  
Lease Obligation

Note 12. Lease Obligation

During 1999, the Company completed a sale and leaseback transaction of its San Diego facility. The facility was sold for $15.0 million, of which $3.8 million was capital contributed by the Company. The sale was an all cash transaction, netting the Company approximately $7.0 million. The Company is a 25% limited partner in the partnership that acquired the facility. The transaction was deemed a financing transaction under the guidance in ASC Topic 840-40, Accounting for Sales of Real Estate. The assets sold remain on the books of the Company and will continue to be depreciated over the estimated useful life. In December 2009, the Company amended the terms of its lease agreement which had no significant impact on the Company’s financial statements. The amended terms include a new ten-year lease term through December 2019, with options to extend the lease for up to three additional five-year periods. The Company will amortize the lease obligation over this new term. The amount of the monthly rental payments remains the same under the amendment. The combined carrying value of the land and building subject to this lease, net of accumulated depreciation, was $2.3 million and $2.4 million as of September 30, 2012 and December 31, 2011, respectively. In addition, the Company has the option to purchase the general partner’s interest in the partnership in January 2015 for a fixed price. The Company has determined that the partnership is a variable interest entity (VIE). The Company is not, however, the primary beneficiary of the VIE as it does not absorb the majority of the partnership’s expected losses or receive a majority of the partnership’s residual returns. The Company made lease payments to the partnership of approximately $0.8 million for each of the nine months ended September 30, 2012 and 2011.

 

XML 38 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Operations (unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Consolidated Statements of Operations [Abstract]        
Total revenues $ 32,998 $ 33,108 $ 101,816 $ 120,212
Costs and expenses        
Cost of sales (excludes amortization of intangible assets of $1,438, $1,670, $4,315 and $5,009, respectively) 14,872 14,996 43,688 47,579
Research and development 5,085 5,884 20,433 19,559
Sales and marketing 7,776 6,487 21,989 18,996
General and administrative 4,759 5,194 15,812 17,135
Amortization of intangible assets from acquired businesses and technology 1,728 1,791 5,165 5,342
Total costs and expenses 34,220 34,352 107,087 108,611
Operating (loss) income (1,222) (1,244) (5,271) 11,601
Other (expense) income        
Interest income 8 42 35 151
Interest expense (286) (485) (985) (1,639)
Other expense (27)    (27)   
Total other expense (305) (443) (977) (1,488)
(Loss) income before taxes (1,527) (1,687) (6,248) 10,113
(Benefit) provision for income taxes (851) (574) (2,501) 3,438
Net (loss) income $ (676) $ (1,113) $ (3,747) $ 6,675
Basic and diluted (loss) earnings per share $ (0.02) $ (0.03) $ (0.11) $ 0.20
Shares used in basic per share calculation 33,004 33,019 33,036 32,833
Shares used in diluted per share calculation 33,004 33,019 33,036 33,189
XML 39 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes
9 Months Ended
Sep. 30, 2012
Income Taxes [Abstract]  
Income Taxes

Note 6. Income Taxes

The Company’s effective tax rate for the nine months ended September 30, 2012 and 2011 was 40.0% and 34.0%, respectively. The Company recognized an income tax benefit of $2.5 million and an income tax expense of $3.4 million for the nine months ended September 30, 2012 and 2011, respectively. The primary difference between the September 30, 2012 and September 30, 2011 effective tax rate is due to the exclusion of the federal research and development tax credit due to the expiration of the statute. In addition, the Company reduced the reserve for uncertain tax positions resulting from a federal statutory audit. During the quarter ended September 30, 2012, the Company was notified by the Internal Revenue Service that it is examining the Company’s federal tax returns for the years ended 2007 through 2010.

The Company is subject to periodic audits by domestic and foreign tax authorities. The Company’s federal tax years for 1995 and forward are subject to examination by the U.S. authorities due to the carry forward of unutilized net operating losses and research and development credits. With few exceptions, the Company’s tax years for 1999 and forward are subject to examination by state and foreign tax authorities. The Company believes that it has appropriate support for the income tax positions taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors, including past experience and interpretations of tax law applied to the facts of each matter.

XML 40 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
Other Current Liabilities
9 Months Ended
Sep. 30, 2012
Other Current Liabilities [Abstract]  
Other Current Liabilities

Note 5. Other Current Liabilities

Other current liabilities consist of the following (in thousands):

 

                 
    September 30,
2012
    December 31,
2011
 

Accrued liability for technology licenses

  $ 530     $ 863  

Customer incentives

    1,400       2,352  

Accrued interest – income taxes

    607       491  

Customer prepayments

    48       202  

Current portion of note payable to state agency

    —         1,498  

Unearned research and development collaboration funds received

    1,222       —    

Other

    953       1,720  
   

 

 

   

 

 

 
    $ 4,760     $ 7,126  
   

 

 

   

 

 

 
XML 41 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
Other Current Liabilities (Tables)
9 Months Ended
Sep. 30, 2012
Other Current Liabilities [Abstract]  
Other current liabilities
                 
    September 30,
2012
    December 31,
2011
 

Accrued liability for technology licenses

  $ 530     $ 863  

Customer incentives

    1,400       2,352  

Accrued interest – income taxes

    607       491  

Customer prepayments

    48       202  

Current portion of note payable to state agency

    —         1,498  

Unearned research and development collaboration funds received

    1,222       —    

Other

    953       1,720  
   

 

 

   

 

 

 
    $ 4,760     $ 7,126  
   

 

 

   

 

 

 
XML 42 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurement
9 Months Ended
Sep. 30, 2012
Fair Value Measurement [Abstract]  
Fair Value Measurement

Note 13. Fair Value Measurement

ASC Topic 820, Fair Value Measurements and Disclosures requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed by the Company in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

As of September 30, 2012 and December 31, 2011, the carrying amount of the Company’s Senior Credit Facility approximates fair value because it has a variable interest rate that reflects market changes to interest rates and changes in the Company’s leverage ratio. As of September 30, 2012 and December 31, 2011, the Company used Level 2 inputs to determine the fair value of its Senior Credit Facility. As of September 30, 2012 and December 31, 2011, the carrying amount of the Company’s cash equivalents approximates fair value. Cash equivalents primarily consisted of funds held in a money market account. As of September 30, 2012 and December 31, 2011, the carrying value of cash equivalents was $10.9 million and $46.9 million, respectively, and was determined based on Level 1 inputs.

XML 43 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-Based Compensation
9 Months Ended
Sep. 30, 2012
Stock-Based Compensation [Abstract]  
Stock-Based Compensation

Note 9. Stock-Based Compensation

The compensation expense related to the Company’s stock-based compensation plans included in the accompanying Consolidated Statements of Operations for the three and nine months ended September 30, 2012 and 2011 was as follows (in millions):

 

                                 
    Three months
ended
September 30,
    Nine months
ended
September 30,
 
    2012     2011     2012     2011  

Cost of sales

  $ 0.2     $ 0.1     $ 0.4     $ 0.5  

Research and development

    0.2       0.3       0.8       0.8  

Sales and marketing

    0.2       0.2       0.4       0.3  

General and administrative

    0.8       1.0       3.4       4.2  
   

 

 

   

 

 

   

 

 

   

 

 

 
    $ 1.4     $ 1.6     $ 5.0     $ 5.8  
   

 

 

   

 

 

   

 

 

   

 

 

 

Total compensation expense recognized for the three months ended September 30, 2012 and 2011 includes $0.9 million and $1.0 million related to stock options and $0.5 million and $0.6 million related to restricted stock, respectively. Total compensation expense recognized for the nine months ended September 30, 2012 and 2011 includes $3.0 million and $3.6 million related to stock options and $2.0 million and $2.2 million related to restricted stock, respectively. As of September 30, 2012, total unrecognized compensation expense related to non-vested stock options was $5.0 million, which is expected to be recognized over a weighted-average period of approximately 2.2 years. As of September 30, 2012, total unrecognized compensation expense related to non-vested restricted stock was $2.0 million, which is expected to be recognized over a weighted-average period of approximately 1.0 years. Compensation expense capitalized to inventory and compensation expense related to the Company’s ESPP were not material for the three and nine months ended September 30, 2012 and 2011.

The estimated fair value of each stock option award was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants.

 

 

                 
    Nine months
ended
September 30,
 
    2012     2011  

Expected option life (in years)

    5.52       5.22  

Volatility rate

    0.46       0.47  

Risk-free interest rate

    0.83     2.05

Dividend rate

    0     0

The weighted-average grant date fair value of stock options granted during the nine months ended September 30, 2012 and 2011 was $6.51 and $5.73, respectively. The Company granted 621,705 and 519,337 stock options during the nine months ended September 30, 2012 and 2011, respectively. The weighted-average grant date fair value of restricted stock granted during the nine months ended September 30, 2012 and 2011 was $15.49 and $12.86, respectively. The Company granted 135,295 and 207,532 shares of restricted stock during the nine months ended September 30, 2012 and 2011, respectively. The grant date fair value of restricted stock is determined based on the closing market price of the Company’s common stock on the grant date.

XML 44 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Line of Credit
9 Months Ended
Sep. 30, 2012
Line of Credit [Abstract]  
Line of Credit

Note 7. Line of Credit

On August 10, 2012, the Company entered into an amended and restated $140.0 million senior secured syndicated credit facility (the “Senior Credit Facility”), which matures on August 10, 2017. The Senior Credit Facility amends and restates the Company’s $120.0 million senior secured credit facility dated October 8, 2008. As part of this amendment, the Company incurred $1.0 million in deferred financing costs related to the Senior Credit Facility in addition to the $0.6 million it had previously recorded related to the original credit facility. As of September 30, 2012, the Company had $1.6 million included as a portion of other non-current assets. The Senior Credit Facility bears interest at either LIBOR or the base rate plus in each case the applicable margin. The base rate is equal to the higher of (i) the lender’s prime rate, (ii) the federal funds rate plus one-half of one percent and (iii) LIBOR plus one percent. The applicable rate is generally determined in accordance with a performance pricing grid based on the Company’s leverage ratio and ranges from 1.25% to 2.50% for LIBOR rate loans and from 0.25% to 1.50% for base rate loans (weighted average interest rate of 1.72% at September 30, 2012). The agreement governing the Senior Credit Facility is subject to certain customary limitations, including among others: limitation on liens; limitation on mergers, consolidations and sales of assets; limitation on debt; limitation on dividends, stock redemptions and the redemption and/or prepayment of other debt; limitation on investments (including loans and advances) and acquisitions; limitation on transactions with affiliates; and limitation on disposition of assets. The Company is also subject to financial covenants which include a funded debt to adjusted EBITDA ratio (as defined in the Senior Credit Facility, with adjusted EBITDA generally calculated as earnings before, among other adjustments, interest, taxes, depreciation, amortization, and stock-based compensation) not to exceed 3:1 as of the end of each fiscal quarter, and an interest coverage ratio of not less than 3:1 as of the end of each fiscal quarter. The Senior Credit Facility is secured by substantially all present and future assets and properties of the Company.

 

As of September 30, 2012, the Company had $60.0 million available under the Senior Credit Facility. The Company’s ability to borrow under the Senior Credit Facility fluctuates from time to time due to, among other factors, the Company’s borrowings under the facility and its funded debt to adjusted EBITDA ratio. As of September 30, 2012, the Company had $19.0 million outstanding under the Senior Credit Facility. As of September 30, 2012, the Company was in compliance with all financial covenants.

XML 45 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stockholders' Equity
9 Months Ended
Sep. 30, 2012
Stockholders' Equity  
Stockholders' Equity

Note 8. Stockholders’ Equity

During the nine months ended September 30, 2012, 135,295 shares of restricted stock were awarded, 17,165 shares of restricted stock were cancelled, 197,109 shares of common stock were issued due to the exercise of stock options and 44,290 shares of common stock were issued in connection with the Company’s employee stock purchase plan (the “ESPP”), resulting in net proceeds to the Company of approximately $3.0 million (excludes $0.6 million included in prepaid expenses and other current assets as of September 30, 2012). Additionally, during the nine months ended September 30, 2012, 231,704 shares of outstanding common stock were repurchased for approximately $3.4 million, which primarily included shares repurchased under the Company’s previously announced share repurchase program, but also included 31,304 shares repurchased in connection with payment of minimum tax withholding obligations for certain employees relating to the lapse of restrictions on certain restricted stock awards during the nine months ended September 30, 2012. There was approximately $22.1 million remaining under the Company’s share repurchase program as of September 30, 2012.

XML 46 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
Industry and Geographic Information
9 Months Ended
Sep. 30, 2012
Industry and Geographic Information [Abstract]  
Industry and Geographic Information

Note 10. Industry and Geographic Information

The Company operates in one reportable segment. Sales to customers outside the U.S. represented $15.9 million (16%) and $13.8 million (11%) of total revenue for the nine months ended September 30, 2012 and 2011, respectively. As of September 30, 2012 and December 31, 2011, balances due from foreign customers were $1.7 million and $4.8 million, respectively.

The Company had sales to individual customers in excess of 10% of total revenue, as follows:

 

                 
    Nine months
ended
September 30,
 
    2012     2011  

Customer:

               

A

    16     15

B

    6     12
   

 

 

   

 

 

 
      22     27
   

 

 

   

 

 

 

As of September 30, 2012, accounts receivable from customers with balances due in excess of 10% of total accounts receivable totaled $8.1 million while, at December 31, 2011, accounts receivable from customers with balances due in excess of 10% of total accounts receivable totaled $5.5 million.

XML 47 R34.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-Based Compensation (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Compensation expense related to stock-based compensation plans        
Stock-based Compensation Expense $ 1.4 $ 1.6 $ 5.0 $ 5.8
Cost of sales [Member]
       
Compensation expense related to stock-based compensation plans        
Stock-based Compensation Expense 0.2 0.1 0.4 0.5
Research and Development Expense [Member]
       
Compensation expense related to stock-based compensation plans        
Stock-based Compensation Expense 0.2 0.3 0.8 0.8
Sales and marketing [Member]
       
Compensation expense related to stock-based compensation plans        
Stock-based Compensation Expense 0.2 0.2 0.4 0.3
General and Administrative Expense [Member]
       
Compensation expense related to stock-based compensation plans        
Stock-based Compensation Expense $ 0.8 $ 1.0 $ 3.4 $ 4.2
XML 48 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
Computation of Earnings Per Share (Tables)
9 Months Ended
Sep. 30, 2012
Computation of Earnings Per Share [Abstract]  
Basic and diluted EPS
         
    2011  

Basic net income per share:

       

Net income

  $ 6,675  

Less: income allocated to participating securities

    (61
   

 

 

 

Net income allocated to common stockholders

  $ 6,614  
   

 

 

 

Weighted average common shares outstanding — basic

    32,833  
   

 

 

 

Net income per share — basic

  $ 0.20  
   

 

 

 

Diluted net income per share:

       

Net income

  $ 6,675  

Less: income allocated to participating securities

    (60
   

 

 

 

Net income allocated to common stockholders

  $ 6,615  
   

 

 

 

Weighted average common shares outstanding — basic

    32,833  

Dilutive securities

    356  
   

 

 

 

Weighted average common shares outstanding — diluted

    33,189  
   

 

 

 

Net income per share — diluted

  $ 0.20  
   

 

 

 
XML 49 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
Basis of Presentation (Details Textual) (USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2011
Sep. 30, 2011
Basis of Presentation (Textual) [Abstract]    
Reclassification of patent and trademark expenses from research and development expense to general and administrative expense $ 0.3 $ 0.8
Reclassification of accrued payroll and related expenses to stock-based compensation expense   0.6
Proceeds from common stock reclassified to non-cash financing activity   $ 0.5
XML 50 R41.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurement (Details Textual) (Money market funds [Member], Fair Value, Inputs, Level 1 [Member], USD $)
In Millions, unless otherwise specified
Sep. 30, 2012
Dec. 31, 2011
Money market funds [Member] | Fair Value, Inputs, Level 1 [Member]
   
Fair Value Measurement (Textual) [Abstract]    
Carrying value of cash equivalents $ 10.9 $ 46.9
XML 51 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Operations (Parenthetical) (unaudited) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Consolidated Statements of Operations [Abstract]        
Amortization of intangible assets $ 1,438 $ 1,670 $ 4,315 $ 5,009
XML 52 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Inventories
9 Months Ended
Sep. 30, 2012
Inventories [Abstract]  
Inventories

Note 4. Inventories

Inventories are recorded at the lower of cost (first-in, first-out) or market and consist of the following (in thousands):

 

                 
    September 30,
2012
    December 31,
2011
 

Raw materials

  $ 5,554     $ 5,239  

Work-in-process (materials, labor and overhead)

    4,708       3,632  

Finished goods (materials, labor and overhead)

    6,647       5,783  
   

 

 

   

 

 

 
    $ 16,909     $ 14,654  
   

 

 

   

 

 

 
XML 53 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6
Computation of Earnings Per Share (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Basic net income per share:        
Net income $ (676) $ (1,113) $ (3,747) $ 6,675
Less: income allocated to participating securities       (61)
Net income allocated to common stockholders       6,614
Weighted average common shares outstanding - basic 33,004 33,019 33,036 32,833
Net income per share - basic       $ 0.20
Diluted net income per share:        
Net income (676) (1,113) (3,747) 6,675
Less: income allocated to participating securities       (60)
Net income allocated to common stockholders       $ 6,615
Weighted average common shares outstanding - basic 33,004 33,019 33,036 32,833
Dilutive securities       356
Weighted average common shares outstanding - diluted 33,004 33,019 33,036 33,189
Net income per share - diluted       $ 0.20
XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 60 209 1 false 23 0 false 6 false false R1.htm 00 - Document - Document and Entity Information Sheet http://quidel.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0110 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://quidel.com/role/BalanceSheets Consolidated Balance Sheets (Unaudited) false false R3.htm 0111 - Statement - Consolidated Balance Sheets (Parenthetical) (unaudited) Sheet http://quidel.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) (unaudited) false false R4.htm 0120 - Statement - Consolidated Statements of Operations (unaudited) Sheet http://quidel.com/role/StatementsOfOperations Consolidated Statements of Operations (unaudited) false false R5.htm 0121 - Statement - Consolidated Statements of Operations (Parenthetical) (unaudited) Sheet http://quidel.com/role/StatementsOfOperationsParenthetical Consolidated Statements of Operations (Parenthetical) (unaudited) false false R6.htm 0130 - Statement - Consolidated Statements of Cash Flows (unaudited) Sheet http://quidel.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (unaudited) false false R7.htm 0201 - Disclosure - Basis of Presentation Sheet http://quidel.com/role/BasisOfPresentation Basis of Presentation false false R8.htm 0202 - Disclosure - Comprehensive (loss) income Sheet http://quidel.com/role/ComprehensiveIncome Comprehensive (loss) income false false R9.htm 0203 - Disclosure - Computation of Earnings Per Share Sheet http://quidel.com/role/ComputationOfEarningsPerShare Computation of Earnings Per Share false false R10.htm 0204 - Disclosure - Inventories Sheet http://quidel.com/role/Inventories Inventories false false R11.htm 0205 - Disclosure - Other Current Liabilities Sheet http://quidel.com/role/OtherCurrentLiabilities Other Current Liabilities false false R12.htm 0206 - Disclosure - Income Taxes Sheet http://quidel.com/role/IncomeTaxes Income Taxes false false R13.htm 0207 - Disclosure - Line of Credit Sheet http://quidel.com/role/LineOfCredit Line of Credit false false R14.htm 0208 - Disclosure - Stockholders' Equity Sheet http://quidel.com/role/StockholdersEquity Stockholders' Equity false false R15.htm 0209 - Disclosure - Stock-Based Compensation Sheet http://quidel.com/role/StockBasedCompensation Stock-Based Compensation false false R16.htm 0210 - Disclosure - Industry and Geographic Information Sheet http://quidel.com/role/IndustryAndGeographicInformation Industry and Geographic Information false false R17.htm 0211 - Disclosure - Commitments and Contingencies Sheet http://quidel.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R18.htm 0212 - Disclosure - Lease Obligation Sheet http://quidel.com/role/LeaseObligation Lease Obligation false false R19.htm 0213 - Disclosure - Fair Value Measurement Sheet http://quidel.com/role/FairValueMeasurement Fair Value Measurement false false R20.htm 0402 - Disclosure - Comprehensive (loss) income (Policies) Sheet http://quidel.com/role/ComprehensiveLossIncomePolicies Comprehensive (loss) income (Policies) false false R21.htm 0503 - Disclosure - Computation of Earnings Per Share (Tables) Sheet http://quidel.com/role/ComputationOfEarningsPerShareTables Computation of Earnings Per Share (Tables) false false R22.htm 0504 - Disclosure - Inventories (Tables) Sheet http://quidel.com/role/InventoriesTables Inventories (Tables) false false R23.htm 0505 - Disclosure - Other Current Liabilities (Tables) Sheet http://quidel.com/role/OtherCurrentLiabilitiesTables Other Current Liabilities (Tables) false false R24.htm 0509 - Disclosure - Stock-Based Compensation (Tables) Sheet http://quidel.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) false false R25.htm 0510 - Disclosure - Industry and Geographic Information (Tables) Sheet http://quidel.com/role/IndustryAndGeographicInformationTables Industry and Geographic Information (Tables) false false R26.htm 0601 - Disclosure - Basis of Presentation (Details Textual) Sheet http://quidel.com/role/BasisOfPresentationDetailsTextual Basis of Presentation (Details Textual) false false R27.htm 0603 - Disclosure - Computation of Earnings Per Share (Details) Sheet http://quidel.com/role/ComputationOfEarningsPerShareDetails Computation of Earnings Per Share (Details) false false R28.htm 06031 - Disclosure - Computation of Earnings Per Share (Details Textual) Sheet http://quidel.com/role/ComputationOfEarningsPerShareDetailsTextual Computation of Earnings Per Share (Details Textual) false false R29.htm 0604 - Disclosure - Inventories (Details) Sheet http://quidel.com/role/InventoriesDetails Inventories (Details) false false R30.htm 0605 - Disclosure - Other Current Liabilities (Details) Sheet http://quidel.com/role/OtherCurrentLiabilitiesDetails Other Current Liabilities (Details) false false R31.htm 0606 - Disclosure - Income Taxes (Details Textual) Sheet http://quidel.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) false false R32.htm 0607 - Disclosure - Line of Credit (Details Textual) Sheet http://quidel.com/role/LineOfCreditDetailsTextual Line of Credit (Details Textual) false false R33.htm 0608 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://quidel.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) false false R34.htm 0609 - Disclosure - Stock-Based Compensation (Details) Sheet http://quidel.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details) false false R35.htm 06091 - Disclosure - Stock-Based Compensation (Details 1) Sheet http://quidel.com/role/StockBasedCompensationDetails1 Stock-Based Compensation (Details 1) false false R36.htm 06092 - Disclosure - Stock-Based Compensation (Details Textual) Sheet http://quidel.com/role/StockBasedCompensationDetailsTextual Stock-Based Compensation (Details Textual) false false R37.htm 0610 - Disclosure - Industry and Geographic Information (Details) Sheet http://quidel.com/role/IndustryAndGeographicInformationDetails Industry and Geographic Information (Details) false false R38.htm 06101 - Disclosure - Industry and Geographic Information (Details Textual) Sheet http://quidel.com/role/IndustryAndGeographicInformationDetailsTextual Industry and Geographic Information (Details Textual) false false R39.htm 0611 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://quidel.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) false false R40.htm 0612 - Disclosure - Lease Obligation (Details Textual) Sheet http://quidel.com/role/LeaseObligationDetailsTextual Lease Obligation (Details Textual) false false R41.htm 0613 - Disclosure - Fair Value Measurement (Details Textual) Sheet http://quidel.com/role/FairValueMeasurementDetailsTextual Fair Value Measurement (Details Textual) false false All Reports Book All Reports Element us-gaap_OtherLiabilitiesCurrent had a mix of decimals attribute values: -5 -3. 'Monetary' elements on report '0608 - Disclosure - Stockholders' Equity (Details Textual)' had a mix of different decimal attribute values. 'Monetary' elements on report '0611 - Disclosure - Commitments and Contingencies (Details Textual)' had a mix of different decimal attribute values. Process Flow-Through: 0110 - Statement - Consolidated Balance Sheets (Unaudited) Process Flow-Through: Removing column 'Sep. 30, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 0111 - Statement - Consolidated Balance Sheets (Parenthetical) (unaudited) Process Flow-Through: 0120 - Statement - Consolidated Statements of Operations (unaudited) Process Flow-Through: 0121 - Statement - Consolidated Statements of Operations (Parenthetical) (unaudited) Process Flow-Through: 0130 - Statement - Consolidated Statements of Cash Flows (unaudited) qdel-20120930.xml qdel-20120930.xsd qdel-20120930_cal.xml qdel-20120930_def.xml qdel-20120930_lab.xml qdel-20120930_pre.xml true true XML 55 R38.htm IDEA: XBRL DOCUMENT v2.4.0.6
Industry and Geographic Information (Details Textual) (USD $)
In Millions, unless otherwise specified
9 Months Ended
Sep. 30, 2012
Segment
Sep. 30, 2011
Dec. 31, 2011
Industry and Geographic Information (Textual) [Abstract]      
Number of reportable segments 1    
Sales percentage 22.00% 27.00%  
Accounts receivable due in excess of 10% $ 8.1   $ 5.5
Minimum percentage of accounts receivable from major customers 10.00%   10.00%
Non-U.S. Customers [Member]
     
Industry and Geographic Information (Textual) [Abstract]      
Sales to customers outside the U.S. 15.9 13.8  
Sales percentage 16.00% 11.00%  
Balances due from foreign customers $ 1.7   $ 4.8
XML 56 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
Comprehensive (loss) income (Policies)
9 Months Ended
Sep. 30, 2012
Stockholders' Equity  
Comprehensive Income: Presentation of Comprehensive Income

During the first quarter ended March 31, 2012, the Company adopted Accounting Standards Update No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income.

Fair Value Measurements and Disclosures

In conjunction with Financial Accountings Standards Board Accounting Standard Update No. 2009-05, Fair Value Measurements and Disclosures (Topic 820), the Company assigned $28.8 million to the licensed technology and $0.7 million as a one-time charge to cost of sales.

Accounting for Sales of Real Estate

The transaction was deemed a financing transaction under the guidance in ASC Topic 840-40, Accounting for Sales of Real Estate.